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ABSTRACT
AMINOOXY REAGENTS IN NANOMEDICINE AND
BIOANALYSIS
Stephanie Mattingly
December 2, 2014

The development of nanomaterials as medical diagnostic and therapeutic agents
is a rapidly expanding field. A brief search of the literature revealed that roughly half of
all articles related to nanoparticle-based drug delivery were published after the onset of
this thesis research, over the past 4 years. A few nano-based formulations have entered
into clinical use, including liposomal drug formulations, protein-linked drugs, and
nanoparticle-based MRI contrast agents. The chemistry that enables conjugation of a
functional cargo, whether a drug, a targeting element, or a radionucleotide, to a
nanocarrier is thus a critical component for development. Oximation is one of the
simplest and most efficient chemical conjugation methods. It entails condensation of an
aminooxy group with an aldehyde or ketone carbonyl yielding an oxime ether. The
versatility of oximation is highlighted and exploited in this thesis.

iv

Chapter 1 provides an overview of the application of iron oxide nanoparticles in
medicine, and more specifically, to nanoparticles as delivery agents for the anticancer
drug doxorubicin.
Chapter 2 describes an oximation methodology for cellular metabolite
derivatization to enhance the detection of carbonyl analytes using mass spectrometry
(MS).

Integration of carbonyl-selective aminooxy functionality with a quaternary

ammonium moiety for MS electrospray enhancement and a hydrophobic domain for
sample cleanup led us to design reagent QDA (quaternary dodecyl aminooxy) and its
13CD3 isotopologue *QDA. Analysis of QDA/*QDA-treated lung adenocarcinoma A549
cells established a profile of carbonyl metabolites spanning multiple structural classes
showing capability for global carbonyl profiling.
In Chapter 4, hydroxylated cationic oxime ether lipids are described for coating
core-shell Fe3O4-SiO2 nanoparticles. Formulation of the nanoparticles produced lipidcoated, highly ζ–potential–positive assemblies: a new form of cationic magnetoliposomes
(CML). The CMLs were evaluated as potential drug carriers by integrating into the bilayer
a hydrophobically modified analog of doxorubicin. On treatment of MCF-7 breast cancer
cells with the drug-loaded CMLs, the assemblies were rapidly internalized and exhibited
higher toxicity than treatments with doxorubicin alone. In a separate assessment of the
oxime ether lipids, complexation with nucleic acids to form cationic lipoplexes similarly
showed high cellular uptake and marked them as viable candidates for siRNA delivery.
Chapter 5 provides all experimental procedures for the aforementioned science.
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1.1.

Aminooxy functionality and oximation
Oximation, the condensation of an aminooxy moiety with an aldehyde or ketone

(Figure 1.1), is one of a select few that meet the criteria for the term “click chemistry”
established by K. Barry Sharpless.1 Click chemistry reactions have high atom and reaction
efficiency, innocuous byproducts, easy purification, and are insensitive to air and
moisture. They take their cue from nature, forming covalent links between discrete
molecules via carbon-heteroatom bonds. Oximation is a model click reaction in that it
usually occurs spontaneously, at room temperature, in numerous solvents, requires no
heat, and produces robust chemical bonds with water as its only byproduct. It is an
elegant reaction that can link independently functionalized components thus enabling
convergent synthesis, and because of its high chemoselectivity, it is suitable for a broad
range of tethering reactions. The great versatility of oximation chemistry is reflected in
this thesis — my investigations have applied aminooxy reagents to such diverse
applications as metabolite derivatization, nanomaterial functionalization, drug delivery,
and gene transfer.

Figure 1.1. Representative oximation reaction: an aminooxy condenses
with an aldehyde or ketone to form an oxime ether.

The high stability of the products of oximation, oxime ethers, comes from the
unique electronic structure of the functionality. In comparison to analogous functional
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groups, hydrazones and acyl hydrazones, oxime ethers have much slower rates of
hydrolysis. Jeet Kalia and Ronald Raines compared the rates of hydrolysis for these
linkages and determined, as depicted in Figure 1.2, that oxime ether 1 had hydrolytic rates
approximately 600 fold and 300 fold slower than hydrazones 2 and 3, respectively. This
effect is likely due to greater inductive electron donation from oxygen into the pi system
as compared to nitrogen.2

Figure 1.2. Compounds examined in a comparative hydrolysis study2 of
oxime ethers, hydrazones, and acyl hydrazones

Whereas the carbonyl carbon of most functional groups is electropositive, in the
case of the sp2 carbon of oxime ethers, electron donation from the attached heteroatoms
weakens the polarity of the bond. An indicator of this phenomenon can be found in
comparisons of the alpha hydrogen pKa’s for oxime ethers versus ketones. The acidity of
alpha hydrogens is heavily influenced by the capacity of the adjacent pi system to
delocalize electron density through resonance. It is thus an indirect indicator of the
electrophilicity of the carbonyl carbon. James Ciula and Andrew Streitwieser have
examined the alpha hydrogen pKa’s for diphenylacetone and an oxime ether analog
(Figure 1.3).3 A tenfold higher pKa for the oxime ether species was reported; this is
evidence of a dramatic reduction in electrophilicity for oxime ether carbonyl carbons.

3

Given that hydrolysis proceeds through nucleophilic attack of water on this carbon, the
reduction in its electrophilicity can be understood to promote a high degree of stability
for the linkage.

Figure 1.3. Comparison of alpha hydrogen pKa for ketone versus oxime
ether

1.2.

Quaternary ammonium salts
The major focus of this work is the synthesis and application of novel compounds

that combine aminooxy functionality with quaternary ammonium moieties.

Such

quaternary aminooxys (QAOs), exemplified in Figure 1.4, are adapted both for oximation
chemistry and the aqueous environment of biological applications.

Figure 1.4. Representative quaternary aminooxy (QAO)

4

Quaternary ammonium salts are a useful class of reagents. The four substituents
of the quaternary nitrogen provide opportunity for functional variety. Depending upon
the hydrophobicity of the attached substituents, amphiphilic species can be prepared
with solubility in aqueous and organic solvents. For this reason, such amphiphiles are
used commercially as phase transfer catalysts and surfactants. They are also relatively
inexpensive, so their use in industry is more common than other phase transfer catalysts,
such as phosphonium salts and crown ethers.4 Another variant of this type of amphiphile,
dual-chain cationic lipids, are often used in gene delivery owing to their ability to
condense DNA and transport it across cell membranes;5 this activity will be discussed in
detail in Chapter 4.
The preparation of ammonium salts is generally straightforward. The protecting
group chemistry for nitrogen is well established and the products of quaternization, being
salts, can often be isolated by recrystallization, thereby avoiding more costly
chromatographic purification.
The custom QAOs we describe in this work were utilized in several different
applications. Chapter 2 details the way in which a QAO reagent was used to capture
cellular aldehydes and ketones from biological samples, as well as the how the permanent
positive charge of the quaternary nitrogen was exploited to maximize the signal intensity
of the conjugated metabolites in mass spectral detection. In chapters 3 and 4, oximation
allowed the linking of QAOs to fluorophores and drugs; in this case, the cationic
ammonium group facilitated electrostatic attraction to negatively charged iron oxide and
silica-coated nanoparticles. Finally, as disclosed at the end of chapter 4, cationic oxime
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ether lipids with quaternary ammonium headgroups were studied for their gene transfer
activity. In subsequent sections of this introductory chapter, I give the background for
traditional carbonyl derivatization strategies for mass spectrometry (MS), and iron oxide
nanoparticle functionalization for drug delivery.

1.3.

Derivatization reagents for mass spectrometry
The analysis of cellular aldehydes and ketones is of considerable importance in the

field of metabolomics since carbonyl species are pervasive intermediates of normal
metabolism as well as common products of oxidative stress,6-7 which has been implicated
in the pathogenesis of many diseases including cancer.8 The detection and identification
of oxidized cellular species, in general, has become an important focus of research efforts
in metabolomics where potential early markers of disease are sought.9-10

The

identification of polar aldehyde and ketone metabolites from aqueous cell extracts is
particularly challenging owing to their low-abundance, high reactivity, and the difficulties
associated with their extraction from the cell matrix. Mass spectrometry (MS) has the
sensitivity required for observing these low-abundant species, but due to insufficient
mass accuracy and resolution, most MS methods are coupled with chromatography to
distinguish analytes with similar m/z. Fourier-transform ion-cyclotron resonance MS (FTICR-MS), however, does not suffer these limitations and can provide unique molecular
formulae of most metabolites. In addition, FT-ICR-MS can achieve simultaneous
resolution of 13C isotopologues and distinguish them from other elemental isotopologues
(such as

15N

or 2H).11 However, direct infusion FT-ICR-MS is often compromised by
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unstable sample introduction (e.g., electrospray) and low ion yields due to interference
from cellular salts and/or interaction with matrix ions in aqueous biological extracts.
Consequently, metabolite derivatization is a strategy that can be employed to overcome
these challenges.
In the case of aldehyde and ketone metabolites, derivatization is commonly
performed to facilitate liquid chromatography with optical or MS detection (LC–MS) or
gas chromatography coupled to mass spectrometry (GC–MS).

Such derivatization

reagents either have distinct absorbances (for optical detection), preserve or increase
volatility (GC), or have easily ionizable groups for MS detection, such as those exemplified
in Figure 1.5.6, 12-17 These reagents react with carbonyls via their amine,12 hydrazine,14
hydrazide,18-20 or aminooxy21-22 moieties to form corresponding imine, hydrazone, acyl
hydrazone, or oxime ether adducts, respectively. For example, dinitrophenylhydrazine
(DNPH) reacts with aldehydes and ketones to form hydrazone derivatives that can be
more readily detected due to characteristic UV absorbances.6, 14 Similarly, O-2,3,4,5,6(pentafluorobenzyl)hydroxylamine (PFBHA) has been used to form stable, and readily
ionizable oxime ether derivatives from aldehydes and ketones.21-22 The silylation of α,βunsaturated ketones, using a catalyst to facilitate ketone to enol tautomerization and thus
enol silylation, also has been performed to improve the GC-MS analysis of this compound
class.23 Some of these reagents also employ a permanent positive charge to enhance
electrospray MS sensitivity.16-18, 20, 24-26 While still suitable for analysis by LC-MS, this
approach precludes the use of GC since the resultant charged adducts have lower
volatility. The added charge enhances MS sensitivity and, more importantly, enables
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direct MS analysis under milder, non-ionizing conditions. For example, the hydrazidebased

derivatization

agent

4-hydrazino-4-oxobutyl-[tris(2,4,6-trimethoxyphenyl)-

phosphonium bromide (TMPP-PrG) reacts with aldehydes and ketones and contains a
quaternary phosphorous to impart a permanent positive charge on its adducts. 27
Additionally, Girard reagents,17, 26 such as Girard-P, also contain hydrazide functionality
for reaction with carbonyl substrates and a quaternary ammonium moiety to enhance
water solubility. Such reagents have been used to enhance detection in secondary ion
MS (e.g. Xe+),26 LC-MS,28 and electrospray ionization MS (ESI-MS).29 More recently, an
aminooxy-based reagent for carbonyl capture was developed by Yuan et al. 30 in which a
biotinylated region of the reagent was used to separate conjugated carbonyls from other
cellular species on streptavidin beads. In this case, release of the derivatized metabolites
was achieved through activation of a photo-cleavable linker.

Figure 1.5. Agents for the derivatization of carbonyl compounds.

8

The disadvantages in these reported approaches include multistep procedures for
metabolite derivatization, potentially damaging UV light exposure, and/or lengthy
chromatographic separation of the resultant metabolite adducts. Chapter 2 will relate
our strategy for using direct infusion FT-ICR-MS to analyze crude biological extracts using
a QAO reagent. Like several of the reagents described above, the reagent we designed
bears a permanent positive charge for ready conversion of carbonyl metabolites into
stable, non-volatile, charged adducts. It was also designed for compatibility with aqueous
medium. Where it departs from traditional reagents is in the addition of a hydrophobic
domain optimized for partitioning of charged adducts into an organic solvent for
enhanced electrospray stability. We apply this new cationic amphiphile to the global
profiling of carbonyl metabolites directly from crude aqueous extracts of cancer cells.

1.4.

Iron oxide nanoparticles in nanomedicine
The introduction of nanoparticles into clinical applications is at the cutting edge of

medical science. The scale of nanoparticles, typically 10-100 nm, makes them perfectly
suited for operating in biological systems. The standard tools of medicine inhabit vastly
different size domains; molecular drugs are on the order of a nanometer, and a scalpel,
at the other extreme, is roughly 50 million times larger. With the emergence of
nanomedicine, there is another tool for medical science, one that is much closer to the
micrometer scale of cells. Although the application of nanoparticles in clinical practice
has been limited, it is a rapidly expanding field with a promising future.

9

Iron oxide, Fe3O4/Fe2O3, nanoparticles (NPs) are a particularly attractive class of
nanomaterial. They possess intrinsic magnetic properties that enable both diagnostic and
therapeutic procedures, such as magnetic resonance imaging (MRI) through contrast
enhancement,31 magnetic targeting,32 and thermotherapy through inductive heating
using an alternating magnetic field.33 Moreover, the attachment of targeting ligands34
and drugs demonstrates their potential for achieving the ultimate goal of directed,
minimal-dose chemotherapy. This versatility makes magnetic nanoparticles appealing
candidates as multifunctional drug delivery systems.
1.4.1. Nanoparticle preparation methods
Iron oxide nanoparticles of Fe3O4 (magnetite) or γ-Fe2O3 (maghemite) can be
prepared by a variety of methods.35 Among the common chemical syntheses are
coprecipitation, thermal decomposition and hydrothermal reactions. In coprecipitation,
NPs form from an aqueous mixture of iron II and III chloride salts in the presence of base
(Equation 1.1). The method was known as far back as 1852, but was not well studied until
the work of René Massart in the 1980s.36 It is the simplest technique as it is a wet
chemistry approach that does not require special equipment. However, coprecipitation
has a drawback in that the control of particle size and shape is somewhat limited, and NPs
made in this way will have a wider size distribution than in more rigorous syntheses.37 In
thermal decomposition, NPs are formed from the decomposition and oxidation of
organometallic precursors, such as iron acetylacetonate, at high temperature in organic
solvents and in the presence of surfactants, typically fatty acids.38 The NPs generated by
this method are hydrophobic and must be modified to confer aqueous solubility. 39
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In

hydrothermal reactions, NPs are generated using ferric nitrate under aqueous conditions
at high temperatures and pressures.40 A number of physical preparations of NPs are also
known including gas-phase deposition, electron beam lithography and laser pyrolysis.40
In perhaps the most inventive methodology, NPs can also be harvested from bacteria;
termed the microbial method, Fe(III)-reducing bacteria incubated with a β-FeOOH
precursor synthesize Fe3O4 NPs under anaerobic conditions.35

Fe2+ + 2Fe3+ + 8OH-  Fe3O4 + 4H2O
Equation 1.1. Precipitation of iron salts to form Fe3O4 NPs

1.4.2. Crystal phase and magnetic properties
The magnetic iron oxides, Fe3O4 and γ-Fe2O3, both have inverted spinel crystal
structure in which the metal ions are located in the tetrahedral and octahedral interstices
of a tight packed face-centered-cubic oxygen lattice. In the case of Fe3O4 (Figure 1.6),41
Fe3+ occupies the tetrahedral coordination sites and Fe2+ and Fe3+, in equal parts, occupy
the octahedral sites. Below 851 K magnetite is ferrimagnetic; the different coordination
sites have antiparallel alignment of magnetic moments, but electron hopping between
the Fe2+ and Fe3+ ions in the octahedral sites produces a net magnetism.39, 42 γ-Fe2O3
differs from magnetite in that iron is present in only the +3 oxidation state. For
maghemite, a somewhat weaker ferrimagnetism (60–80 emu/g compared to 92–96
emu/g for magnetite)43 is still present due to an uneven distribution of the metal ions
among the coordination sites, i.e. the presence of vacancies. The aligned magnetic
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moments of iron ions in very small NPs combine to create a single large magnetic moment
for each individual particle. These small NPs are said to exhibit superparamagnetism 44
where in the absence of a magnetic field thermal energy causes particle magnetic
moments to orient randomly, thus creating a zero net magnetism. In the presence of a
field, however, the magnetic moments of the particles align with the external field. This
lack of remnant magnetism allows NPs to amass when a magnetic field is present, but
redisperse into colloidal form when released from the field, making them ideal for
biological applications.39

Figure 1.6. Crystal structure of Fe3O4: green balls (Fe2+), brown balls (Fe3+),
white balls (O). Reprinted from Chem. Commun. (Cambridge, U. K.) 2011,
47, 5130-5141 with permission from the Royal Society of Chemistry.

12

1.4.3. Magnetic targeting and imaging
The magnetic properties of NPs enable magnetic targeting through external
magnetic field application. In a survey of the literature, several in vivo targeting studies
are reported.32, 45-46 Ma and coworkers, for example, injected alginate-coated NPs into a
rat femoral artery and were able to demonstrate retention of the NPs at a target site by
magnetic field application.47

Similarly, Pisciotti et al. showed accumulation of

intravenously injected polyethylene glycol (PEG)-coated NPs in a mouse tumor where an
external field was applied.45 Although promising, magnetic targeting to this point has
been applied only to superficial tumors; deep tissue targeting poses a challenge because
the strength of a magnetic field rapidly weakens (r-3) with distance from the source
magnet.
NPs have also been applied in magnetic resonance imaging (MRI) where they
provide negative contrast enhancement in NP-bearing tissues. The proton signal intensity
in MRI in tissue is influenced by proximity to NPs. Both T1 and T2 relaxation processes are
affected; however, because the NPs produce local field inhomogeneity, faster T2
relaxation (decoherence of the transverse nuclear spins) dominates. Thus NPs are used
in T2-weighted pulse sequences.39 There are a few ferrofluids approved by the FDA for
MRI use in humans including ferumoxsil and ferrumoxide, siloxane-coated and dextrancoated NPs, respectively.
investigated.

The biocompatibility of such formulations have been

Radiotracer evidence suggests that clinically administered NPs are

biodegraded and incorporated into erythrocyte heme iron48 or bound to transferrin and
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eliminated through defecation.35 Although organic coatings, particularly polymers, can
carry their own intrinsic toxicity, ferrofluids are generally regarded as biocompatible. 35
There is presently a thrust in nanomedicine toward theranostics, the practice of
combining therapy and diagnostics. Along those lines, MRI contrast enhancement from
NPs could be combined with other therapies enabled by the ferrofluid. One such therapy
that has the potential to excel in this capacity is thermotherapy, as described below.

1.4.4. Heating by alternating magnetic field
In the presence of an alternating magnetic field, the magnetic properties of NPs
cause heat to be generated in a process called induction heating. This can take place
through a few different mechanisms depending upon the size of the particles as
illustrated in Figure 1.7.49 In the case of small superparamagnetic NPs (<20 nm diameter),
Néel relaxation is the primary mechanism of heating. In this process the magnetic
moment of a NP will reorient to align with the shifting external field direction, and
resistance to this change in dipole orientation generates heat. For larger particles (>20
nm diameter), Brownian motion relaxation is the primary heating mechanism; the particle
itself rotates to align its magnetic dipole with the external field, and the friction between
the NP surface and the surrounding medium induces heating. The third mechanism of
heating, hysteresis losses, similarly occurs in larger particles. Here, the particles are not
superparamagnetic but instead are multi-domain particles where regions of the NPs have
net magnetic moments oriented randomly with respect to one another. Hysteresis
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heating is a consequence of the growth of the domain best aligned with the magnetic
field at the expense of neighboring domains.

Figure 1.7. Illustration of NP heating mechanisms: (a) Néel relaxation; (b)
Brownian motion relaxation; (c) Hysteresis losses

Although this discussion has focused on the mechanisms of NP heating, it is
important to note that the increase in temperature of the bulk solution of a ferrofluid is
not necessarily indicative of the local environment at the NP surface.

There is

considerable evidence to suggest that the energy transfer from AMF-induced NPs to
attached ligands/polymers has exaggerated effects at the particle interface.50 Riedinger
et al., for example, used a thermally sensitive azo molecule to probe NP surface
temperature at subnanometer distances and found that a local temperature increase up
to 44 °C during one hour of AMF exposure (17 mT, 334.5 kHz) could be found within 0.5
nm of the NP surface.51
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The heat-generating ability of NPs exposed to AMF is used clinically in magnetic
fluid hyperthermia where ferrofluids are injected into tumor sites and heated by AMF
induction. The tumor tissue is heated to between 40 and 45 °C to achieve hyperthermia,
as heating above 45 °C, termed thermoablation, causes tissue necrosis.52 Surrounding
tissues, absent NPs, are unharmed by a well-directed oscillating field. Hyperthermic
temperatures can contribute directly to tumor regression, but they also boost the efficacy
of traditional therapies (chemotherapy, radiation) through a process of tumor
sensitization.53 The established use of hyperthermia therapy has led to the development
of instrumentation designed for AMF administration in humans.

MagForce

Nanotechnologies (AG, Berlin), for example, manufactures units for AMF application to
human patients. AMF is also used in NP applications as an external trigger for the release
of bound substrates (drugs/fluorophores), as will be discussed shortly.

1.4.5. Surface modifications
Surface coating of NPs is typically employed to improve their aqueous solubility,
prevent aggregation, and neutralize surface reactivity. There are several classes of
coating agents; iron chelators are common, including catechols43, 54 and carboxylates,
both single molecule (oleic acid,55 citrate56) and polymeric species (alginate,32
carboxymethyl dextran57). These species bind to the iron at the surface of the NP.
Hydrogen bond donors for NP surface oxyanions/hydroxyls are frequently used as well,
including polymeric amines (polyethylenimine58), alcohols (polysaccharides,59 polyvinyl
alcohol58), and ethers (polyethylene glycol).60
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Creating composite core-shell

nanostructures with inorganic material surrounding iron oxide cores is also frequently
employed, as these shells can contribute additional functionality to the NPs. Gold-coated
NPs,61 for example, can be imaged by surface plasmon resonance. Silica coating of iron
oxide is also common and will be discussed in detail in Chapter 4.

1.5.

Nanoparticle-mediated drug delivery
To date, the clinical use of NPs has largely been confined to imaging and

hyperthermia therapy, but the greater potential for NPs in nanomedicine is in multimodal
therapies that augment the techniques enabled by NP magnetism with attachment of
functional molecules, like pharmaceutical agents or targeting ligands. Perfecting the
technology of functionalized NPs carries big implications for human health. The following
excerpt62 from Amy Pope-Harman concerns progress in the field of cancer treatment and
sums up the challenges and the motivations for nanotechnology in medicine quite
poignantly.

Clinical medicine has seen tremendous improvements in the past several
decades. Despite the progress . . . patients still are called on to endure toxic
and uncomfortable whole-body chemotherapy and other treatments with
the hope that their cancers will succumb. There is expectation, however,
that all of this will change radically with the use of nanotechnology . . .
allowing improvements in mortality and prevention of suffering from
cancer and other devastating diseases . . . By working on a nanometer,
molecular scale, there is the potential to simultaneously assess and
intervene, with accuracy in space and time, which is an ability that has
never before been available.
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In subsequent sections of this chapter, I will outline some of the recent
innovations in adapting NPs to function as drug carriers. Specifically, this overview will
focus on the NP-mediated delivery of the anticancer agent doxorubicin.

1.5.1. Doxorubicin
Doxorubicin (Dox, Figure 1.8), is an anthracycline antibiotic known for its potent
activity against a broad spectrum of cancers.63 Several modes of action for Dox have been
detailed in the literature including DNA intercalation, helicase inhibition, free radical
generation, and topoisomerase II interaction leading to apoptosis.64 In the case of MCF7, the breast cancer cell line used in the in vitro studies described in Chapters 3 and 4, the
antiproliferative action of Dox may be related to interference with DNA unwinding.65 In
the absence of a NP carrier, targeting agent, or liposomal formulation, Dox has
nonspecific toxicity and is known to damage kidney tissue and bone marrow, but its most
troubling side-effect is cardiotoxicity.66-68

Figure 1.8. Doxorubicin hydrochloride
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1.5.2. Progress in nanoparticle-mediated doxorubicin delivery
Dox is frequently the model drug of choice for demonstrating targeted delivery
using NP platforms. Such platforms have incorporated Dox in a variety of ways using
different methods of attachment. Covalent attachment is a strategy that is occasionally
used offering the benefit of good retention of Dox on the particle. The drawback of
covalent linkage is that release of the drug often requires cleavage of covalent bonds in
the absence of an activator. For example, Hua and coworkers formed an amide linkage
between Dox and an activated carboxylic acid at the surface of acidic polymer-coated NPs
to demonstrate MRI contrast enhancement and magnetic retention in a mouse
hypodermic tumor (Figure 1.9).69 Similarly, Li et al.70 used silica-coated iron oxide NPs to
covalently bind Dox via a urea linkage that tethered the Dox amine to an isocyanate group
on the silane monomer used for constructing the silica shell.

Figure 1.9. Dox covalently linked to superhigh-magnetization nanocarriers
(SHMNCs). Adapted from Biomaterials 2011, 32 (34), 8999-9010 with
permission from Elsevier.
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Tumor sites are known to be more acidic than healthy tissue,71 and for this reason
pH-triggered release is sometimes planned into the design for NPs with covalently bound
Dox. In this vein, a few investigators have covalently attached Dox to NPs via acidcleavable hydrazone bonds formed from hydrazine/hydrazide-functionalized NPs
reacting with the Dox C-13 carbonyl.72-74 Patra and coinvestigators, for example, used
hydrazide functionalized poly(styrene)-b-poly(acrylic acid) block copolymer to bind Dox
on folate-conjugated NPs for targeted delivery to breast and colon cancer cells. 73 In an
alternate approach, that likewise used a pH-based cleavage strategy, Gautier and
coauthors installed an Fe2+ ion bridging the oxygens of the Dox quinone system in order
to bind Dox directly to NPs.75 PEG chains were added to stabilize the linkage and release
profiles showed a pH dependence, as protons gradually displaced Fe 2+ and freed the Dox
from the NP surface. This formulation was found to be effective against MCF-7 cells.
Hydrophobic interactions have also been used as a means to reversibly attach Dox
to NPs. Jain et al.55 incorporated free base Dox, prepared by bubbling gaseous ammonia
into an organic suspension of Dox HCl,76 into the hydrophobic shell of oleic acid coated
iron oxide NPs. A capping polymer, Pluronic (similar to PEG), was then added to retain the
Dox and confer aqueous solubility to the complex. Drug release was achieved slowly over
several hours by passive diffusion (Figure 1.10). Chen and coworkers similarly utilized
hydrophobic interactions to entrap Dox into the hydrophobic interior of a NP-containing
micelle.77 Figure 1.11 illustrates this novel formulation in which a reduction sensitive
copolymer generates the layered nanostructure pictured. Release of Dox was designed
to be mediated by the reducing environment of circulation and cytoplasm. In vitro real-
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time fluorescent monitoring and in vivo tumor growth studies were used to demonstrate
the efficacy of the formulation.

Figure 1.10. Left: charge neutral Dox (red dots) incorporated into an oleic
acid hydrophobic layer surrounding a NP; right: confocal laser scanning
microscopic images of MCF-7 cells incubated for 2, 24, and 48 h with the
Dox-NPs. Adapted from Molecular pharmaceutics 2005, 2 (3), 194-205
with permission from American Chemical Society. Copyright (2005)
American Chemical Society.

Figure 1.11. Hydrophobic oleic acid nanoparticles coincorporated with Dox
into a reducing-polymer/PEG-capped nanoassembly. Adapted from
Biomaterials 2014, 35 (4), 1240-1248 with from permission from Elsevier.
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Noncovalent interactions such as electrostatic interactions and hydrogen bonding
are likewise frequently used for Dox conjugation to NPs. For example, Lübbe and
coworkers in a phase I clinical trial, exploited noncovalent interactions by chemisorbing a
Dox analog, epirubicin, to anhydroglucose polymer coated NPs.78 The magnetic targeting
ability of the drug-loaded NPs were tested in vivo in 14 patients with solid tumors, and
targeting was found to be successful in half of the patients. In another noncovalent
approach from Lee and coauthors,79 mesoporous silica particles were loaded with Dox,
then magnetite nanocrystals and PEG chains were attached at the silica surface (Figure
1.12). Dox was administered in this formulation to a mouse tumor model where
accumulation of the particles in tumor tissue as well as cell death were observed. Li et
al.80 used amphiphilic gelatin to incorporate NPs and to electrostatically bind Dox to the
carboxylated surface of the gelatin. Calcium phosphate was then used as a capping agent
to facilitate acidic pH-mediated degradation of the complex. An in vitro study with HeLa
cells verified the release of Dox by confocal laser scanning microscopy. Finally, Fan and
colleagues used a lipid to electrostatically bind Dox in a novel construct illustrated in
Figure 1.13.81 Here, gas bubbles of perfluoropropane were prepared in a lipid sphere that
contained embedded NPs in addition to the adsorbed Dox. Next, focused ultrasound was
used to rupture the bubbles and simultaneously generating blood-brain barrier openings
in an in vivo study with a rat glioma model. The microbubbles were targeted with an
external magnet and tracked by MRI.
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Figure 1.12. TEM image of NP loaded onto the surface of mesoporous silica
spheres. Adapted with permission from J. Am. Chem. Soc. 2010, 132 (2),
552-557. Copyright (2010) American Chemical Society.

Figure 1.13. Microbubble with lipid embedded NPs (labeled SPIO-C4)
Adapted from Biomaterials 2013, 34 (14), 3706-3715 with permission from
Elsevier.
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AMF application has also been applied to NPs to effect Dox release, most often in
the context of heat-sensitive polymers or gels. For example, Brulé et al.82 incorporated
NPs and Dox into alginate gel beads and used AMF to induce Dox diffusion from the
heated gel. They observed no leakage of Dox at 4 °C, moderate release at 37 °C, and
significant release from AMF heating at 53 °C. Peiris and coworkers used the mechanical
effect of AMF application, rather than heat generation, to trigger release of Dox from
liposomes.83 In this creative approach, a string of NPs were tethered by crosslinking
chains to a liposome containing encapsulated Dox (Figure 1.14). The authors were able
to demonstrate superior tumor distribution of Dox in an in vivo model by the AMFactivated nanochains as compared to Dox liposomes alone.

Figure 1.14. Depiction of AMF-triggered release of Dox from nanochainbound liposome. Adapted with permission from ACS Nano 2012, 6 (5),
4157-4168. Copyright (2012) American Chemical Society.

The above reports reflect the most recent advances in nanocarrier-mediated
delivery of doxorubicin. Several of these innovations were reported after the onset of
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our own investigations and informed the evolution of our strategies. In Chapters 3 and 4
of this thesis, I will present our contributions to this emergent field of nanotherapy.
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2.1.

Limitations of current derivatization methods
Chapter 1 introduced derivatization as a technique for improving the detection by

mass spectrometry (MS) of volatile, charge-neutral, or low molecular weight metabolites.
The shortcomings of traditional ketone/aldehyde derivatization reagents highlighted
earlier included the requirements of harsh reaction conditions (acidic pH and/or high
temperature), and chromatographic separation of derivatives prior to MS detection. We,
along with our collaborators, Dr. Teresa Fan, Dr. Richard Higashi, and Mr. Tao Xu, set out
to design a derivatization reagent and accompanying methodology that would overcome
the drawbacks of the more common approaches to enable an aqueous phase, low-temp
conjugation to carbonyl metabolites. We aimed for a minimal processing method suitable
for analysis of crude biological extracts using direct infusion Fourier-transform ioncyclotron resonance mass spectrometry (FT-ICR-MS).

2.2.

Reagent design
There were four key components of our reagent design. We saw in the mild and

aqueous-friendly reaction conditions of oximation chemistry an opportunity for facile
derivatization of carbonyl metabolites in cell extracts. The formation of oxime ether
bonds from an aminooxy reagent to a bioanalyte carbonyl would stabilize the resultant
adduct (recall from Chapter 1 the comparison of α-proton acidity for 1,3 diphenyl
acetone, pKa ≈ 18, versus its corresponding methyl oxime ether, pKa ≈ 28).3 The second
critical feature of the reagent was the incorporation of a permanent positive charge to
maximize MS sensitivity, increase the aqueous solubility of the probe, and generate
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nonvolatile adducts. For this purpose, a quaternary ammonium cation seemed ideal.
Third, to overcome the interference of cellular salts and cell matrix ions in the
establishment of a stable electrospray, we sought a reagent that, when conjugated to an
analyte, could be extracted into an organic solvent. Lastly, we desired a reagent that
could easily be labeled with a stable isotope both for the purpose of verification of
adducts as carbonyl derivatives, as well as for quantitative MS analysis.
Figure 2.1 is a representative structure of our initial design. Present are an
aminooxy moiety for chemoselective carbonyl capture, a cationic ammonium headgroup
for MS sensitivity, an aliphatic tail to facilitate organic phase partition, and methyl groups
for stable-isotope labeling through quaternization with commercially available and
inexpensive iodomethane.

Figure 2.1. Representative structure of derivatizing agent

2.3.

Results and discussion

2.3.1. Chain length variations
To examine the effect of aliphatic chain length on the efficiency of metabolite
extraction, dodecyl and octyl versions of the reagent were prepared as depicted in
Schemes 2.1 and 2.2 with designations QOA (quaternary octyl aminooxy) and QDA
(quaternary dodecyl aminooxy). These preliminary syntheses were three step reactions
beginning with quaternization of a tertiary amine with an alkyl halide of the desired chain
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length. A modified Mitsunobu reaction84 generated the phthalimide-capped alcohol, and,
in the final step, hydrazinolysis of the phthalimide revealed the aminooxy functionality.

Scheme 2.1. Preparation of QOA iodide. Reagents and conditions: (a) 1iodooctane (1.1 eq), acetone, reflux, 15h, 92% (b) N-hydroxyphthalimide
(1.1 eq), PPh3 (1.1 eq), DIAD (1.1 eq), THF, 0 °C-rt, 12h, 87% (c) N2H4 · H2O
(5 eq), CH2Cl2, rt, 2 h, 92%

Scheme 2.2. Preparation of QDA bromide. Reagents and conditions: (a) 1bromododecane (1.1 eq), acetone, reflux, 10h, 49% (b) Nhydroxyphthalimide (1.1 eq), PPh3 (1.1 eq), DIAD (1.1 eq), THF:CH2Cl2 2.5:1,
0 °C-rt, 15h, 82% (c) N2H4·H2O (4 eq), anhyd. EtOH, 50 °C, 5 h, 90%

Figure 2.2 shows 1H NMR stacked plots of the alcohol precursor 2.3 (Scheme 2.2)
and QDA∙Br that highlight the disappearance of the hydroxyl proton (t, δ 4.99) as well as
downfield shifts in the methylene protons of the aminooxy arm of QDA∙Br. Product
formation was also confirmed by high resolution mass spectrometry.
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Figure 2.2. Stacked 1H NMR spectra of alcohol 2.3 and QDA∙Br in CDCl3

2.3.2. Extraction solvent determination
To compare the two analogs, QOA and QDA, and to determine the best solvent
for extraction of adducts into an organic phase, each analog was reacted with a mixture
of ketone and aldehyde standards (pyruvate, α-ketoglutarate, α-ketobutyrate, and
glucose1) in ammonium acetate buffer and subjected to extraction with one of three
solvents: chloroform, ethyl acetate, or n-butanol. The ion intensities of the resultant
conjugates, normalized to a standard of known concentration, were used to compare
carbonyl capture efficiency between the two reagents (Figure 2.3). In both cases, n-

1

In the case of glucose, the aldehyde of the open-chain isomer is reactive with the reagent.
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butanol was the most efficient extraction solvent. In addition, QDA, the dodecyl reagent,
proved superior at partitioning the standards into the organic phase as compared to the

Normalized ion count

octyl version.
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1-Butanol
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Figure 2.3. Comparison of normalized ion counts for adducts of QOA
(upper) and QDA (lower) with standards pyruvate (Pyr), α-ketoglutarate (αKg), α-ketobutyrate (α-Kb), and glucose (Glc)
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2.3.3. Stable isotope labeled analog
To prepare a stable isotope labeled version of QDA, we redesigned the original
synthesis to allow for quaternization with a doubly labeled iodomethane, 13CD3I (Scheme
2.3) and designated this analog *QDA. As the QDA previously synthesized (Scheme 2.2)
had a bromide counterion, we prepared both unlabeled QDA iodide and *QDA iodide by
this new route so that direct comparisons of the salts could be made. The successful
incorporation of the label is apparent in Figure 2.4 in a mass spectrum of a mixture of the
two salts showing a mass difference corresponding to 1 13C + 3 2H.

Scheme 2.3. Reagents and conditions: (a) 1-bromododecane (1.0 eq),
anhydrous Na2CO3 (1.0 eq), EtOH, reflux, 20 h; 70%; (b) Nhydroxyphthalimide (1.1 eq), PPh3 (1.1 eq), DIAD (1.1 eq), THF, rt, 12 h;
98%; (c) CH3I or 13CD3I (2.5 eq), CH2Cl2, 50 °C, 12 h; (d) N2H4·H2O (5.0 eq),
anhydrous ethanol, rt (for QDA) or 50 °C (for *QDA), 12 h; 65-75% (2 steps).
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Figure 2.4. Mass spectrum of a 1:1 mixture of QDA∙I and *QDA∙I

2.3.4 Counterion effects
With analogs QDA bromide and *QDA iodide in hand, we examined the effect of
the differing counterions by comparing MS signal intensity for derivatized mixtures of
standards conjugated to each analog. Equal volume aliquots of the standards mixture
described above were combined with solutions containing excess QDA bromide or *QDA
iodide. The results, represented in Figure 2.5, indicated a slight advantage for the iodo
salt adducts, presumably through better partition of the larger ion pair into the organic
layer during extraction.
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Figure 2.5. Comparison of QDA bromide and *QDA iodide salts on
extraction of standards (single sample).

The efficiency of the partitioning process was also examined; we repeatedly
extracted the same standard adducts from buffer into n-butanol five times.

The

comparison of normalized ion counts suggested that the majority of the adducts (ca.
>98%) were recovered within the first two extractions (Table 2.1).

Therefore, in

subsequent cellular extract studies we performed three solvent partitions of the
derivatized extracts to ensure high adduct recovery.
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Extraction

QDA-Pyruvate

QDA-αKetoglutarate

QDA-αKetobutyrate

QDA-Glucose

1
2
3
4
5
Aqueous Layer
(post extraction)

0.833
0.155
0.002
0.009
0.000

0.865
0.118
0.016
0.000
0.000

0.802
0.196
0.001
0.000
0.000

0.989
0.011
0.000
0.000
0.000

0.000

0.000

0.000

0.000

Table 2.1. Fraction of total QDA-standard adducts partitioned per
extraction into n-butanol from 5 mM, pH 6 ammonium acetate buffer
based on normalized ion count.

2.3.5. Cell extract derivatization and analysis
The partitioning of the constituents of lysed cells into a polar acetonitrile/water
layer and a nonpolar chloroform layer is a common technique used for metabolite
collection. Freeze-drying of the aqueous phase produces a cell extract that can be stored
frozen and reconstituted when desired for analysis. These salty extracts are difficult to
analyze by MS using traditional means; their high salt content can destabilize the
electrospray, the size of the metabolites may fall below the more sensitive range of the
MS (>150 m/z), and the ubiquity of anionic functionality (carboxylates, phosphates) often
precludes detection by the more sensitive positive mode. As our custom reagent was
designed to address these challenges, we set out to test its efficacy using the aqueous
extracts of human lung adenocarcinoma A549 cells.
In a typical derivatization experiment, an aqueous solution of QDA was combined
with a buffered solution of aqueous cell extract (pH 6 NH4OAc buffer). Mildly acidic pH
facilitates oximation as loss of water is rate determining under such conditions.85 The
mixture was then vortexed, sonicated, and placed in a 40 °C dry bath for 23 hours. This
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reaction time was chosen because increased ion counts were observed at up to 23h of
reaction time in 63% of the metabolites assigned, even though 85% of all assigned
metabolites were observable after 30 minute of reaction time. In the case of reducing
sugars, for example, the rate of ring opening will dictate the availability of the reactive
aldehyde. Following reaction, the aqueous mixture was extracted with n-butanol three
times, and dried by vacuum centrifugation. The resultant residue was dissolved in
methanol with 0.1% v/v formic acid and analyzed by FT-ICR-MS as a 1:1 mixture with an
external standard. Figure 2.6A and B show representative FT-ICR-MS spectra from such
experiments. Figure 2.6A represents a control condition, *QDA with a standards mixture;
here, the adducts with the four standards are distinct. Figure 2.6B reflects QDAderivatized A549 cell extracts, where the QDA adducts of endogenous pyruvate, αketobutyrate, α-ketoglutarate, and glucose are readily observed, along with several other
adducts. From the exact masses, the molecular formulae of additional observed adducts
were assigned (see figure caption).
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Figure 2.6. Derivatization of carbonyl standards and A549 cell extract. a)
FT-ICR-MS spectrum of *QDA adducts of four carbonyl standards after
partitioning from ammonium acetate buffer into n-butanol: a’ = pyruvate,
b’ = α-ketobutyrate, f’ = α-ketoglutarate, k’ = glucose. b) FT-ICR-MS
spectrum of QDA-derivatized A549 cell extract: a = pyruvate, b = αketobutyrate, c = C7H14O, d = C8H16O, e = C6H10O3, f = α-ketoglutarate, g =
C5H10O5, h = C10H20O, i = C11H22O, j = C9H16O3, k = glucose
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N-butanol was selected as an appropriate extraction solvent both for its high
polarity and for the reportedly low partition of salts such as NaCl and KCl into the solvent
(0.02-0.1 wt % at 25 °C).86 In fact, the partitioning of QDA adducts into n-butanol did
appear to minimize the contribution of non-volatile salts in the final assay solution as
confirmed by our finding that the sodiated peaks of the adducts of spiked carbonyl
standards extracted from A549 cell extract represented, on average, only 0.1% of the total
ion count (H+ + Na+) for a given adduct.

2.3.6. Metabolite identification
As mentioned above, the value of the labeled analog, *QDA, is two-fold: first,
derivatization using *QDA helps verify whether species observed in positive mode FT-ICRMS are genuine carbonyl adducts of QDA as opposed to other n-butanol-soluble cellular
metabolites. “Sister signals” will be apparent in the case of a genuine adduct as a given
pair of adducts represents a carbonyl metabolite that has reacted with both derivatizing
agents.29,

87

Second, isotopic labeling enables quantitative analysis of carbonyl

metabolites in cell extracts, as will be demonstrated shortly for pyruvate, the product of
glycolysis and the entry metabolite of the Krebs cycle.
Figure 2.7 illustrates how *QDA made possible the global visualization of carbonyl
metabolites in a crude A549 cell extract. QDA and *QDA were added in equal amounts
to an aqueous cell extract and carbonyl adducts were extracted as described above. This
resulted in many pairs of adduct signals with comparable ion counts separated by 4.02188
m/z (1x13C + 3x2H). Example QDA and *QDA adduct pairs are delineated in Figure 2.7,
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where the full FT-ICR-MS spectrum (top inset) along with an expanded spectral region
(bottom main panel) are shown. This spectrum was further processed to assign many
likely carbonyl metabolites based on the derived molecular formulae of adducts matched
against a custom database that compiles the molecular formulae of many known carbonyl
metabolites. The adducts identified include α-keto acids of the Krebs cycle (oxaloacetate
and α-ketoglutarate), carbohydrates (erythrose), lipid peroxidation products (eicosanal),
serotonin metabolites (hydroxykynurenamine), nucleotide metabolites (deoxyribose), cofactors (pryidoxal-5-phosphate), and metabolites of glycolysis (pyruvate) and the pentose
phosphate pathway (sedoheptulose). Table 2.2 is an abridged list of the QDA adducts
assigned. Since structural isomers exist for many of these molecular formulae, the
assignments shown here represent the most likely species based on known mammalian
biochemistry. Further interrogation of these structural isomers by tandem MS and/or
separation-based FT-ICR-MS methods is required to fully resolve their identity.
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Figure 2.7. Companion unlabeled and labeled mass peaks reveal QDA adducts of carbonyl metabolites in A549 cancer
cells. The inset depicts the raw FT-ICR-MS spectrum of a QDA + *QDA-derivatized crude A549 cancer cell extract.
Blue and red lines (below spectrum) respectively denote the m/z values of unlabeled and 13CD3-labeled QDA
derivatives, giving a “bar-code” profile of the derivative pairs. The main panel shows an expanded spectral region
from the inset (as depicted by the green box) to more clearly illustrate the companion peaks.
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Table 2.2. Selected metabolites assigned based on Figure 2.7 spectral data

Mass isomer assignments

Molecular
formula

Theoretical
m/z for QDA
adducts

Pyruvate

C3H4O3

DHAP/GAP a

Observed m/z

Mass error

Ion count

343.295519

343.295769

0.00025

905472.8

C3H7O6P

425.277501

425.277999

0.000498

36810.4

Oxaloacetate

C4H4O5

387.285349

387.285619

0.00027

2621.8

D-Erythrose

C4H8O4

375.321734

375.322089

0.000355

22845.9

L-glutamate γ-semialdehyde

C5H9NO3

386.337718

386.338069

0.000351

33337.8

Deoxyribose

C5H10O4

389.337384

389.337689

0.000305

8659.2

α-Ketoglutarate

C5H6O5

401.300999

401.301469

0.00047

193346.3

5-Methylthio-D-ribose
Hexose (ketose and aldose)
Hydroxykynurenamine

C6H12O4S
C6H12O6
C9H12N2O2

435.325104
435.342864
435.369352

435.325029
435.343289
435.370609

-7.5E-05
0.000425
0.001257

2982.9
3235226.3
1106.1

Sedoheptulose

C7H14O7

465.353429

465.353969

0.00054

10502.8

Oxo-dodecanoic acid
S-(3-oxo-3-carboxy-npropyl)cysteine
N-Acetylhexosamine
5-isobutylthioribose
Pyridoxal 5-phosphate
Muramic acid
Octadecenal
Eicosanal

C12H22O3

469.436369

469.437049

0.00068

33371.2

C7H11NO5S

476.315268

476.316249

0.000981

1017.3

C8H15NO6
C9H18O4S
C8H10NO6P
C9H17NO7
C18H34O
C20H40O

476.369413
477.372054
502.30405
506.379978
521.540439
551.587389

476.370119
477.373469
502.304809
506.380799
521.541639
551.588249

0.000706
0.001415
0.000759
0.000821
0.0012
0.00086

291404.4
77115.6
69620.1
3817.1
1657.1
26901.3

a

DHAP: dihydroxyacetone phosphate; GAP: glyceraldehyde-3-phosphate.

2.3.7. Quantification of pyruvate
An accurate quantification of carbonyl metabolites by the QDA method requires
consideration of several factors. Among these are the linearity of instrumental response
to concentration changes, the “ion suppression” (loss of signal intensity) due to the
abundant charged species recovered from crude cell extracts, and the reaction and
extraction efficiency of the derivatizing agent.
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We first verified linear instrumental response using a *QDA-derivatized standards
mixture. Figure 2.8, a scatter plot of ion counts versus concentration, illustrates that the
FT-ICR-MS instrument response was linear in the range from 0.025 to 25 μM for all four
metabolite derivatives. Linear regression parameters are listed in Table 2.3.

Ion count (x10^6)

100

10

1

0.1

0.01
0.01

0.1
*QDA-Pyr

1
*QDA-αKg

10
*QDA-αKb

100

*QDA-Glc

Figure 2.8. Log-log scatter plot of concentration versus ion count for four
*QDA standard adducts. αKg = α-ketoglutarate; Pyr = pyruvate ; αKb = αketobutyrate; Glc = glucose.

*QDA-Pyr *QDA-αKg *QDA-αKb *QDA-Glc
Slope
536847
579435
470851
265815
Intercept 813724
1523225
781273
488369
RSQ
0.97
0.92
0.97
0.96
Table 2.3. Slopes, intercepts, and r-squared values for the linear
regressions of Figure 2.6.

To correct for the effects of QDA reaction efficiency and adduct solvent
partitioning efficiency, an internal standard of uniformly labeled 13C3-pyruvate was spiked
into cell extracts at a series of known concentrations prior to derivatization. For an
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estimate of the ion suppressing effects of the extract matrix, the ion counts of QDApyruvate (endogenous pyruvate) and QDA-13C3-pyruvate (spiked) were normalized by
dividing by the ion counts of an external standard, separately prepared *QDA-pyruvate,
which was added at the same concentration to every sample. Figure 2.9 summarizes the
results. As can be seen, the internal [13C3]-pyruvate standard produced ion counts
significantly higher for the mixture in buffer than for the mixture in cell extracts.
3.5
3

Normalized ion count

2.5
2
1.5
1
0.5
0

2.5

5

7.5

Buffer

2.5

5

7.5

Cell extract

Adduct concentration (μM)
Labeled Pyr

Endogenous Pyr

Figure 2.9. Uniformly 13C-labeled pyruvate spiked at three concentrations
into either buffer (left bars) or cell extract (right bars) and derivatized in
situ with excess QDA. Ion counts were normalized against that of an
external standard of 2.5 μM *QDA-pyruvate. Labeled Pyr = QDA-13C3pyruvate; endogenous Pyr = QDA-pyruvate. Error bars represent one
standard deviation over three injections of a single sample.
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The normalized ion counts of QDA-13C3-pyruvate were then plotted against the
known concentrations of 2.5, 5, and 7.5 µM in buffer conditions and cell extract
conditions, along with linear regressions (Figure 2.10). The ratio of the two slopes of the
linear regressions indicated that there was a cellular extract ion suppression factor of
4.97.

Normalized ion count

3.5
3
2.5

y = 0.3364x + 0.4802
R² = 0.9824

2
1.5
1
0.5

y = 0.0676x + 0.2984
R² = 0.9878

0
2

3

4

5

6

7

8

13C -pyruvate concentration
3

Adduct from buffer

Adduct from cell extract

Figure 2.10. Scatter plot with linear regressions of the normalized ion
counts of QDA-13C3-pyruvate from buffer sample and cell extract sample at
three concentrations, averaged over three injections.

Using these calibrations in a manner consistent with the stable isotope-based
quantitation methodology commonly employed in quantitative proteomics, 88 we
estimated the pyruvate concentration to be 0.4 nanomoles in ca. 625,000 cells or
approximately 106 nmol/g cell wet weight, when cell numbers were calibrated against
cell wet weight. This result is within the reported concentration range for pyruvate in
serum (22-258 μM).89
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2.4.

Conclusions
In summary, we developed a new cationic aminooxy reagent for the selective

derivatization of carbonyl metabolites in aqueous cell extracts. QDA is sufficiently
hydrophobic that its oxime ether adducts can be extracted efficiently into n-butanol for
rapid analysis by FT-ICR-MS. Furthermore, we demonstrated a stable isotope labeling
approach wherein *QDA and QDA were used to generate mass spectral ion pairs
separated by 4.02188 m/z for global profiling of carbonyl metabolites in crude extracts.
The reagent could be easily adapted for multiplex analysis as the presence of two methyl
groups permits the synthesis of 9 isotopologues using variably

13C/D-labeled

iodomethane. When applied to human lung cancer A549 cell extracts, numerous carbonyl
metabolites across multiple structural classes were assigned, including important
metabolites of the central metabolic pathways. Thus, this approach enables both high
sample and information throughput analysis of key components of the overall cellular
oxidation state. Lastly, this approach can facilitate quantification of these often lowabundant and labile metabolites, as exemplified by the analysis of cellular pyruvate. As
such, our chemoselective derivatization approach coupled with high resolution and
sensitive FT-ICR-MS analysis can overcome the difficult challenge of mapping key carbonyl
metabolites as well as cellular oxidation states which may be indicators for the onset of
diseases.
Since this work was disclosed in the journal Metabolomics in 2012, it has been
expanded upon by other researchers in our group. A similar reagent with iodoacetimide
functionality was developed for capture and profiling of thiols, for example, by my
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colleague Sadakatali Gori. We also continue to supply two groups of collaborators with
the reagents QDA and *QDA, for additional profiling of cell extracts, and also for
derivatizing human fluid samples at the University of Louisville’s Diabetes and Obesity
Center. The methodology for the use of QDA has been further optimized in studies by Dr.
Pawel Lorkiewicz who has looked at how changes in pH, temperature, and timing can
achieve better reaction efficiency for specific classes of carbonyls.
Our Metabolomics article was cited by the researchers who developed the photocleavable linker for carbonyl capture described in Chapter 1.30 Their reagent incorporated
an aminooxy group for carbonyl capture, but used biotin to sequester derivatives onto
streptavidin beads for subsequent release by UV light. The critique that Yuan and
coworkers had for our work was that their methodology detected 1784 carbonyl
metabolites, whereas we listed only 31. In fact, the QDA/*QDA derivatization of cell
extracts produced thousands of sister signals in the mass spectra. However, there is a
difference between detection and assignment.

We chose to only report those

metabolites for which a specific chemical formula could be unequivocally assigned based
on the detected exact mass. Additionally, we chose a very conservative threshold (1000
ion counts) to label a signal to be above the level of instrumental noise. As the work that
we disclosed was only the proof of principle for the methodology, we are confident that
the work being done by our collaborators on optimizing the reaction conditions and using
a more sophisticated method for determining signal significance will lead to a broader
and more comprehensive profile of carbonyl metabolites in biological samples.
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3.1.

Externally triggered release of drugs by AMF
The magnetic properties of iron oxide NPs described in chapter 1 highlight their

potential for use in biological applications.

Of particular interest to us was the

phenomenon of inductive heating from exposure to an alternating magnetic field (AMF).
Magnetic fluid hyperthermia, one of the most common medical application of ferrofluids,
takes advantage of only the heating ability of NPs but fails to exploit their potential as
carrier platforms for drugs, tracers, or targeting agents. Our intention in working with
magnetic NPs, was to contribute to recent efforts focused on expanding NP applications
to multipurpose therapies, and, in particular, to combine inductive heating with externally
triggered drug delivery.
Typical NP formulations designed for AMF-triggered release of bound substrates
rely upon a thermally labile mediator. For example, when NPs are associated with
liposomes,90-91 lipid coatings,92 or solid lipid particles,93 temperature elevation triggers
changes in lipid packing and permeability which become the basis for substrate release.
Otherwise, thermosensitive polymers, gels,94 and macrocyclic “nanovalves”95 have also
been used for heat-gated release of drugs from NP platforms.
In developing reagents for external triggering, we aimed for a more
straightforward approach, one in which a drug could be directly bound through an
optimized linker to a NP via electrostatic interactions or hydrogen bonding. We pursued
a binding motif that would be strong enough to stabilize the attachment of a drug onto
the NP surface, but weak enough for AMF-mediated release. To explore the concept, we
prepared a panel of aminooxy functionalized quaternary ammonium salts for attachment
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to a NP surface and, using a fluorophore, probed its AMF release properties. This led us
to do a more fundamental study of the influence of hydroxyl groups and counterions on
the binding of organic molecules to NPs. We then prepared a Dox analog for reversible
attachment to NPs and looked at its release properties as well as its efficacy in vitro.
Inconsistencies in the results led us to consider modifications to the NP surface to
facilitate stronger binding of Dox analogs. A brief exploration of sulfur modified NPs
yielded data that were revealing of the complexity of the iron oxide surface and
peculiarities at the nanoscale.

3.2.

Results and discussion

3.2.1. Preparation of iron oxide NPs
To synthesize iron oxide NPs, we followed a well-established36, 96-97 wet chemistry
approach based on the coprecipitation of iron II and III chloride salts in aqueous base as
described by Mikhaylova et al.98 Transmission electron microscopy (TEM) imaging99 of
particles prepared using this method revealed particle diameters of 5-10 nM. Zeta
potential measurements, which measure the electrophoretic mobility of charged colloidal
suspensions, showed a surface charge of ≈ -32 mV.
Whereas the coprecipitation method intends to produce the magnetite phase of
iron oxide crystal (Fe3O4), it is also well documented that exposure to air and moisture
can lead to oxidation and conversion to γ-Fe2O3 particles.100-102 Washing of the freshly
prepared nanoparticle precipitate with a dilute hydrochloric acid solution is
recommended97 in order to peptize the particles and form a stable colloid and it is
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documented that avoiding this step tends to prevent colloid formation in aqueous media
unless a hydrophilic coating species is introduced in its place.36 We reasoned that rinsing
of the freshly prepared nanoparticle precipitate was likely sufficient to cause substantial
oxidation. Moreover, we found that depending upon how the particles were handled
after precipitation, there were batch-to-batch inconsistencies in the color, texture and
magnetoviscocity of the resultant NPs. Color changes can be indicative of crystal phase
changes,100 so we examined the phase of magnetite generated by our synthetic and
workup procedures.

Crystallography and Mössbauer spectroscopy are commonly

employed to differentiate the two phases, however the data generated from these
methods can be difficult to interpret as the crystal structures of the two phases are
similar, and nanoscale properties may differ from those of the bulk crystal.103 This point
is illustrated in Figure 3.1 which depicts a Mössbauer spectrum of a sample of our NPs
acquired by Dr. Charles Johnson from the University of Tennessee Space Institute. The
black lines (experimental data) are overlayed with reference peaks (red and green lines)
that distinguish the subtle chemical shift differences for Fe3+ in octahedral versus
tetrahedral coordination.
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Figure 3.1. Mössbauer spectrum of NPs prepared by coprecipitation

We quantified the relative proportions of the two crystal phases in our NPs
through a spectrophotometric method104 developed by Amonette and Templeton105 that
enables the quantification of Fe2+ present exclusively in the Fe3O4 phase. During chemical
analysis the synthesized NPs were dissolved in an acid matrix and complexed with iron II
chelator 1,10-phenanthroline.

Absorbance at 510 nm of the digestate allowed

quantification of Fe2+. Further, reduction of Fe3+ in the NP sample using hydroxylamine
allowed for a total Fe determination. Our results for the assay indicated that during the
surface acidification work-up phase dictated by the Mikhaylova procedure, the amount
of Fe2+ decreased and the amount of Fe3+ increased indicating over-oxidation. For
comparison, particles that were washed with neutral water alone were closer in
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composition to stoichiometric Fe3O4. (Table 3.1). In either case, our characterization
established the prepared products as a mixture of Fe2O3 and Fe3O4 phases. And indeed
many investigators acknowledge this phenomenon and choose to report their
preparations as a combination of the two phases.101, 106

Fe2+(weight %)
Fe3+ (weight %)
Neutral rinse
14.8
55.6
Acid rinse
7.7
64.8
Ref. for stoichiometric Fe3O4
24.1
48.24
Table 3.1. Effect of work-up conditions on Fe composition

We also observed a second effect when rinsing NPs, namely neutralization of
surface charge. Figure 3.2 shows that NPs exposed to a single neutral rinse remain
anionic, whereas multiple rinses generate neutral particles, and acid rinses produce highly
positive NPs. Given the greater magnetic susceptibility of Fe3O4 as compared to Fe2O3,
and the better charge pairing of anionic NPs with cationic ammonium salts, we chose to
continue our work with NPs prepared without surface acidification.
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Figure 3.2. ζ-potential measurements of NPs under three work-up
conditions

3.2.2. AMF heating properties
To test the potential of our NPs for heating in the presence of an AMF, several
concentrations of uncoated NPs were prepared in water with 3% alginate. The rationale
for the use of alginate was twofold; first, the bare particles are poorly dispersible in water,
so the alginate provides increased viscosity to maintain suspension, and secondly,
electrolytes are necessary for effective NP-mediated heating of the bulk solution. The
aqueous NP solutions were exposed to AMF for up to 60 minutes while temperature
measurements were made with a fiber optic probe. As can be seen in Figure 3.3, solution
heating was dependent upon NP concentration, and 5 mg NP/mL was sufficient to raise
the temperature of the surrounding solution by 10 °C. Hyperthermia therapy, by
comparison, requires temperature increases of 5-8 °C.107
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Figure 3.3. Change in temperature of water with 3% alginate during AMF
exposure of 201 A, 203 kHz

3.2.3. Fundamental study on the influence of hydroxyl substituents
Our rationale for preparing anionic NPs was ultimately to utilize their charge
properties to noncovalently bind a pharmaceutical agent. In light of this goal, we focused
on developing agent-linkers based on positively charged ammonium salts (i.e., prodrug
modifiers) to promote electrostatic interactions with the negatively charged NP surface.
Secondly, given that the surface of iron oxide supports oxyanions, 59 we also wanted to
demonstrate that hydrogen bonding groups could promote binding of small molecules to
NPs. To systematically investigate the binding impact of hydroxyl substituents, we
synthesized a panel of ammonium salts (and for comparison, a free amine) which varied
by the number and arrangement of hydroxyethyl groups (Figure 3.4). The salts were
prepared by alkylation of tertiary ammonium precursors with iodomethane, generating
iodo salts.
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Figure 3.4. Panel of variably hydroxylated ammonium salts

We also were interested to see the effect of varying the counterion on binding
properties, so the chloride forms of each salt were prepared through ion exchange
methodology. Exchange of iodide for chloride produced little change in the NMR of the
compounds, however exchange was verified in two other ways. In the first method, silver
nitrate was added to aqueous solutions of the ammonium salts and the color of the
precipitated silver halide was observed; silver chloride forms white crystals, whereas
silver iodide forms yellow crystals. MS was also used to verify anion exchange by looking
for a signal representing the mass of dimers of the salts (m = 2 ammonium cations + 1
halide, net charge = +1). For example, the mass of 1OH∙Cl was calculated at m/z
243.18283 and observed at 243.18357, but no iodide dimer was detected.
To quantify the amount of organic material bound to ammonium coated NPs,
thermogravimetric analysis (TGA) was used. The precise weight of the NP sample was
monitored while the sample was heated to 700 °C. Sample weight loss below 200 °C was
attributed to adsorbed water108 and above 200 °C was assigned to the desorption of
bound organic molecules.
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Figure 3.5. A representative TGA of ≈ 6 mg each of NPs coated with variably
hydroxylated ammonium salts (iodide form) and free base amine

The results of the TGA study supported our hypothesis that an ammonium ion
motif having hydroxyl substituents would enhance binding to anionic NPs through both
electrostatic and hydrogen bonding interactions at the NP interface. A representative
TGA depicting the iodo salts can be seen in Figure 3.5; descending lines represent actual
percent weight loss and, for clarity, the derivatives of those lines are overlaid. Figure 3.6
defines the number of bound organic molecules, calculated according to equations
supplied by Galeotti et al.,109 on each of the coated NP formulations. There was enhanced
binding of ammonium salts when more hydroxyethyl substituents were present.
Additionally, the chloride salts proved to be more efficient binders than the iodide salts.
This may have resulted because ion pairs of quaternary ammonium cations with chloride
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are weaker than their iodide counterparts;110 thus displacement of the counter-ion by NP

Molecules per nm2

surface anions may be more readily achieved for the chloride salts.
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Figure 3.6. TGA results of bound panel members (see Figure 3.4 for
structures).

3.2.4. Fluorescein release
From our fundamental study we understood that hydroxyl groups aid in the binding
of small molecules to NPs. As our ultimate goal was AMF mediated release of NP bound
substrates, we needed to determine the degree of binding that would cause ammoniumbased linkers to adhere tightly to NPs under normal conditions, but release from the
particles under AMF exposure. A fluorescent probe was chosen for this purpose as it
would enable spectroscopic monitoring of release as well as function in the capacity of a
drug mimic. To this end, fluorescein isothiocyante (FITC) was modified as shown in
Scheme 3.1 to install an aldehyde functional group for ease of conjugation with aminooxy
functionality.
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Scheme 3.1. Reagents and conditions: (a) 4-aminobutyraldehyde
diethylacetal (1.2 eq), dimethyl-formamide, rt, 4 h (b) 30% aq. acetic acid,
3h, 55% (2 step)

Next, three quaternary aminooxy (QAO) salts (Figure 3.7) were prepared for
conjugation with the FITC aldehyde (FITC-CHO). The first, designated QAO, was prepared
by phthalimide protection of the alcohol dimethylethanolamine. Methylation with
iodomethane produced the quaternary amine and hydrazinolysis cleaved the phthalimide
to an aminooxy. QAO-2OH was prepared by first protecting two of the alcohols on
triethanolamine with silyl groups, then proceeding with the phthalimide protection and
methylation as before, and finally deprotecting the alcohols to achieve the final bishydroxy product (Scheme 3.2). A 1H NMR expansion showing the methylene protons of
QAO-2OH reveals the 4:2 integrations anticipated for the difunctional molecule (Figure
3.8). QAO-OH was prepared by my colleague Xuan Huang.111
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Figure 3.7. QAOs with variable hydroxyl substituents

Scheme 3.2. Synthesis of QAO-2OH. Reagents and conditions: (a) TBSCl,
Et3N, CH2Cl2, 0 °C-rt, 8h, 13%; (b) N-hydroxyphthalimide, PPh3, DIAD, THF,
0 °C-rt, 12h, 81%; (c) CH3I, CH2Cl2, 50 °C, 6h (d) H2NNH2 monohydrate,
EtOH, rt, 12h, 91% (2 steps); (e) TBAF (1.1 eq), THF, CH2Cl2, 0 °C-rt, 1.5h,
73%
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Figure 3.8. 1H NMR expansion of methylene region of QAO-2OH in D2O

Using a stepwise approach, the three QAOs were first coated onto the NPs followed
by addition of FITC-CHO. The resultant oxime ether adducts, FITC-I, II, and III, are pictured
in Figure 3.9. As a negative control, FITC-CHO was added to bare NPs as well. The coated
NPs generated by this method were then magnetically separated, washed to remove
loosely bound fluorophore, and exposed to AMF (201.4A, 203 kHz, 30 min) to induce
QAO•FITC conjugate release. After magnetic separation, the supernatant solutions were
collected, and fluorophore release was detected by fluorescence HPLC. Prior to this,
excitation-emission spectra were acquired on the FITC adducts to verify that QAO linkers
did not significantly alter the fluorescent properties of the probe: deviations in excitation
maxima varied by less than the excitation beamwidth of the fluorescence detector, and
the emission maxima were unaffected by the structural modifications.
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Figure 3.9. Cationic aminooxy-based oxime ether conjugates of FITC-CHO

The results of this initial screen revealed that the negative control showed
negligible fluorescence after AMF exposure; thus, no retention of FITC-CHO on NPs in the
absence of an aminooxy linker. However, under identical conditions, the NP•FITC-II and
NP•FITC-III formulations showed an increase in supernatant fluorescence after AMF
exposure indicating release of the conjugates in response to the external stimulus (Figure
3.10). The FITC-I adduct peak, however, could not be resolved from unreacted FITC-CHO
in the HPLC run. These results suggested that the hydroxyl motif was important for

Relative fluorescence

retention of drug surrogates prior to AMF induction.
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Figure 3.10. Fluorescence intensity of sampled solutions of three
formulations of coated NPs
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3.2.5. Doxorubicin oxime ether analogs
The model fluorescence study of FITC analogs had supported the idea that AMF
could be used to free noncovalently bound species from the surface of NPs.
Consequently, we set out to prepare a NP platform with an attached anticancer drug,
doxorubicin (Dox, Figure 3.11). As mentioned in the introductory chapter, Dox is a potent
chemotherapeutic agent that, in the absence of a targeting agent or nanocarrier, exhibits
nonspecific toxicity. The C-13 carbonyl is a convenient reactive partner for a QAO-based
aminooxy linker. Thus, we aimed to demonstrate in an in vitro model how iron oxide NPs
could be used to deliver modified doxorubicin to cancer cells in response to AMF
induction. To simplify the strategy, we altered our methodology to a direct rather than
stepwise loading route; we chose for the Dox studies to first generate, purify, and
characterize Dox-QAO adducts and then attach the adducts directly onto NPs. Two Dox
analogs were prepared using QAO-OH and QAO-2OH (Figure 3.6). Since chloride salts
were found to bind more effectively than iodide salts in the fundamental study of
hydroxylated QAOs, the QAO-Dox conjugates were converted to chloride salts for these
studies. The Dox analogs Dox-OH and Dox-2OH (Figure 3.11) were characterized by NMR
and high resolution mass spectrometry (Figure 3.12) to confirm the formation of the
desired oxime ether conjugates.
Upon loading the Dox analogs onto NPs by stirring in DMSO, a color change in the
solution from red (the color of Dox∙HCl) to purple was noted. This may be the result of
the formation of an Fe2+ 112 or Fe3+ complex113 as these species have been documented to
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occur and are associated with purple colors. After rinsing to separate unbound Dox
analogs, TGA indicated 7.51 weight percent organic material for both species.

Figure 3.11. Unmodified doxorubicin hydrochloride (Dox) and mono- or dihydroxylated oxime ether conjugates

Figure 3.12. FTMS spectrum of Dox-2OH showing the calculated exact mass
and the observed peak

3.2.6. AMF release profiles
AMF induction of magnetic fluids in living tissue has limitations; nonspecific tissue
heating can lead to tissue necrosis. Pulsed AMF, however, has been employed in mouse
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models to avoid this problem.114 We looked at the release profiles of Dox-OH and Dox2OH during pulsed AMF exposure over one hour. In this study, an aqueous solution of
Dox analog-coated NPs received AMF pulses (203 kHz, 350 A, rt) at five minute intervals
with intervening five minute incubations at 30 °C. The NPs were then magnetically
sedimented and the solution phase absorbance was measured by UV-Vis spectroscopy at
480 nm (the maximum absorbance for Dox) to measure drug-analog release. The
responsiveness of the Dox analogs to AMF induction can be seen in the time course in
Figure 3.13 in which the yellow bars indicate AMF “on” time. Although Dox-OH exhibited
greater release overall, Dox-2OH release was more closely associated with AMF
stimulation; absorbance for Dox-OH rose steadily during AMF pulses as well as during
intervening incubation, whereas Dox-2OH showed an increase in absorbance primarily for
AMF on times, and flat absorbance during the intervening incubation periods. This
increased AMF responsiveness for Dox-2OH may be attributable to a more proximal
interaction with the NP surface (facilitating AMF-induced energy transfer), presumably
due to the presence of an additional hydrogen bond donor. By comparison with a
calibration curve, the 60 minute endpoint corresponded to 15 µM Dox-OH and 11 µM
Dox-2OH. Comparison with TGA data suggested this represented only 4.5 or 5.9% of
payload release for Dox-OH and Dox-2OH respectively, however absorbance declined
after further incubation at 30 °C indicating reattachment of the linker to the NP (likely an
equilibrium phenomenon); additionally, in our experience TGA can overestimate loading.
The better test for release, we reasoned, would be a non-equilibrium system, one in
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which released Dox analog could be removed from proximity to the NP before
readsorbance could occur, specifically, a living system.

Figure 3.13. UV-Vis detection of Dox analogs released from Dox-NPs by
pulsed AMF (203 kHz, 350 A, rt) as indicated by absorbance at 480 nm of
the solution after magnetic separation of the particles. Error bars
represent +/- 1 standard deviation for triplicate samples.

3.2.7. In vitro studies
A pilot study conducted by my colleague, Dr. Souvik Biswas, on MCF-7 breast
cancer cells had generated promising results using NPs conjugated to the iodo form of
Dox-OH. 99 The key findings of his study were an initial demonstration of low toxicity for
bare NPs, and high toxicity for NP-Dox-OH formulations upon AMF exposure. Most
exciting was the finding that the drug analog displayed very low toxicity in its bound state,
but high toxicity upon release, effectively functioning as an inactive pro-drug until
external triggering with AMF—a promising scenario. We hoped that the new analogs,
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with chloride counterions and, in the case of Dox-2OH, an additional hydrogen bond
donor, could surpass the efficacy of the first generation analog. We also hoped to
overcome a challenge encountered with the first generation Dox-OH of premature drug
release upon incubation at body temperature (≈14 % payload loss).
To test the NP-Dox formulations in vitro, MCF-7 breast cancer cells were cultured
and plated into either 35 mm dishes or a 96 well plate modified to fit within the AMF coil.
NP-Dox formulations were typically administered by suspending the NPs in PBS and
adding the solution to cells in medium. Half of the cells would then be exposed to AMF
(350A, 203 kHz, 3 min on, 3 min off pulses, 30 min total time) by placing the culture dish
within the coil of the AMF generator. During pulsed AMF application, cells were
incubated at 37 °C between pulses. Cells would then be incubated with treatments for
24 hours after which toxicity would be assayed by trypan blue exclusion and counting of
living cells using a hemocytometer.
The toxicity studies presented a number of challenges. As the synthesis and
loading of NPs involved a great deal of processing, reproducibility in the toxicity
measurements was poor. Small differences in loading concentrations or post-loading
washes of the NPs could produce particles with differing amounts of bound drug.
Formulations with a lower coating of Dox were more prone to aggregate in PBS buffer
resulting in uneven application to cells. As a result, the toxicity studies were highly
variable. In a representative toxicity study (Figure 3.14) some effects were consistent
between the first generation drug trial and the latter one. For example, AMF alone did
not produce significant cell death, nor did bare NPs induced by AMF cause cell death. In
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addition, the NP-Dox-OH formulation did demonstrate a modest degree of toxicity
exclusively when AMF was applied. Unfortunately, the NP-Dox-2OH formulation gave an
undesirable result showing minor toxicity with or without AMF.

Living cells (1000s)
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Control

NPs

NP-Dox-OH

No AMF

NP-Dox-2OH

AMF

Figure 3.14. Toxicity of NP-Dox formulations and controls on MCF-7 breast
cancer cells for cells grown in a 96 well plate to 40% confluence and treated
with 12.3 µg/well NP-Dox formulations. Error bars reflect standard error
over biological triplicates. NP-Dox-2OH data reflect the average of
biological duplicates.

Reproducibility in trials of a NP-mediated drug carrier is crucial for establishing the
practical utility of the system. And given the multi-step preparations involved with NP
formulations, the components of the system must be robust with predictable
interactions. Since our modifications to Dox in this approach led to disappointing results
in regard to toxicity, we began to consider modifications to the NP side of the drugnanocarrier interface — how could the surface of the iron oxide NP be altered to actuate
the desired drug delivery strategy?
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3.3.

Sulfur-modified NPs

3.3.1. Dextran sulfate NPs
A quaternary ammonium cation is a large, diffuse positive charge. We reasoned
that a size-matched large anion on the NP surface could elicit a stronger electrostatic
interaction with a QAO than the Fe-O-/OH- of the bare particle.115 In our first effort to
modify the NPs, we elected to change the anion at the Fe 3O4 surface to a sulfate. We
selected dextran sulfate as a coating agent to modify our NPs because dextran, a sugar
polymer, was already a common coating reagent for NPs.
After coating NPs with dextran sulfate, QAO-2OH conjugated to an anthracene
fluorophore (Figure 3.15) was added.

The release properties under AMF of this

chromophore were then measured by UV-Vis. As is shown in Figure 3.16, unfortunately
the formulation exhibited slow leakage of the anthracene analog both in the presence
and absence of AMF exposure.

Figure 3.15. QAO-2OH anthracene derivative
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Figure 3.16. AMF-mediated release of anthracene derivative (rt) versus
incubation at 37 °C

3.3.2. CS2-modified NPs
The next strategy we examined for modifying the NPs was to incorporate xanthate
functionality (ROCS2-M+) at the iron oxide surface with an eventual aim to pair the
constituent dithiocarboxylate anion with a QAO. Xanthates are typically prepared from
reaction of an alcohol with carbon disulfide in the presence of base, but we wondered if
reaction of iron oxyanions with CS2 might generate an analogous ferric xanthate (Figure
3.17). Some precedent for this concept is found in the adsorption of carbon disulfide and
carbonyl sulfide (O=C=S) onto iron oxide.116-117 In fact, hydrated iron oxides are employed
industrially as scrubbers for volatile sulfurous compounds generated during coke fuel
production.118 Though these triatomic species are known to bind to iron oxide, they have
not been applied to NP surface modifications as potential functional organic coatings.
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Figure 3.17. Traditional xanthate preparation and ferric xanthate variant.

To ascertain what functional transformations could be made on the surface of the
NP, we used the strategies summarized in Figure 3.18. Carbon disulfide was reacted with
bare NPs 1 to produce product 2. The zeta potential of 2 remained negative (bare NPs: 35.9; CS2-coated: -29.3), indicating either no reaction or the formation of a sulfanion.
There were indications that some type of reaction had taken place because the color and
texture of the NPs changed upon coating, and off-gassing was noted after CS2 addition
and workup (rinsing and drying the NPs). Further, an IR of the product in comparison with
bare NPs 1 showed the emergence of two new peaks in the fingerprint region at 1231 and
1212 cm-1.
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Figure 3.18. Strategies for incorporating organics onto sulfur-modified
NPs.

The CS2-modified NPs 2, were then reacted with either deuterated iodomethane,
to cap the sulfanion with a methyl group, or they were mixed with deuterated ammonium
salt 3 to test their potential for electrostatically binding substrates. Deuterated reagents
were selected in the hopes that attenuated total reflectance IR (ATR-IR) of the NPs on a
germanium crystal could detect the C-D stretching vibrations of the products, as this
vibration occurs in an otherwise sparse region of the IR spectrum (2075 cm-1).
C-D stretches for compounds 6 and 7 were not observed, however surface
changes were evident using other characterization techniques. Figure 3.19 shows the
results of elemental analysis (EA) that gives the weight percent of carbon, hydrogen, and
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sulfur for NPs 1, 2, 8, and a control prepared by addition of iodomethane to bare NPs 1.
The values displayed in the graph represent the weight percent of each element divided
by its molecular weight to give relative moles of each element. Of course, the bulk of the
weight of these NP formulations is iron and oxygen which are not represented in this
graph. EA revealed an increase in the sulfur content of NPs 2 as compared with bare NPs
1, but surprisingly no increase in the carbon content. EA of 8 showed an increase in
carbon content, but not the 3:1 ratio of H to C that would be expected for methyl group
addition. Meanwhile the sulfur content decreased for compound 8. Most surprisingly,
the negative control showed an increase in carbon content implying retention of
iodomethane (b.p. 40 °C) on bare NPs, despite 24-48 hours under vacuum.
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Figure 3.19. Elemental analysis of NPs formulations from Figure 3.18
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TGA also demonstrated high electrostatic binding properties for the CS 2-modified
NPs. TGA of NPs 6 showed a large amount of bound ammonium salt 3 compared to a
control of bare NPs 1 with the same salt (Figure 3.20). The weight loss curves were
integrated above 200 °C to exclude weight loss due to adsorbed water from the
calculation.

Figure 3.20. TGA curves for select NPs from Figure 3.18

Presuming formation of methyl xanthate 8, amines 2 and 3 were prepared in the
hopes of forming more stable thiocarbamates (ROC(=S)NR2) 9 and 10 by displacing
methane thiolate. IR of 9 revealed aromatic C-C stretching vibrations, C-H stretching, and
a peak at 1036 cm-1, close to the reference peak for C=S of 1050 cm-1. And MALDI-TOFMS of 9 detected a peak at m/z 108, the mass of the protonated form of 3 (108.08).
Compound 10 showed the greatest change in morphology with NPs turning from brown
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to beige after coating. TGA validated the heavy loading on NPs 10 indicating 28.6 weight
percent of bound organic.
We wondered how the CS2-modified NPs would compare to unmodified NPs in
affinity for hydroxylated ammonium salts. Using the earlier study as our model, we mixed
CS2-modified NPs 2 with the variably hydroxylated ammonium salts from Figure 3.4. As
can be seen from Figure 3.21, we did not observe the same trend for greater binding with
increased hydroxylation, nor did the counterion have the same effect. Strangely, the
chloride salts appeared to displace some of the bound CS2.
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Figure 3.21. Weight % of bound organics based on TGA of CS2-modified
NPs with variably hydroxylated ammonium salts.

Although we were intrigued by the properties of the CS2-modified NPs, there was
a lack of clarity as to the exact nature of its interaction with the NP surface. Prior to these
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experiments, we had conceived of the NPs as passive platforms for adsorbing organics,
but the unexpected results of the EA in particular indicated a surface reactivity or catalytic
activity that we had failed to appreciate. A deeper look into the literature on the
interaction of iron oxide with species like CS2 confirmed this reactivity. Wang et al., for
example, identified oxidation of CS2 on iron oxide atmospheric particles to carbonyl
sulfide (COS).119 In fact, this is something we had observed with our own NPs; GC-MS of
the headspace during off-gassing of CS2-modified NPs had shown a mass corresponding
to COS. And neither is such catalysis exclusive to CS2. Chen and coworkers found
oxidation of COS to CO2 on hematite, another form of iron oxide. The proposed
mechanism is given in Figure 3.22.120 Dissociative chemisorption of carbon dioxide on iron
oxide has also been proposed.121 Even room temperature water splitting has been
observed on the surface of magnetite.122 These phenomena would eventually lead us to
a rethinking of attachment of sensitive molecules to NP surfaces. Rendering the surface
more inert would become a priority.
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Figure 3.22. Proposed mechanism for oxidation of COS to CO2 on
hematite. Reprinted with permission from Environ. Sci. Technol. 2007, 41
(18), 6484-6490. Copyright 2007 American Chemical Society.

In our final investigation into sulfur-modified NPs, we turned our attention to an
entirely different route for putting sulfur on the surface, one that makes sulfur an intrinsic
component of the NPs themselves.
3.3.3. Greigite NPs
Iron sulfide, Fe3S4, or greigite, shares many properties with its cousin, Fe3O4. Like
magnetite, it has a spinel crystal structure and is magnetic. Greigite NPs can be prepared
from an acidified mixture of iron II sulfate and sodium sulfide as described by Chang and
colleagues.123
To assess whether the presence of sulfur anions as opposed to oxyanions at the
particle surface could enhance adsorbance of quaternary amines, akin to the CS2modified NPs, we prepared greigite NPs and coated them with the QAO-2OH anthracene
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derivative pictured in Figure 3.15. TGA of the isolated product (Figure 3.23) showed that
iron sulfide, like iron oxide, could bind ammonium salts.

Figure 3.23. TGA showing percent weight lost from bare Fe3S4 NPs or QAO2OH anthracene-loaded particles.

AMF release properties of the anthracene adduct from the Fe 3S4 NPs were then
assessed by UV-Vis at 384 nm, however no increase in solution absorbance relative to
incubation at 30 °C was observed. When the heating properties of Fe 3S4 NPs were
examined it was discovered that the greigite NPs did not heat significantly upon exposure
to AMF, likely the culprit for the absence of release.
It was at this point that we decided to retool our strategy for binding organics to
NPs. Iron oxide had proven the more efficient material for the sake of AMF heating, so
we would return to that architecture, but the surface reactivity would need to be
neutralized by coating with a more inert material. As discussed in the next chapter, we
would turn to silica coating to serve this purpose.
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4.1.

Composite NPs: silica on iron oxide
Modifications to the surface of iron oxide NPs are often required to generate

stable aqueous colloids and to render the catalytically active119, 121 surface inert for the
sake of ligand/drug stability.

Silica coating also allows for functional group

interconversion to a variety of other functionalities including alkyne, azide, carboxyl,
nitrile, phosphate, and thiol.124 To this end, coating NPs with silicon dioxide is commonly
employed, particularly for multi-component nanosystems.125 Creating a core-shell Fe3O4SiO2 structure is desirable because the silica shell enhances the hydrophilicity of the
particles and reduces cellular toxicity,126 while largely preserving their magnetic
properties.127 Moreover, as silicon is a metalloid, rather than a metal, the composite
structure has a less reactive surface than iron oxide.
The surface of silica-coated NPs (SNPs) is inherently negatively charged due to the
presence of silanol groups, but positively charged particles may be more desirable for
oncological applications considering the favorable pairing of cationic particles with the
negative exterior of many cells, including cancer cells.128-129 Further, a self-assembly
process for formation of a therapeutic nanosystem is desirable since ultimate broad
application would depend upon its ease of preparation.
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4.2.

Cationic magnetoliposomes
Dual-chain lipids, typically zwitterionic phospholipids, have been used to coat NPs

and have been shown to self-assemble into bilayers surrounding anionic NPs forming
what are termed classical magnetoliposomes.130 In that the lipid is directly bound to the
particle surface, these constructs differ from extruded magnetoliposomes that are
composed of NPs entrapped within the aqueous core of a lipid vesicle. 131

Direct

attachment of lipids at a NP surface offers the advantage of size control. Namely, the size
of the magnetopliposome is dictated by the dimensions of the NP, a tunable property.
Thus classical magnetoliposomes are usually smaller (<100nm) than their extruded
counterparts.131 In addition, the preparation of extruded liposomes generally requires
more involved techniques, such as sonication or freeze-thaw cycling. Positively charged
magnetoliposomes, termed “cationic magnetoliposomes” (CMLs), are typically formed
from a mixture of zwitterionic phospholipids, cationic aminium lipids, and neutral lipids.
Marcel De Cuyper and Stefaan Soenen have studied such cationic magnetoliposomes 132
extensively, elucidating their cellular interactions, toxicity, and cell-labeling potential.133140

Cationic lipids containing a quaternary ammonium headgroup, and thus a
permanent positive charge, are known in the context of gene transfection to promote
rapid cellular uptake when complexed with nucleic acids in a “lipoplex”. Their high charge
density encourages association with cell membranes and facilitates endocytosis.141-142
This capacity has also been exploited in concert with NPs in the practice of
magnetofection where cationic lipid-coated NPs have been explored as magnetic gene
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vectors.141,

143-144

As the surface of SNPs, like iron oxide, is anionic, we envisioned

constructing a CML that could auto-assemble by simple mixing of a custom quaternary
ammonium-based lipid and SNPs.
We aimed to prepare a self-assembling CML-SNP tailored for biological
applications with suitable size and charge character for efficient cellular internalization.
To demonstrate the potential of the system as a nanocarrier, we prepared an amphiphilic
derivative of Doxorubicin (Dox) for incorporation into the CML bilayer. We envisioned
that mixing of SNPs, our custom cationic lipid, and the Dox analog would produce a CMLSNP drug carrier (Figure 4.1).

Figure 4.1. Cationic magnetoliposome with a core-shell iron oxide-silica NP
surrounded by a cationic lipid bilayer and a bilayer-embedded amphiphilic
drug

4.3.

Results and Discussion

4.3.1. Cationic oxime ether lipids
Traditionally, lipids are constructed with ester linkages that tether hydrophobic
and polar domains. In conceiving of a lipid to coat SNPs for Dox delivery applications, we
turned to oximation for lipid construction. By mixing an aminooxy headgroup with
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aldehyde tails of the desired chain lengths and unsaturation, a wide variety of oxime ether
lipids can be prepared. 141, 145
The panel of oxime ether-based cationic lipids we synthesized for loading onto
SNPs were designed with quaternary ammonium headgroups as the permanent positive
charge ensures that pH changes in the particle environment will not alter the electronic
character of the lipid. Building on our work with hydroxylated QAOs and Fe 3O4 NPs, we
also added hydroxyl functionality to the lipid headgroups to encourage association with
the hydrophilic surface of the SNPs. Hydroxyl groups have also been shown to enhance
cell membrane interaction.146
Three lipids were prepared (Scheme 4.1 and Figure 4.2) with varying chain lengths
(C12, C14, and C18) by reaction of aminooxy 4.1 with 2 equivalents of aldehydefunctionalized alkyl chains. The bis-oxime ether adducts (4.2-4.4) were formed as
mixtures of E,E, and E,Z isomers and were not typically isolated as separate
diastereomers. In Figure 4.3 the 1H NMR triplets for the oximyl protons in E and Z
configurations are shown for a representative lipid. The dissymmetry provided by
incorporation of the (E,Z)-containing lipid fraction likely will contribute to the formation
of more fluid lipid bilayers as it prevents tight lipid packing.
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Scheme 4.1. Conditions: a. N-hydroxyphthalimide, PPh3, DIAD, 0 °C to rt,
12h; b. N2H4∙H2O, CH2Cl2, rt, 2.5h (16%, 2 steps); c. corresponding dodecyl,
tetradecyl, or oleyl aldehyde, CH2Cl2, rt, 10h (47-71%); d. TFA, CH2Cl2, 0 °C
to rt, 3h (91-100%); e. glycidol, EtOH, rt, 60h (38-41%); f. CH3I, CH2Cl2
(sealed tube), 55 °C, 5h (63-64%).

Figure 4.2. Cationic oxime ether lipids
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Figure 4.3. 1H NMR expansion showing oximyl proton shifts for E and Z
configurations of lipid 2

To add hydroxyl functionality to the lipid headgroup we turned to nucleophilic
addition of the amines generated from step d of Scheme 4.1 to the C-3 carbon of glycidol
(Figure 4.4) as a strategy for installing a 1,2, diol functionality.147 Normally the reaction is
performed at elevated temperatures, with an excess of amine, or catalysts such as lithium
perchlorate.148-149 Kuwabe et al.,150 for example, reported addition of a secondary amine
to glycidol after 48 hours refluxing in ethanol. However, a recent report of room
temperature reaction of secondary amines with glycidol in water148 piqued our interest.
As our starting material was not soluble in water, we instead used ethanol. Reaction of
bis-oxime ether secondary amines with glycidol in ethanol (rt, 24h) was successful in
yielding 1,2 diol substituted tertiary amines. A representative FT-MS spectrum is depicted
in Figure 4.5.
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Figure 4.4. Nucleophilic addition of a secondary amine to C-3 of
glycidol

Figure 4.5. Calculated exact mass of 4.6 and FTMS spectrum of the
observed mass

4.3.2. Preparation of Dox-AH
Model drug, Dox, can be modified at the C-13 carbonyl group through
condensation with a hydrazide, to from an acyl hydrazone. In this way, the lipophilicity
of an otherwise highly hydrophilic drug is increased, better suiting it for incorporation into
a lipid bilayer.
Several examples of Dox C-13 hydrazones have been documented in the literature.
Effenberger et al.151-152 prepared Dox hydrazones using C17 and C18 fatty acids and
menthyl/bornyl esters. The cytotoxic efficacy of these analogs and mechanism of cell
death were investigated in several cancer lines, and in many cases the derivatives were
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more effective than the native form. Particularly interesting was the efficacy against
multidrug resistant cells, possibly a consequence of superior diffusion of the analogs
through cellular membranes.153 Maleimide substituted acyl hydrazones of Dox have also
been prepared and demonstrated to be practical derivatives, such as aldoxorubicin,
currently in phase II clinical trials.154-155 Consequently, to adjust lipophilicity, we prepared
a C-13-hydrazone (Scheme 4.2) by reaction of Dox with hexadecanoic acid hydrazide in
the presence of an aniline activator156 to obtain Dox acyl hydrazone Dox-AH. Hydrazone
formation was verified by 13C NMR where the disappearance of the C-13 carbonyl peak at
213.6 ppm was noted along with the appearance of a peak at 152.2 ppm (Figure 4.6). This
ppm shift is comparable to that reported for a similar Dox hydrazone.154

Scheme 4.2: Preparation of Doxorubicin hexadecanyl acyl hydrazone, DoxAH
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Figure 4.6. Stacked 13C NMR of Dox (upper) and Dox-AH (lower), showing
emergence of the C-13 hydrazone chemical shift

4.3.3. CML formation and stability
To evaluate the formation and stability of CMLs, SNPs were stirred with cationic
lipids 1, 2, or 3 in DMSO. Particle size was monitored over 24 hours mixing time by
measuring dynamic light scattering (DLS). Lipids 2 and 3 with 14 and 18 carbon chains,
respectively, did not form compact, stable CMLs (see appendix). However, lipid 1 with
saturated C12 chains, formed small, stable CMLs averaging 67 nm in hydrodynamic
diameter (Figure 4.7) and positive surface charge as indicated by zeta-potential of 31.72
+/- 2.40 mV. Consequently, lipid 1 was selected for use in subsequent studies.
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Figure 4.7. Dynamic light scattering measurements of CML diameter. The
data represent direct measurements of a mixture of 13 µmols lipid 1
(Figure 4.2) with 1 mg SNP in 2 mL DMSO taken over 24 hours mixing time.

4.3.4. Titration of SNP with cationic lipid 1
To determine the amount of lipid sufficient to coat SNPs with a bilayer, an aqueous
solution of SNPs was titrated with increasing amounts of lipid 1 and the change in surface
charge, as indicated by zeta-potential, was measured to determine a saturation point. A
log-log plot of the data generated a sigmoidal curve with a plateau indicative of saturation
of the particle (Figure 4.8). This zeta potential plateau represents approximately 28005700 lipid molecules per SNP (see appendix for calculation).

In subsequent CML

formulations, we aimed for a lipid amount just sufficient to reach the onset of the positive
plateau of the charge titration curve to avoid using excess lipid. In the case of extruded
MLs, a ratio of 4-13 mmol lipid/gm NPs is required to reach NP encapsulation efficiencies
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of >70%.157 By comparison, the charge titration curve for CML formation indicated that
significantly less lipid is required, 0.2-0.5 mmol lipid 1/gm SNP.
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Figure 4.8. Zeta-potential of SNP titrated with lipid 1 in water.

4.3.5. Estimation of lipid: Dox-AH ratio
To determine the amount of Dox-AH to add for co-loading with lipid 1 onto SNPs,
we examined the DLS of liposomal formulations of varying molar ratios of the two
amphiphiles. We presumed that smaller liposomes would be indicative of tighter packing
and greater stability.

Liposomes were prepared using thin film hydration with

sonication.158 DLS measurements were taken for each solution in water. Figure 4.9 shows
the plot of the percent of Dox-AH added versus the diameter of the liposomes. From the
data it was estimated that a Dox-AH percent less than 30 should be used for the sake of
membrane stability.
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Figure 4.9. Diameter versus percent Dox-AH in a liposomal formulation
with lipid 1.

4.3.6. Cytotoxicity study
Having established effective conditions for CML formation, we next examined
incorporation of Dox-AH into CMLs to assess in vitro efficacy against MCF-7 breast cancer
cells. Dr. Geoffrey Clark, a collaborator at the University of Louisville Medical School,
kindly provided the use of his facilities, resources, and the assistance of his postdoctoral
student, Dr. Katharine Hobbing, for this work.
Dox-AH-loaded CML were prepared by making a thin film of a 3:1 mixture of lipid
1 and Dox-AH. An aqueous dispersion of SNPs then was added to the lipid/Dox-AH film
and the mixture was stirred for 12 hours to form loaded CMLs. Aliquots containing 50 μg
CMLs were diluted by 10% with 10x PBS and the formulation was added directly to cells
in growth medium (serum supplemented DMEM). Control conditions using separate
constituents of the complete formulation were prepared similarly, including, as a positive
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control, aliquots of Dox and Dox-AH alone at 4 times the dose of the CML drug complexes.
After 2h incubation with treatments at 37 °C, the medium was removed and replaced with
fresh medium. Cell viability (Figure 4.10) was assayed by trypan blue exclusion after 48
hours incubation. SNPs alone showed very low toxicity, as expected. Lipid 1 was
somewhat cytotoxic but much more so when delivered in the form of CMLs, presumably
a consequence of higher intracellular incorporation when associated with a cationic
particle that is rapidly internalized. This carrier-mediated cytotoxicity, likely a result of
cell membrane destabilization by intercalated cationic lipids, is undesirable, and future
studies will examine how the effect can be mitigated. Nevertheless, the most potent
formulations were the drug-loaded CMLs (both Dox and Dox-AH analogs), killing over 90%
of the cells. It is noteworthy that the positive controls of Dox and Dox-AH alone displayed
lower toxicity than the CML-drug complexes, despite being added at four times higher
dose, again suggesting efficient CML internalization and thus intracellular accumulation
of the cytotoxic cargo. To our surprise there was no significant difference between the
cytotoxicity of Dox-AH CMLs and Dox CMLs. We had anticipated that the lipophilicity
imparted by the added C16-acyl hydrazone would be necessary for CML-mediated
conveyance of Dox into the cells.
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Figure 4.10. Cytotoxicity of treatment formulations in MCF-7 cells as
indicated by trypan blue exclusion. Uncoated particles (SNP), Lipid 1 alone
(Lipid 1), Lipid 1-coated SNP (CML), Dox-AH alone *administered at 4X
higher drug dose than Dox-AH CML (Dox-AH), Dox alone *at 4X higher drug
dose than Dox CML (Dox), Dox-AH-loaded CML (Dox-AH CML), and Doxloaded CML (Dox CML). Error bars represent standard error over biological
triplicates.

To determine the degree to which the modification of Dox to acyl hydrazone DoxAH altered the drug-CML formulation as a whole, we turned to fluorescence imaging. Dox
has a strong emission at 580 nm, so fluorescence microscopy can be used to trace it within
cells. Two hours after incubating MCF-7 cells, as above, with CML formulations containing
either Dox-AH or Dox, fluorescence images were taken. The acquired images are paired
with their bright-field counterparts in Figure 4.11. The more intense fluorescence was
seen for the Dox-AH CML, so although the two drug-loaded CML function nearly
identically with respect to toxicity, there is an apparent difference in the nature of their
internalization. We hypothesize that Dox adsorbs to the SNP surface during CML
formation via electrostatic interaction/hydrogen bonding from its ammonium sugar
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moiety and thus benefits from the uptake enhancement conferred by the CML, but suffers
from greater fluorescence quenching due to its tighter association with the SNP.
Dox●HCl CML

Dox-AH CML

Figure 4.11. Stacked bright-field (lower) and fluorescence (upper) images
of MCF-7 cells after two hours treatment with (left) Dox-AH-loaded CML,
and (right) Dox-loaded CML. Scale: 200 µm.

Although unanticipated, we were gratified to find that CML formulations
increased the efficacy of both hydrophilic and amphiphilic forms of our model drug. Still,
for the purpose of Dox delivery by CML, an acyl hydrazone modification may yet be
advantageous since Dox hydrazones have been shown to be more effective against
multidrug resistant cell lines.
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4.3.7. AMF and bilayer disruption
A few investigators have examined the application of AMF to lipid-coated NPs for
achieving substrate release. Hsu and coworkers, for example, prepared “solid lipid”
nanostructures with embedded NP.

They were constructed with a lipid core of

triglyceride and an encapsulating polymeric surfactant.

Embedded within the

hydrophobic interior were NPs and a model drug. Application of AMF at 25 kHz for 20
minutes resulted in release of 35% of the embedded drug.93 Similarly, Bringas et al.92
reported AMF-mediated release of a dye from a lipid-coated SNP system. In this work,
NPs were capped with mesoporous silica into which the dye methylene blue was
incorporated. The mesoporous silica was then coated with a lipid bilayer consisting of
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC). They observed full release of the dye
after AMF exposure at 50 Hz for 350 minutes. These reports encouraged us to think that
AMF application might be used to induce Dox release in our CML system. However
several toxicity trials failed to show a difference in cell survival for treatment conditions
that incorporated AMF exposure. The studies mentioned previously differ from our
system in that the AMF frequency used was lower than our own, which is fixed by the size
of the coil on our generator. Additionally, both involve structures that contain multiple
NPs. We theorize that these factors may have lessened the impact of AMF exposure on
substrate release in our system.
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4.4.

Gene transfection studies
As noted in the opening of this chapter, cationic lipids are commonly utilized as

synthetic gene vectors owing to their ability to condense nucleic acids and form cationic
lipoplexes that are rapidly taken up by cells through endocytosis. Given the similar but
distinct structures of the oxime ether lipids prepared for the CML study as compared to
those that had previously proven141 to be efficient transfection agents (Figure 4.12), we
chose to examine these novel compounds for their potential for nucleic acid delivery. We
were especially interested to see the effect that the 1,2 diol component of lipids 2 and 3
might have on transfection efficiency, as recent reviews of structure-activity relationships
in cationic lipids had cited enhanced transfection for lipids with hydroxylated
headgroups.146, 159

4
5
6
Figure 4.12. First generation oxime ether lipids for gene transfection

In work done by collaborators at the National Cancer Institute, lipids 2 and 3 were
evaluated and compared to the previous set of transfection lipids (4, 5, and 6) for
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DNA/RNA binding efficiency, transfection efficiency, cell viability, and RNA release. In this
section, the results related to lipids 2 and 3 are featured.

4.4.1. Binding affinity
Liposomes were formed from each lipid in combination with a zwitterionic co-lipid
(DOPE) and the binding affinity of the liposomes for a fluorescently tagged hybrid
DNA/RNA was studied by fluorescence anisotropy, a technique that measures changes in
polarization/tumbling time. In this assay, lipids 2 and 3 were shown to bind nucleic acids
as efficiently as or more so than the first generation lipids (Figure 4.13).

Figure 4.13. Binding affinity of liposomes at different concentrations (1-40
µM) with 100 nM of Alexa 488 RNA/DNA hybrid as measured by
fluorescence anisotropy
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4.4.2. Transfection efficiency
The transfection efficiency of the lipids was then assessed using the fluorescently
labeled hybrid RNA/DNA in MDA-MB-231 breast cancer cells. The results, depicted in
Figure 4.14, show a concentration dependence, where lipid 2 showed the highest
transfection efficiency at lower doses and lipid 3 showed the highest efficiency at higher
doses. In either case, the hydroxylated lipids performed well in comparison to their first
generation analogs.

Figure 4.14. Transfection efficiency of oxime ether lipids with Alexa 488tagged hybrid DNA/RNA
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4.4.3 Cell viability
Cell viability was assessed 24 hours after treatment of MDA-MB-231 cells with
liposomes of each lipid by fluorescence of CellTitre blue reagent, a dye (resazurin) which
becomes fluorescent by enzymatic conversion to resorufin in live cells. None of the lipids
elicited significant reduction in viability as shown in Figure 4.15.
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Figure 4.15. Viablilty of MDA-MB-231 cells with liposome/RNA complexes
by CellTitre blue assay

4.4.4. Gene expression
Gene silencing was used to assess nucleic acid release and gene expression for
cells transfected with lipoplexes of each lipid. In this examination, MDA-MB-231 cells
expressing green fluorescent protein (GFP) were prepared, along with lipoplexes of lipids
paired with anti-GFP dicer substrate (DS) RNA. Gene expression was then evaluated
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based upon the silencing of the fluorescent protein (Figure 4.16A). Lipids 2 and 3
demonstrated silencing of the GFP gene indicating release of dicer RNA. In this regard,
lipid 3 bested the other analogs. Figure 4.16B shows the reduction in green fluorescence
for the lipoplex of lipid 3.

Lipid 2
Lipid 3
Lipid 4
Lipid 5
Lipid 6

Figure 4.16. (a) Silencing of GFP by lipoplexes of lipids with DS RNA (b)
Fluorescent microscope images of MDA-MB-231/GFP cells showing
silencing of GFP by DS RNA lipoplex with lipid 3
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The results of the transfection studies indicated that the hydroxylated cationic
oxime ether lipids are promising candidates for non-viral nucleic acid delivery. In our
examination of the relationship between lipid structure and siRNA transfer efficacy, some
trends emerged. Polar domain hydroxylation had the greatest influence on binding and
release properties, where hydroxylated lipids 2 and 3 outperformed their nonhydroxylated counterparts both in regard to tighter binding, based on fluorescence
anisotropy measurements, as well as in nucleic acid release on cellular internalization, as
indicated by GFP silencing. Whereas tight lipid complexation with nucleic acids is
desirable for protection against enzymatic degradation, the nucleic acid phosphate–lipid
ammonium interactions160 in concert with hydrophobic domain packing and any polar
domain hydrogen bonding interactions must be readily overcome for later stage lipoplex
disassembly to occur. In this regard, the hydroxylated lipids appear well-structured for
effective siRNA protection and release. Hydrophobic domain dissymmetry has been
suggested as a structural factor that is beneficial for nucleic acid release, thus ultimately
enhancing transfection activity.161-162 All of the lipids in these studies were used as a
mixture of (E,E)- and (E,Z)-oxime ether isomers, meaning a nontrivial amount of nonsymmetric (E,Z)-lipid was present. Non-symmetric hydrophobic domains likely benefit
transfection due to better DNA release through looser lipid packing in the lipoplex
formulation.163-164
Lipoplex uptake and activity also was facilitated by lipid hydroxylation, and this
observation agrees well with the assessment of a recent review146 citing greater
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transfection efficiencies for lipids possessing hydroxylated headgroups. This effect is
thought to be mediated by the decrease in headgroup hydration that results from the
incorporation of functionality capable of hydrogen bonding. Neighboring lipid-lipid
interactions in the lipoplex bilayers lead to exclusion of interstitial water, and the resulting
high positive charge/low hydration motif promotes electrostatic interactions not only
with the polynucleotide but also with cell membranes.165
Lipid 3 was arguably the frontrunner in these studies where the unsaturation in
the hydrophobic domain appeared to enhance gene expression. Recent findings may
explain this behavior; unsaturated lipids are thought to fluidize endosomal bilayers,
facilitating lipoplex escape and have also been correlated with better nuclear
localization.159

4.5.

Conclusions
Novel oxime either lipids were synthesized with the aim of optimizing their ability

to self-assemble into bilayers surrounding silica-coated magnetic NPs. The resultant
cationic magnetoliposomes were assessed for their ability to function in vitro as drug
carriers in a preliminary study with Dox and a modified amphiphilic analog. Association
of the drugs with the CML increased the potency of the nanoassembly over that of the
free drug. The preparation of the CML-drug complex was accomplished by simple mixing
of SNPs (room temp., H2O, neutral pH) with small quantities of lipid and drug: 0.3-0.4 mg
lipid + .085-0.12 mg anthracycline per mg SNP. The CML-drug formulations showed high
toxicity to MCF-7 cancer cells after 2 hours exposure to doses of 50 µg SNP/>50,000 cells
102

(3.6 µM with respect to the anthracycline). The CML-drug formulations functioned
effectively in the presence of serum-supplemented cell growth medium. These results
point to the potential for cationic magnetoliposomes built on Fe3O4-SiO2 nanoparticles as
magnetic drug delivery vehicles, thus providing opportunity for use of the tandem
techniques of magnetic targeting, imaging, and inductive heating. Further, in vitro
assessment of the transfection activity of hydroxylated oxime ether lipids and a
comparison with similar lipids of that class highlighted their distinctive efficacy as gene
delivery agents.
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5.1.

General Procedures
Reagents were typically purchased from Aldrich Chemical Company (Milwaukee,

WI). Reagent grade ACS dichloromethane, tetrahydrofuran (THF), acetone, hexanes,
ethyl acetate (EtOAc), and diethyl ether were purchased from Pharmco-AAPER
(Shelbyville, Ky). THF and CH2Cl2 were purified, when indicated, using a SPBT-101 Bench
Top Solvent Purification System (LC Technology Solutions, Inc., Salisbury, MA). CDCl 3
(99.8%) was purchased from Cambridge Isotope Laboratories (Andover, MA).

NMR

spectra were acquired on a Varian Inova 500 MHz or Varian 400 MHz spectrometer, as
indicated. Spectra were referenced to the residual solvent peaks according to Gottlieb et
al.166 FTIR spectra were acquired on a Perkin Elmer Spectrum 100 FT-IR Spectrometer
(diamond crystal) with range: 4000-650 cm-1, resolution: 4 cm-1, interval: 1 cm-1, and
scans: 4. Solid samples were scanned using an ATR attachment, liquid samples were
scanned neat or after being dissolved in CH2Cl2, placing a droplet onto the crystal, and
allowing the solvent to evaporate. Alternatively, DRIFT IR spectra were acquired on a
Mattson galaxy series 5000 DRIFT spectrometer using 64 scans, at a scan speed of 2.1 kHz
and a resolution of 4ν. DRIFT samples were prepared as a loose powder in KBr. High
resolution mass spectra were acquired on a Finnigan LTQ- FT spectrometer (Thermo
Electron Corp). MALDI-TOF-MS detection was done on a Voyager DE-Pro MALDI-TOF
instrument (PE Biosystems) using 2,5-dihydroxybenzoic acid (2,5-DHB) matrix. Melting
points were determined using a Fisher-Johns melting point apparatus or an SRS Digimelt.
Heating of cell extract samples was done on a Barnstead/Thermolyne Type 17600 Dribath. Centrifugation was performed on an Eppendorf Centrifuge type 5415R; vacuum
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centrifugation was performed on an Eppendorf Vacufuge.

Reaction progress was

monitored by thin layer chromatography (silica gel 60 Å F-254 plates) using UV
visualization and staining with ninhydrin, phosphomolybdic acid, or p-anisaldehyde
solutions. Column chromatography was performed using silica gel (230-400 mesh) or by
using a Teledyne Isco combiflash system. Cell microscopy was done on an EVOS FL Cell
Imaging System (Advanced Microscopy Group, WA). Dynamic light scattering and ζ–
potential measurements were acquired on a Brookhaven ZetaPALS Zeta Potential
analyzer.
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5.2.
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5.2 Experimental Procedures for Chapter 2
5.2.1 Syntheses of reagents and intermediates

N-Hydroxyethyl-N,N-dimethyl-octylammonium iodide (2.1)
Following

a

previously

reported

protocol,167

a

solution

of

N,

N-

dimethylethanolamine (0.50 mL, 4.98 mmol) and iodooctane (0.099 mL, 5.47 mmol) in
acetone (15 mL) were heated to reflux. After 30h, the reaction was cooled to room
temperature and dried by rotary evaporation. To the resultant yellow solid, hexanes were
added (6mL) and the solution was triturated with sonication until the solid dispersed.
Buchner filtration of the suspension followed by vacuum drying of the collected solids
yielded 2.1 (1.77 g, 92%) as white crystals; mp 76-78 °C; 1H-NMR (500 MHz, CDCl3) δ 0.82
(t, J = 6.7 H, 3H); 1.24 (m, 10H); 1.73 (m, 2H); 3.32 (s, 6H); 3.52 (m, 2H); 3.71 (m, 2H); 4.08
(m, 3H); 13C NMR (125 MHz, CDCl3) 11C δ 14.1, 22.5, 22.9, 26.2, 29.0, 29.1, 31.6, 52.4;
55.5, 65.5, 66.2. IR 3277, 2952, 2920, 2853, 1483, 1464, 1410, 1104, 1073, 1006, 968,
938, 843, 728, 594 cm–1; HRMS m/z calcd [C12H28NO]+ 202.2165, observed 202.2166.
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N-Aminooxyethyl-N,N-dimethyl-octylammonium iodide (QOA)
To a solution of alcohol 2.1 (1.50 g, 4.55 mmol), N-hydroxyphthalimide ( 0.817g,
5.01 mmol) triphenylphosphine (1.31 g, 5.00 mmol) in THF (15 mL) at rt was added
diisopropyl azodicarboxylate (DIAD) (0.993 mL, 5.01 mmol). After stirring 12h at room
temperature, the solvents were removed by rotary evaporation. To the crude yellow
residue was added ethyl acetate (7.0 mL). The resultant suspension of white solids was
filtered, and the retentate (phthalimide intermediate) was used directly in the next step.
1H

NMR (500 MHz, CDCl3) δ 0.85 (t, J = 6.5 Hz, 3H); 1.32 (m, 10H); 1.85 (m, 2H); 3.57 (s,

6H); 3.78 (m, 2H); 4.37 (m, 2H); 4.74 (m, 2H); 7.80 (m, 2H); 7.85 (m, 2H).
To the phthalimide protected salt (1.88 g, 3.96 mmol) in CH2Cl2 was added
hydrazine monohydrate (0.59 g, 11.9 mmol) and the mixture was stirred at rt for 2h.
Collection of the CH2Cl2 filtrate followed by drying yielded QOA·I (1.26 gm, 93%) as a white
powder; mp 55.5-58.6 °C. 1H NMR (500 MHz, CDCl3) δ 0.80 (t, J = 6.5 Hz, 3H); 1.24 (m,
10H); 1.69 (m, 2H); 3.33 (s, 6H); 3.51(m, 2H); 3.84 (m, 2H); 4.12 (m, 2H); 4.95 (bs, 2H -NH2). Key 1H-1H COSI correlations: δ 4.12-3.84 (C(1’)H2-C(2’)H2 ); 3.51-1.69 (C(1)H2 – C(2)H2).
13C

NMR (125 MHz, CDCl3) 11C δ 14.0, 52.2; 22.5, 22.9, 26.2, 28.9, 29.1, 31.6, 62.5, 65.8,

69.0. IR: 3273, 3029, 2927, 2855, 1472, 1172, 954 ν(O-N), 858, 495 cm-1. HRMS m/z calcd
[C12H29N2O]+ 217.227439, observed 217.22779.
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Dodecyl(2-hydroxyethyl)dimethylazanium bromide (2.3)
A solution of N,N-dimethylethanolamine (0.5 mL, 4.97 mmol) and 1bromododecane (1.31 mL, 5.47 mmol) in acetone (25 mL) were heated to reflux, After
24h, the reaction was cooled to rt and the precipitated solids were collected by filtration,
washed with chilled acetone and dried under vacuum. The reaction filtrate was dried
under rotary evaporation and to the resulting yellow residue hexane was added.
Trituration with sonication of the hexane produced a white precipitate which was
collected by filtration and combined with the precipitate from acetone to afford 2.3
(0.977 gm, 58 %) as white crystals; mp (decomp) 190 °C. 1H NMR (500 MHz, CDCl3), δ 0.87
(t, J = 6.75 Hz, 3H);1.25 (m, 18H); 1.75 (m, 2H); 3.37 (s, 6H); 3.54 (m, 2H); 3.75 (m, 2H);
4.15 (m, 2H); 4.99 (t, J = 5.5 Hz, 1H).

13C-NMR

(125 MHz, CDCl3) δ 15C δ 14.1; 22.6; 22.9;

26.2; 29.2; 29.3; 29.4; 29.5; 29.6 (2 signals); 31.8; 52.0, 55.9, 65.4, 66.1. IR: 3248, 3006,
2952, 2917, 2850, 1475, 1421, 1375, 1078, 1073, 1055, 1016, 965, 918, 900, 730, 718,
601, 571, 432 cm–1.
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N-Aminooxyethyl-N,N-dimethyl-dodecylammonium bromide (QDA·Br)
To a solution of alcohol 2.3 (0.699 g, 2.06 mmol), N-hydroxyphthalimide (0.371 g
2.27 mmol), triphenylphosphine (0.596 g, 2.27 mmol) in CH2Cl2 (10 mL) at rt was added
DIAD (0.45 mL, 2.27 mmol). After stirring for 15h at rt, the solvents were removed by
rotary evaporation. To the crude yellow residue was added ethyl acetate (20 mL). The
resultant suspension of white solids was filtered, and the retentate (phthalimide
intermediate) was used directly in the next step. 1H-NMR (500 MHz, CDCl3) δ 0.86 (t, J =
6.7 Hz, 3H); 1.30 (m, 18H); 1.83 (m, 2H); 3.56 (s, 6H -N(Me)2-); 3.76 (m, 2H); 4.41 (m, 2H);
4.74 (m, 2H); 7.82 (m, 2H); 7.84 (m, 2H).
To the phthalimide protected salt (1.93 g, 3.98 mmol) in anhydrous ethanol was
added hydrazine monohydrate (1.24 g, 24.7 mmol). The reaction was stirred for 6hr at
50°C. The ethanol was then removed by rotary evaporation and CH2Cl2 was added (17
mL). The resulting white precipitate was filtered over a Buchner funnel and washed with
CH2Cl2. The CH2Cl2 filtrate was dried by rotary evaporation. To the resultant off-white
residue toluene was added (30 mL), heating and sonication yielded a suspension of fine
white particles which were collected over a glass Buchner funnel. This afforded QDA∙Br
as a white powder; mp (decomp) 187 °C. 1H-NMR (500 MHz, CDCl3) δ 0.84 (t (J = 6.7 Hz),
3H); 1.27 (m, 18H); 1.70 (m 2H); 3.36 (s, 6H); 3.54 (m, 2H); 3.94 (m, 2H); 4.17 (m, 2H); 5.30
(bs, 2H).

13C-NMR

(125 MHz, CDCl3) 15C δ 14.1; 22.1 (2 signals); 22.7; 22.9; 26.3; 29.2;

29.3; 29.5; 29.6; 31.9; 51.8, 62.2, 65.6. IR: 3280, 2921, 2848, 1653, 1576, 1472, 1173,
111

1073, 954 ν(O-N), 719, 494 cm-1. HRMS m/z calcd [C16H37N2O]+ 273.290588, observed
273.28983.

N-(2-hydroxyethyl)-N-methyl-1-dodecanylamine (2.6)
A solution of 2-(methylamino)ethanol (1.37 mL, 17.0 mmol), 1-bromododecane
(4.08 mL, 17.0 mmol), and anhydrous sodium carbonate (1.93 g, 17.0 mmol) in anhydrous
ethanol (34 mL) was heated to reflux. After 20h, the reaction suspension was cooled to
room temperature and the precipitated solids were removed by filtration. The filtrate
was concentrated to one-third volume by rotary evaporation and then transferred to a
centrifuge vial and centrifuged to pellet precipitated solids. The supernatant was
collected and evaporated by rotary evaporation. Bulb-to-bulb distillation (Kugelrohr, 190
°C, ca. -0.986 atm) of the crude residue afforded 2.6 (2.91 g, 70%) as a clear liquid.
Spectral characterization of 2.6 gave values identical to those reported.168 1H NMR (500
MHz, CDCl3) δ 0.88 (t, J = 6.0 Hz, 3H); 1.25 (m, 18H); 1.45 (m, 2H), 2.22 (s, 3H); 2.38 (t, J =
8.50 Hz, 2H); 2.50 (t, J = 4.25 Hz, 2H); 3.57 (t, J = 5.5 Hz, 2H).
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2-(2-(dodecyl(methyl)amino)ethoxy)isoindoline-1,3-dione (2.7)
To a solution of 2.6 (2.91 g, 11.9 mmol) in THF (50 mL) at 0 °C were added Nhydroxyphthalamide (2.14 g, 13.1 mmol), PPh3 (3.44 g, 13.1 mmol) and DIAD (2.6 mL, 13.1
mmol). The reaction mixture was warmed to rt and stirred 12h before removing the
solvents by rotary evaporation. To the yellow residue was added hexane (60 mL) and the
resultant suspension was triturated and sonicated (rt bath, 30 sec intervals). The
resultant fine solids were removed by filtration, and the filtrate was removed by rotary
evaporation to afford crude 2.7 as an orange solid. The crude product was dissolved in
ethyl acetate (50 mL) and the solution was washed with saturated NaHCO3 (3X). The
organic layer was dried (Na2SO4) and then evaporated by rotary evaporation to yield 2.7
(4.53 g, 98%) as a yellow, low melting semi-solid (38.7-40.1 °C); 1H NMR (500 MHz, CDCl3)
δ 0.87 (t, J = 7.0 Hz, 3H); 1.24 (m, 18H); 1.41 (m, 2H); 2.29 (s, 3H); 2.39 (t, J = 7.8 Hz, 2H);
2.83 (t, J = 5.5 Hz, 2H); 4.32 (t, J = 5.5 Hz, 2H); 7.74 (m, 2H); 7.83 (m, 2H).

13C-NMR

(125

MHz, CDCl3) δ 14.1; 21.9; 22.6; 26.9; 27.4; 29.3; 29.5-29.6 (m); 31.9; 42.1; 55.4; 57.8; 75.6;
123.4; 128.9; 134.4; 163.4.
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N-[2-(Aminooxy)ethyl]-N, N-dimethyl-1-dodecylammonium iodide (QDA)
A glass pressure tube was charged with 2.7 (0.10 g, 1.79 mmol), dry CH2Cl2 (5 mL)
and iodomethane (1.53 g, 10.8 mmol). The tube was sealed and then immersed in an oil
bath heated to 50 °C. After 12h, the reaction was cooled to rt. The tube was opened and
the solvent was evaporated in a fume hood using a steady nitrogen stream. The resulting
off-white solid 2.8 was used directly in the next step. 1H NMR (500 MHz, CDCl3) δ 0.85 (t,
J = 7.0 Hz, 3H); 1.24 (m, 16H); 1.36 (m, 2H); 1.84 (m, 2H); 3.56 (s, 6H); 3.77 (m, 2H); 4.37
(t, J = 4.3 Hz, 2H); 4.75 (t, J = 4.0 Hz, 2H); 7.80 (m, 2H); 7.85 (m, 2H).
To a solution of 2.8 (0.90 g, 1.70 mmol) in anhydrous ethanol (9 mL) was added
hydrazine monohydrate (0.43 g 8.49 mmol). The reaction mixture was stirred at rt for
12h whereupon the solvent was removed by rotary evaporation. To the residue was
added CH2Cl2 (20 mL) and the resultant suspension was filtered. The filtrate was
concentrated by rotary evaporation and toluene (15 mL) was added. The mixture was
triturated with sonication (rt bath, 30 sec intervals) and the solids were collected and
dried (vacuum) to afford QDA (0.45 g, 65%); mp 85.9-88.9 °C; 1H-NMR (500 MHz, CDCl3)
δ 0.87 (t, J = 7.0 Hz, 3H); 1.20-1.43 (m, 18H); 1.75 (m, 2H); 3.42 (s, 6H); 3.58 (m, 2H); 3.96
(t, J = 4.5 Hz, 2H); 4.16 (m, 2H); 6.85 (br. s, 2H); 13C NMR (125 MHz, CDCl3) δ 14.1; 22.6;
22.9; 26.2; 29.2; 29.3; 29.35; 29.4; 29.6 (2 signals); 31.9; 52.1; 62.4; 66.0; 68.9; IR (DRIFT,
KBr powder) 3270, 2917, 2848, 1468, 1172, 956, 900 cm-1; HRMS m/z calcd [C16H37N2O]+
273.2906, observed 273.2903.
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N-[2-(Aminooxy)ethyl]-N-methyl-N-[(13C2H3)-methyl]-1-dodecylammonium

iodide

(*QDA)
Using the procedure described for synthesis of QDA, amine 2.7 (0.50 g, 1.29 mmol)
was reacted with

13CD

3I

(0.47 g, 3.21 mmol) and hydrazine monohydrate (0.302g,

6.02mmol) to give *QDA (0.37 g, 75%) as a white powder; mp 86.6-87.5 °C; 1H NMR (500
MHz, CDCl3) δ 0.86 (t, J = 7.0 Hz, 3H); 1.14-1.43 (m, 16H); 1.74 (m, 2H); 3.41 (d, J = 3.5 Hz,
3H); 3.58 (m, 2H); 3.92 (m, 2H); 4.16 (m, 2H); 5.91 (br s); 13C NMR (125 MHz, CDCl3) δ 14.3;
22.8; 23.1; 26.4; 29.4; 29.5; 29.6; 29.7; 29.8 (2 signals); 32.1; 51.6 (m); 52.2; 62.6; 66.0;
69.2; IR (DRIFT, KBr powder) 3278, 2913, 2850, 1468, 1173, 1048, 947 ν(O-N), 720, 482,
418 cm-1; HRMS m/z calcd [C1513C2H3H34N2O]+ 277.3119, observed 277.3124.
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5.2.2 Mass spectrometry methods
Samples were analyzed on a hybrid linear ion trap (LIT) FT-ICR mass spectrometer
(LTQ-FT, Thermo Electron, Bremen, Germany) equipped with a TriVersa NanoMate ion
source (Advion BioSciences, Ithaca, NY) with an “A” electrospray chip (nozzle inner
diameter 5.5 µm). The TriVersa NanoMate was operated in positive ion mode by applying
1.85 kV with 0.1 psi head pressure. MS runs were recorded over a mass range from 150
to 1200 Da. Initially, low resolution LIT-MS scans were acquired for 0.75 minute to track
the stability of the ion spray, after which high mass accuracy data were collected using
the FT-ICR analyzer where MS scans were acquired for 8 min. The AGC (automatic gain
control) maximum ion time was set to 10 ms and 500 ms for the LIT and ICR operations,
respectively, using default ion count targets for both and 5 “microscans” (ICR transients)
were accumulated before Fourier transformation to produce each saved spectrum; thus
the cycle time for each transformed, saved spectrum was about 5 s, the exact timing of
which varied slightly with the AGC operations for each. The LTQ-FT was tuned and
calibrated according to the manufacturer’s default standard recommendations, which
typically achieved better than 0.2 ppm mass accuracy at 400,000 resolving power (m/z =
400).
FT-ICR mass spectra were exported as exact mass lists into a spreadsheet file using
QualBrowser 2.0 SR2 (Thermo Electron, “Bremen” version for the LTQ-FT) by exporting all
of the recorded peaks so that s/n decisions can be made in downstream data processing.
QDA/*QDA adducts were assigned based on their accurate mass by using an in-house
software tool PREMISE (PRecaculated Exact Mass Isotopologue Search Engine)11 which
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was also manually validated. PREMISE is a simple algorithm that corrects small mass
errors based on a selectable known peak (such as internal standard, or a known analyte),
then matches observed with theoretical m/z values within a selectable window that is
typically set to 0.0008 Da or smaller. The theoretical m/z values of a large number of
QDA-metabolite adducts were calculated and compiled in a reference table for the
PREMISE assignment.

5.2.3 Extraction solvent determination, counterion comparison, and partition efficiency
One of three aminooxy reagents (QOA, QDA or *QDA) 9 µM was added to a
mixture of aldehyde/ketone standards (pyruvate, α-ketoglutarate, α-ketobutyrate, and
glucose, 2 µM each) in 5 mmM pH 6 NH4OAc buffer in microcentrifuge tubes. The
mixtures were sonicated 2h at rt and placed in a dribath at 40 °C for 12h. The aqueous
mixtures were then subjected to 5 equal volume extractions with either CHCl 3, EtOAc, or
n-butanol; each extraction was separately retained. The organic extractions were dried
by vacuum centrifugation. The resultant residues were dissolved in MeOH with 0.1%
formic acid and were detected by FT-ICR-MS after addition of a 200 nM standard (QOAacetone-d6 adduct) for normalization purposes. Ion counts were normalized to the
standard and compared across the 5 extractions for the three solvents and the three
aminooxy reagents.

117

5.2.4 Verification of linear instrument response
As the automatic gain control of the FT-ICR-MS prevents the use of simple serial
dilution of standards for signal intensity comparisons, the feature can be compensated
for by adding a known standard at high concentration to all samples. A mixture of *QDA
standard adducts (pyruvate, α-ketoglutarate, α-ketobutyrate, and glucose) were
prepared in methanol and diluted to concentrations ranging from 25 µM-25 pM. QOAacetone-d6 adduct (100 µM) was added as a standard for normalization and for use as a
compensation for automatic gain control.

5.2.5 Cell culture and extract preparation
Human lung adenocarcinoma A549 cells were grown in 10-cm plates with 8 mL
RPMI 1640 medium (Sigma) supplemented with 2 mM glutamine, 0.2% glucose, 10% fetal
bovine serum, 100 U/mL penicillin, and 0.1 mg/mL streptomycin at 37°C, 5% CO2 and 95%
humidity. When cells became 70% confluent, the medium was removed, and the cells
were washed three times on ice each with 5 ml cold 1X PBS (phosphate buffered saline)
to remove medium components. 1 ml of cold acetonitrile (-20 °C) was added to quench
metabolism. Then, 0.75 mL of nanopure water was added before cells were scraped and
collected into a 15 mL polypropylene conical centrifuge tube (Sarstedt, Newton, NC)
containing three 3 mm diameter glass beads. These steps were then repeated to collect
any remaining cells. Next, 1 mL HPLC-grade chloroform (Fisher Scientific) was added to
the centrifuge tube containing the cell lysate. Extraction of polar metabolites via solvent
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partitioning was performed as described previously.169

The aqueous extract was

lyophilized and stored at -80 °C prior to analysis.

5.2.6 Cell extract derivatization
50 μL of a 1:1 mixture of 100 μM QDA and *QDA as solutions in nanopure water
was added to a 1.5 mL microcentrifuge tube containing the aqueous extract of
approximately one quarter of a 10 cm cell plate in 50 μL of 10 mM pH 6 NH 4OAc buffer.
The tube was briefly vortexed, sonicated for 1 hr and placed in a 40 °C dry bath for 23
hours. Following reaction, the aqueous layer was extracted with n-butanol three times,
and dried by vacuum centrifugation. The residue was dissolved in methanol with 0.1%
v/v formic acid and analyzed by FT-ICR-MS as a 1:1 mixture with an external standard of
2 μM QOA-acetone-d6 adduct. For each experiment, three replicate samples were made.
A buffer blank consisting of 50 μL 10 mM pH 6 NH4OAc buffer and 50 μL of the QDA/*QDA
mixture was prepared and analyzed similarly to serve as a negative control.
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5.2.7 Data analysis and statistics
Each sample was acquired for nine minutes on FT-ICR-MS and the resultant
spectra were averaged over all saved scans. Next, all peaks of a single (representative)
acquisition were exported to excel. Any peaks with ion counts less than 1000 were
deleted in order to eliminate noise, which typically appeared to be values around 200
counts or below. A theoretical “+4” m/z list was created by adding 4.02188 to all of the
parent peaks. PREMISE software was then used to find matches between the original
data and the +4 peak-list with an error range of 0.0009 m/z. This simplified list was then
crosschecked manually against the negative control peak-list and any duplicate masses
were deleted, except in cases where the intensity was significantly higher in the sample
than the negative control (>80%). Where multiple +4 peaks were matched, the peaks
with ion counts most closely matching the parent (n) peak were retained. Finally, any
peaks identified as both n and n+4 peaks were deleted.
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5.2.8 Estimation of cellular suppression factor and quantification of pyruvate
For an estimate of the “ion suppression” (loss of signal intensity) factor in cellular
extracts, the ion counts of the parent ions (protonated) of QDA-pyruvate and QDA-13C3pyruvate were normalized by dividing by the ion counts of the external standard *QDApyruvate which was added at the same concentration to every sample. The normalized
ion counts of QDA-13C3-pyruvate were then plotted against the known concentrations of
2.5, 5, and 7.5 µM in buffer conditions, and cell extract conditions, along with linear
regressions. The quotient of the slopes of the two linear regressions gives a cellular
extract ion suppression factor of 4.97.
The concentration of endogenous pyruvate was calculated using the standard
curve established by the internal standard QDA-13C3 pyruvate.

Specifically, the

normalized ion counts for QDA-pyruvate were averaged across three nine-minute FT-ICRMS acquisitions, then over three replicate samples. Normalized ion counts of QDApyruvate from the blank (QDA added to buffer alone) were subtracted. This value was
then entered as the y value into the linear regression equation of Figure 2.10 and the μM
concentration was calculated. This concentration indicated the amount of pyruvate (plus
mass isomers) partitioned into the aqueous extract of 1/8th of a 70% confluent 10 cm well
plate (approx. 625,000 cells) dissolved in 100 μL of methanol with 0.1% formic acid.

121

5.3.

Experimental Procedures for Chapter 3

5.3.1 Preparation of iron oxide NPs
5.3.2 Quantification of Fe2+ and total Fe for determination of NP
composition
5.3.3 AMF heating properties
5.3.4 Syntheses of variably hydroxylated ammonium salts
5.3.5 NP coating with variably hydroxylated ammonium salts
5.3.6 Thermogravimetric analysis of NP-bound ammonium salts
5.3.7 Synthesis of FITC-CHO
5.3.8 Syntheses of aminooxy linkers
5.3.9 Fluorescence study of FITC-loaded NPs
5.3.10 Syntheses of doxorubicin analogs
5.3.11 Preparation of NP formulations of Dox analogs
5.3.12 UV-Vis detection of Dox-OH and Dox-2OH release by pulsed AMF
5.3.13 Toxicity of Dox-NPs in MCF-7 cells
5.3.14 Synthesis of QAO-2OH anthracene derivative
5.3.15 Dextran sulfate coating of NPs
5.3.16 Coating of dextran sulfate NPs with QAO-2OH anthracene derivative
5.3.17 Release of QAO-2OH anthracene derivative from dextran sulfate NPs
122

5.3.18 CS2 and CS2/CH3I coating of NPs
5.3.19 Synthesis of deuterated ammonium salt 3
5.3.20 Coating of CS2 NPs with 3
5.3.21 Synthesis of anthracen-9-ylmethanamine (4)
5.3.22 Preparation of thiocarbamate NPs 10
5.3.23 Elemental analysis
5.3.24 CS2 modified NPs with variably hydroxylated ammonium salts
5.3.25 Synthesis of greigite NPs
5.3.26 Greigite NP coating with QAO-2OH anthracene derivative

123

5.3 Experimental Procedures for Chapter 3
5.3.1 Preparation of iron oxide NPs
180 mL of 0.1 M NaOH (0.719 g, 18.0 mmol) in Millipore water was prepared and
deoxygenated by bubbling with N2 for 1h. 5.29 mL of 0.4M iron III chloride (0.573 g, 2.12
mmol) and 5 mL 0.2M iron II chloride (0.232 g, 1.17 mmol) were likewise prepared in
deoxygenated Millipore water. 5ml each of the iron chloride solutions were combined
and added dropwise to the aqueous base under rapid stirring. After 30 min the NPs were
magnetically sedimented and the supernatant was aspirated under positive N 2 pressure.
The precipitate was washed with 40 mL degassed Millipore water (“water wash
condition”) and again magnetically separated for supernatant aspiration. NPs were
transferred in a minimal amount of Millipore water to vials and freeze dried (0.2417 g,
89%).
For “acid washed” condition, NPs were prepared as above with the addition of 4X
40 mL washes with Millipore water followed by 1X 40 mL wash with 0.01M aqueous HCl.
For “multiple water wash” condition, NPs were simply washed 4X with 40 mL Millipore
water.

5.3.2 Quantification of Fe2+ and total Fe for determination of NP composition
As outlined by Amonette and Templeton,105 the assay of Fe II and total Fe in iron
oxide nanoparticles samples was accomplished by dissolving 1) 25 mg of “water washed”
particles or 2) 27mg of “acid washed” particles in a preheated acid matrix consisting of
10% sulfuric acid (12 mL), hydrofluoric acid (1 mL), and 10% 1,10 phenanthroline in 95%
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ethanol (2 mL). After boiling for 30 minutes, boric acid solution (5%, 10 mL)) and
deionized water (90 mL) were added. An aliquot of each sample was reduced with 1%
NH2OH in 1% Na3-citrate (10 mL) to convert remaining Fe III to Fe II for a total Fe assay.
Solutions were diluted in 1% Na3-citrate and absorbances were detected on a Beckman
Coulter DU 800 spectrophotometer. Absorbance at 510 nm was used to calculate total
Fe and Fe II concentrations for each samples using equation 5 (ibid). Fe III was determined
by the difference of Fe II from total Fe concentrations.

5.3.3 AMF heating properties
Solutions of NPs with concentrations of 0.2, 1, 5, 25 mg/mL in Millipore water
were prepared along with a control without NPs. Alginate (Tica-algin 613 sodium alginate:
sodium phosphate, and calcium sulfate) was added such that each solution contained 3%
w/v alginate. Each sample was exposed to AMF for 1h at 201.4A, 203 kHz while
temperature measurements were made at 15 minute intervals with a fiber optic
temperature probe (Neoptix).
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5.3.4 Syntheses of variably hydroxylated ammonium salts

(2-hydroxyethyl)trimethylazanium iodide (1OH)
N,N-dimethylethanolamine 4.99 mmols was added to a pressure vial as a 0.2 M
solution in CH2Cl2 and cooled to 0° C. Iodomethane was added (14.97 mmols) and the
reaction was allowed to come to room temperature. After 12 hours at room temp, the
solution was filtered of the white precipitated product. The precipitate was dried using a
vacuum desiccator (1.61g, quantitative, mp. >260). 1H NMR (500 MHz, D2O) δ 3.21 (s, 9H,
N(CH3)3); 3.54 (t, 2H, J = 5.00 Hz, C(1)H2); 4.08 (m, 2H, C(2)H2).

13C

NMR (100 MHz, D2O)

3C δ 53.8; 55.5; 67.3. m/z calcd [C5H14NO]+ 104.10699, observed 104.10693.

(2,3-dihydroxypropyl)trimethylazanium iodide (1,2 diol)
3-(dimethylamino)-1,2-propanediol (1.0 g, 8.4 mmols) was added to a pressure
vial as a 1M solution in CH2Cl2. The vial was cooled to 0 °C and iodomethane (3.6 g, 25.2
mmols) was added.

The sealed tube was capped and the reaction ran at room

temperature for 10 hours with stirring. Post reaction, a white precipitate was filtered
from solution. This retentate was rinsed with CH2Cl2 and dried (vacuum) affording the 1,2
diol (2.077 g, 95%) as a white, crystalline solid, mp. 130.6-132.1°C. 1H NMR (400 MHz,
D2O) δ 3.29 (s, 9H, N(CH3)3); 3.50 (m, 2H C(1)H, C(1)H’); 3.64 (m, 2H, C(3)H2); 4.35 (m, 1H,
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C(2)H).

13C

NMR (125 MHz, D2O) 4C δ 54.29; 63.74; 66.49; 68.30. m/z calcd [C6H16NO2]+

134.117555, observed 134.11748.

bis(2-hydroxyethyl)dimethylazanium iodide (2OH)
N-methyl diethanolamine (1.0 g, 8.4 mmols) was added to a pressure vial as a 1M
solution in CH2Cl2. Iodomethane (5.9 g, 42.0 mmol) was added and the sealed tube was
heated in an oil bath at 50°C for 10 hours with magnetic stirring. Post reaction, the upper
clear solution was decanted and the yellow oil was washed with CH2Cl2 (15 mL).
Acetonitrile was used to dissolve the yellow oil, the solvent was removed by rotary
evaporation and drying (vacuum) afforded 2OH as a hygroscopic orange solid, mp. 76.478.9°C (2.55 g, 119%). 1H NMR (500 MHz, D2O) δ 3.25 (s, 6H, N(CH3)2); 3.62 (t, 4H, J = 5.00
Hz, C(1)H2); 4.09 (m, 4H, C(2)H2).

13C

NMR (100 MHz, D2O) 3C δ 52.2; 55.3; 66.9. m/z

calcd [C6H16NO2]+ 134.117555, observed 134.11749.
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tris(2-hydroxyethyl)(methyl)azanium iodide (3OH)
Triethanolamine (1.0 g, 6.7 mmols) was added to a pressure vial as a 1M solution
in CH2Cl2. Iodomethane (2.85 g, 20.1 mmol) was added and the sealed tube was heated
in an oil bath at 50°C for 6 hours with magnetic stirring. Post reaction, the upper clear
solution was decanted and the amber oil was washed with CH2Cl2 (8 mL). Acetonitrile
was used to dissolve the oil, the solvent was removed by rotary evaporation and drying
(vacuum) afforded 3OH as an orange semisolid (2.55 g, 119%).

1H

NMR (400 MHz, D2O)

δ 3.28 (s, 3H, N(CH3)); 3.70 (t, 6H, J = 5.00 Hz, C(1)H2); 4.09 (m, 6H, C(2)H2).

13C

NMR (100

MHz, D2O) 3C δ 50.0; 55.1; 64.4. m/z calcd [C7H18NO3]+ 164.12812, observed 164.12804.

(2-hydroxyethyl)trimethylazanium chloride (1OH)
A Dowex ion exchange resin (10g, 200-400 mesh, chloride form) was hydrated and
packed in water; the eluent was then gradually switched to methanol. The iodide form
of 1OH (0.21g, 0.89 mmols) was passed through the resin using gravity elution with
methanol. The product, a white solid (0.143g, 115%), was verified as the chloride salt
using the silver nitrate method as well as by mass spectrometry. 1H NMR (500 MHz, D2O)
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δ 3.21 (s, 9H, N(CH3)3); 3.53 (t, 2H, J = 5.00 Hz, C(1)H2); 4.07 (m, 2H, C(2)H2).

13C NMR (125

MHz, D2O) 3C δ 54.0; 55.7; 67.5. m/z calcd [C5H14NO]+ 104.10699, observed 104.10693.
Dimer (chloride counterion) m/z calcd 243.182833, observed 243.18357, no iodide dimer
observed.

(2,3-dihydroxypropyl)trimethylazanium chloride (1,2 diol)
The iodo form of the 1,2 diol (0.21g, 0.79 mmols) was passed through an ion
exchange resin prepared as above using gravity elution with methanol. The product, a
pale yellow semi-solid (0.142g, 106%), was verified as the chloride salt using mass
spectrometry. 1H NMR (500 MHz, D2O) δ 3.24 (s, 9H, N(CH3)3); 3.46 (m, 2H C(1)H, C(1)H’);
3.60 (d, 2H, J = 5.00 Hz, C(3)H2); 4.30 (m, 1H, C(2)H). 13C NMR (125 MHz, D2O) 4C δ 68.3;
66.5; 63.7, 54.3. m/z calcd [C6H16NO2]+ 134.117555, observed 134.11748. Dimer (chloride
counterion) m/z calcd 303.203963, observed 303.20481, no iodide dimer observed.
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bis(2-hydroxyethyl)dimethylazanium chloride (2OH)
The iodo form of 2OH (0.21g, 0.82 mmols) was passed through an ion exchange
column prepared as above using gravity elution with methanol.

The product, a

transparent solid (0.146g, 105%, 104 °C (d)), was verified as the chloride salt using mass
spectrometry. 1H NMR (500 MHz, D2O) δ 3.23 (s, 6H, N(CH3)2); 3.60 (t, 4H, J = 5.00 Hz,
C(1)H2); 4.08 (m, 4H, C(2)H2).

13C

NMR (100 MHz, D2O) 3C δ 52.3; 55.5; 66.3. m/z calcd

[C6H16NO2]+ 134.117555, observed 134.11748. Dimer (chloride counterion) m/z calcd
303.203963, observed 303.20479, no iodide dimer observed.

tris(2-hydroxyethyl)(methyl)azanium chloride (3OH)

The iodo form of 3OH (0.21g, 0.72 mmols) was passed through an ion exchange
column prepared as above using gravity elution with methanol.

The product, a

transparent hygroscopic solid (0.148g, 104%), was verified as the chloride salt using mass
spectrometry. 1H NMR (500 MHz, D2O) δ 3.26 (s, 3H, N(CH3)); 3.69 (t, 6H, J = 5.25 Hz,
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C(1)H2); 4.08 (m, 6H, C(2)H2).

13C

NMR (125 MHz, D2O) 3C δ 50.1; 55.3; 64.5. m/z calcd

[C7H18NO3]+ 164.12812, observed 164.12818. Dimer (chloride counterion) m/z calcd
363.225093, observed 363.22728, no iodide dimer observed.

5.3.5 NP coating with variably hydroxylated ammonium salts
3M solutions in methanol of each ammonium salt (or amine free base) were
prepared and added to microcentrifuge tubes containing ≈10 mg NPs such that there
were 10 mmol ammonium salt per g NP. The microcentrifuge tubes were briefly vortexed
and sonicated (rt, 1h) followed by rotating on an inverter at rt for 3h. NPs were pelleted
by centrifugation (16000 rcf, 20 min) and the supernatant was removed. The NPs were
then washed with water (3X 0.5 mL) with intervening pelleting by centrifugation. The
pellets were then freeze dried.

5.3.6 Thermogravimetric analysis of NP-bound ammonium salts
TGA was performed on a TA Instruments Hi-Res 2950 Thermogravimetric
Analyzer. Approximately 6 mg of each lyophilyzed NP sample was loaded into a platinum
sample pan for analysis. After an initial equilibration phase at 35 °C, the temperature was
increased 20 °C/min up to 700 °C under nitrogen gas. Triplicate samples were analyzed.
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5.3.7 Synthesis of FITC-CHO

To a solution of fluorescein isothiocyanate (80% isomer 1, 1.28 g, 3.28 mmol) in
DMF (10 mL) was added 4-aminobutyraldehyde diethyl acetal (0.771 g, 3.94 mmol) via
syringe. The mixture was stirred 4h at rt. The reaction solvent was diluted with 100 mL
dilute aq. HCl (pH4) and extracted with diethyl ether (8X 100 mL). The organic phase was
dried over sodium sulfate and evaporated by rotary evaporation. The product was passed
through a silica gel plug (CH2Cl2:MeOH, 1:0-9:1) and was used in the next step without
further purification.
To the acetal was added 30% v/v aqueous acetic acid (150 mL) and stirred 15h at
rt. The solvent was removed as an azeotrope with toluene to yield FITC-CHO as an orange
solid (0.550 g, 55% 2 steps). 1H NMR (400 MHz, dmso) major isomer δ = 10.11 (br s, 2H);
8.12 (s, 1H); 7.84 (m, 1H); 7.26-7.12 (m, 2H); 6.66 (s, 2H); 6.58 (m, 4H); 5.76 (br s, 1H);
3.78 (m, 1H); 3.61 (m, 2H); 2.30 (s, 1H); 2.09 (br, 2H); 1.89 (br, 2H). HRMS m/z calcd
[C6H16NO2]- 475.0969, observed 475.09688.
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5.3.8 Syntheses of aminooxy linkers

2-[2-(dimethylamino)ethoxy]-2,3-dihydro-1H-isoindole-1,3-dione
To a solution of triphenylphosphine (5.3 g, 20.2 mmol) and N-hydroxyphthalimide
(3.29 g, 20.2 mmol) in anhydrous THF (50 mL) at 0 °C was added N,N dimethyl
ethanolamine (1.50 g, 16.80 mmol). After stirring 20 min, DIAD (4.08 g, 20.18 mmol) was
added dropwise. The reaction mixture was then allowed to warm to room temperature.
After 12 h, the solvent was removed by rotary evaporation. EtOAc (300 mL) was added
to dissolve the residue and the organic phase was washed with saturated aq. NaHCO 3 (3
X 200 mL), and brine (3X 200 mL). The EtOAc was dried (Na2SO4), and concentrated by
rotary evaporation. The residue was redissolved in EtOAc (250 mL) and extracted 3X with
50 mL portions of 5% v/v aqueous HCl and washed with Et2O. Saturated NaHCO3 was
then added until the pH registered slightly basic and the aqueous phase was extracted
with CHCl3 (3X 100 mL). The CHCl3 was evaporated to yield a yellow solid (1.56 g, 40%).
1H

NMR (500 MHz, DMSO-d6) δ 7.86 (s, 4H); 4.21 (s, 2H); 2.61 (s, 2H); 2.18 (s, 6H).
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O-[2-(trimethylazaniumyl)ethyl]hydroxylamine iodide (QAO)
To the phthalimide protected amine shown above (0.78 g, 3.33 mmol) in CH 2Cl2
(10 mL) in a pressure vial was added iodomethane (11.4 g, 79.7 mmol). The reaction was
sealed and heated at 50 °C for 12h. After cooling, the solvent and excess iodomethane
were evaporated under N2 stream in a fume hood. The isolated white solids were used
directly in the next step. 1H NMR (400 MHz, DMSO-d6) δ 7.90 (s, 4H); 4.67 (s, 2H); 3.79 (s,
2H); 3.23 (s, 9H).
To the iodo salt (1.46 g, 5.77 mmol) in ethanol (20 mL) was added hydrazine
monohydrate (0.92 g, 17.8 mmol). The reaction was stirred 4h at rt and the solvent was
removed by rotary evaporation. The resultant residue was triturated in hot acetonitrile,
filtered, and the filtrated was evaporated to yield a yellow amorphous solid (QAO). 1H
NMR (400 MHz, D2O) δ 4.14 (m, 2H); 3.63 (t, J = 4.6 Hz, 2H), 3.19 (s, 9H).
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[2-(aminooxy)ethyl](2-hydroxyethyl)dimethylazanium iodide (QAO-1OH)
QAO-1OH was prepared by my colleague, Dr. Xuan Huang as reported in Tetrahedron
Letters 2010, 51 (13), 1727-1729.

Synthesis of 3.1
To a solution of triethanolamine (56.7 g, 380.0 mmol) and triethylamine (38.4 g,
380.0 mmol) at 0 °C, a solution of tert-butyldimethylsilyl chloride (68.7 g, 455.9 mmol) in
CH2Cl2 (40 mL) was added via cannula. The reaction mixture was stirred 1h at 0 °C then
was allowed to warm to rt. After 12h the reaction solvent was removed by rotary
evaporation.

The crude residue was purified by flash chromatography using 2:1

hexanes:ethyl acetate as eluant. The product was a clear oil (12.7g, 13%). 1H NMR (CDcl3,
400 MHz)  3.66 (m, 4H), 3.52 (m, 2H), 6.14 (m, 6H), 0.89 (s, 18H), 0.05 (s, 12H).
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Synthesis of 3.2
To a solution of triphenylphosphine (3.055 g, 11.649 mmol) and Nhydroxyphthalimide (1.90 g, 11.65 mmol) in anhydrous THF (50 mL) at 0 °C was added
dropwise the bis- t-butylated amine 3.1 (4.0 g, 10.59 mmol). After stirring 30 min,
diisopropyl azodicarboxylate (DIAD) (2.3 g, 11.6 mmol) was added dropwise via syringe.
The reaction mixture was then allowed to warm to room temperature. After 12h, the
solvent was removed by rotary evaporation. Diethyl ether (150 mL) was added to dissolve
the orange residue and the organic phase was washed with successive washings of
saturated aq. NaHCO3 (3 X 100 mL), and brine (100 mL). The ether was dried (Na2SO4),
filtered, and concentrated to a viscous yellow-orange semisolid by rotary evaporation.
The product was purified by silica gel chromatography eluting in 4:1 CH 2Cl2/EtOAc. Rf
0.59 in 2:1 hexanes:EtOAc. The product is a yellow oil (4.5 g, 81%). 1H NMR (CDCl3, 400
MHz)  7.83 (m, 2H), 7.74 (m, 2H), 4.27 (t, J = 6.0 Hz, 2H), 3.67 (t, J = 6.4 Hz, 4H) 3.06 (t, J
= 6 Hz, 2H); 2.77 (t, J = 6.6 Hz, 4H), 0.86 (s, 18H), 0.04 (s, 12H).
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Synthesis of 3.3
The phthalimide protected amine 3.2 (4.5 g, 8.5 mmol) was dissolved in anhydrous
CH2Cl2 (20 mL) and placed in a pressure vial. Iodomethane (6.1 g, 42.8 mmol) was added
dropwise. The vial was sealed and warmed to 50 °C. After 5 h, the vial was cooled,
opened, and the solvent was evaporated under reduced pressure in a fume hood to afford
the crude ammonium iodide 3.3 as a light yellow solid (5.3 g, 92%) which was used directly
in the next step. 1H NMR (CDcl3, 400 MHz)  7.82 (m, 4H), 4.73 (m, 2H), 4.41 (m, 2H), 4.15
(m, 8H) 3.64 (s, 3H); 0.88 (s, 18H), 0.11 (s, 12H).
The crude iodo salt 3.3 (15.2 g, 22.8 mmol) was dissolved in 95% EtOH (115 mL).
Hydrazine monohydrate (4.6 g, 91.3 mmol) was added. The reaction mixture was stirred
24h at room temperature. The solvent was removed by rotary evaporation and the
residue was dissolved in CH2Cl2 (10 mL). The white precipitate was filtered over a Buchner
funnel and the CH2Cl2 filtrate was condensed by rotary evaporation. A pale yellow solid
was isolated (12.0 g, 98%, Rf 0.61in 9:1 MeOH/CH2Cl2). 1H NMR (CDCl3, 400 MHz) δ 5.90
(bs, 2H), 4.17 (m, 2H), 4.09 (m, 4H), 4.02 (t, J = 4.2 Hz, 2H), 3.97 (m, 4H), 3.47 (s, 3H), 0.88
(s, 18H), 0.09 (s, 12H).
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[2-(aminooxy)ethyl]bis(2-hydroxyethyl)methylazanium iodide (QAO-2OH)
The silylated aminooxy salt 3.3 (2.971g, 5.55 mmol) was stirred in anhydrous CH2Cl2
at 0 °C for 5 minutes, tetrabutylammonium fluoride (11.1 mL of 1M in THF) was added
dropwise to the reaction mixture. The reaction was stirred at room temperature for 3h.
The solvent was removed by rotary evaporation. The resulting pale yellow solid was
dissolved in water and purified by C18 reverse phase flash chromatography eluting in 97:3
water:acetonitrile. The aqueous solvents were removed by rotary evaporation and
vacuum drying. The product was isolated as colorless oil (0.61g, 36%). 1H NMR (D2O, 400
MHz) δ 4.17 (m, 2H), 4.07 (m, 4H), 3.80 (t, J = 4.8 Hz 2H), 3.67 (t, J = 5.0 Hz, 4H), 3.25 (s,
3H). 13C NMR (125 MHz D2O)  68.5, 64.4, 61.6, 55.2, 49.9.
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5.3.9 Fluorescence study of FITC-loaded NPs
Aqueous solutions (0.1 M) of QAO, QAO-1OH, and QAO-2OH compound were
added to suspensions of iron oxide nanoparticles (3 mg each) in vials (5 μmoles of
aminooxy compound/mg of nanoparticles). The vials were briefly sonicated (15 minutes)
and then vortex mixed for 45 minutes at room temperature. The resultant QAO-coated
NPs were magnetically separated from the supernatant solution, washed with water to
remove unbound QAO salts, and freeze dried.
To a suspension of the QAO-NPs (3 mg) in methanol at room temperature was
added a solution of FITC-CHO in methanol (0.01M, 50 μL/mg of NPs). The reaction
mixture was vortex mixed 2 hours at room temperature. The particles then were
magnetically separated, the supernatant was removed and analyzed. The particles were
washed twice with methanol (3X reaction volume) and the supernatants collected each
time and analyzed. Water was then added (50 μL/mg NPs), an aliquot was collected for
analysis, and the aqueous suspensions then were placed in an Easy Heat LI alternating
electromagnetic field at 201.4A and 203 kHz for 30 minutes. After AMF exposure, the
particles were removed by magnetic separation and an aliquot of the final supernatant
was collected for analysis.
The collected aliquots, both pre- and post-AMF exposure, were identically diluted
and their fluorescence was measured during reverse phase HPLC using a Waters Atlantis
C18 column (5μm, 3.9x150mm) on an Agilent 1100 series HPLC. The total run-time was
45 minutes with the following gradient: (% line B, elapsed time in minutes) 0,0; 0,3; 60,10;
80,25; 100,30; 100,35; 0,45 where the A line was 5mM ammonium acetate (pH 6) and the
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B line was 75% v/v aqueous acetonitrile. Excitation-emission spectra (EES) of FITC-CHO,
FITC-I, and FITC-II were acquired on a PerkinElmer LS55 fluorescence spectrometer in
order to determine the excitation wavelengths that would yield maximum emission for
each adduct. The fluorescence excitation beam-width of the Agilent instrument was
20nm.

5.3.10 Syntheses of doxorubicin analogs

Synthesis of Dox-2OH
To a solution of doxorubicin•HCl (105.3 mg, 0.18 mmol) in anhydrous methanol (9
mL) at room temperature was added QAO-2OH (162.3 mg, 0.54 mmol) and trifluoroacetic
acid (9.0 μL). After stirring the reaction mixture in the dark at room temperature for 110h,
the solvent was removed by rotary evaporation. The product was purified from the crude
mixture by C18 reverse phase flash chromatography (C18Aq) with gradient elution in
water/methanol with 0.1% TFA. The product eluted at 55% water 45% methanol/TFA. A
hygroscopic red solid was isolated. The residue was dissolved in methanol and gravity
eluted through an ion exchange resin as previously described to yield a red solid (0.13 g,
93%). 1H NMR (500 MHz, CD3OD) δ 1.28 (d, J = 5, 3H); 1.91 (m, 1H); 2.01 (m, 1H); 2.18 (d,
J = 5.0 Hz, 1H); 2.45 (d, J = 15 Hz, 1H); 2.90, 3.01 (ABq, 2H, JAB = 17.5 Hz); 3.27 (m, 1H);
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3.30 (s 3H); 3.60 (d, J = 15 Hz, 1H); 3.67-3.75 (m, 6H); 3.82 (bs, 3H); 3.91-4.05 (m, 9H); 4.23
(m, 1H); 4.49, 4.53 (ABq, 2H, JAB = 15 Hz); 4.63 (m, 4H); 4.74 (splitting and integration
obscured by water peak, presumed to be 1H on C7, according to ref);170 5.35 (bs, 1H), 7.23
(d, J = 10 Hz, 1H); 7.43 (d, J = 10 Hz, 1H); 7.51 (t, J = 7.5 Hz, 1H). 13C NMR (125 MHz, CD3OD)
δ 185.9, 185.63, 162.9, 160.7, 156.0, 154.5, 135.7, 134.8, 134.7, 134.3, 119.5, 118.8,
118.7, 110.5, 110.3, 99.5, 71.6, 70.8, 67.7, 66.6, 66.4, 64.9, 62.2, 55.8, 55.4, 54.2, 49.9,
37.7, 33.2, 28.1, 15.9. m/z calcd [C34H46N3O13]+ 704.302518, observed 704.30269.

Synthesis of Dox-OH
To a solution of doxorubicin•HCl (103.0 mg, 0.178 mmol) in anhydrous methanol
(9 mL) at room temperature was added QAO-1OH (146 mg, 0.533 mmol) and
trifluoroacetic acid (9.0 μL). After stirring the reaction mixture in the dark at room
temperature for 72h, the solvent was removed by rotary evaporation. The product was
purified from the crude mixture by C18 reverse phase flash chromatography (C18Aq) with
gradient elution in water/methanol with 0.1% TFA. The product eluted at 55% water 45%
methanol/TFA. The hygroscopic red solid was then converted to a chloride salt by gravity
eluting through an ion exchange resin prepared as described previously (0.1348 g, quant).
1H

NMR (500 MHz, CD3OD) δ 1.28 (d, J = 6, 3H); 1.91 (m, 1H); 2.01 (m, 1H); 2.23 (m, 1H);
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2.50 (br d, J = 14 Hz, 1H); 3.03 (m, 2H); 3.26 (d, J = 3.5 Hz, 6H); 3.58 (m 3H); 3.72 (br s, 1H);
3.88 (m, 5H); 3.99 (m, 2H); 4.25 (m, 1H); 4.49,4.55 (ABq, 2H, JAB = 13.3 Hz); 4.61 (m, 2H);
5.37 (m, 1H), 7.33 (m, 1H); 7.59 (m, 2H). One 1H signal was obscured by water
contamination in methanol, but was verified in DMF-d7 at δ 5.15.

13C

NMR (125 MHz,

CD3OD) δ 15.8, 22.6, 23.5, 28.1, 28.7, 30.2, 33.2, 37.9, 38.7, 51.9, 54.3, 55.5, 55.8, 63.8,
66.4, 66.6, 67.7, 67.8, 71.0, 71.7, 99.6, 110.5, 110.7, 118.9, 118.9, 119.8, 135.0, 135.8,
154.7, 156.1, 160.9, 163.0, 186.0, 186.3. m/z calcd [C33H44N3O12]+ 674.291953, observed
674.29305.

5.3.11 Preparation of NP formulations of Dox analogs
To NPs (30.1 and 29.9 mg) was added 1.5 mL of either Dox-OH or Dox-2OH
(respectively) as 0.1M solutions in anhydrous DMSO such that 5 μmols Dox analog per 1
mg NP was added. Vials were vortex mixed, then inverted (Labquake microcentrifuge
tube shaker, Barnstead Thermolyne) at room temperature for 12 h. The drug-loaded
particles were then magnetically separated from the supernatant and washed with
methanol (2X 1.5 mL) and water (2X 1.5 mL) to afford NP∙Dox-OH (30.9 mg) and NP∙Dox2OH (30.3 mg).

142

5.3.12 UV-Vis detection of Dox-OH and Dox-2OH release by pulsed AMF
2.5 mg/mL solutions of either NP∙Dox-OH or NP∙Dox-2OH were prepared in 1X
phosphate buffered saline and added to polystyrene cuvettes (Brookhaven Instruments).
The cuvettes were placed, one per trial, in the center of an induction coil (Easy Heat LI
AMF generator). The solutions were exposed to AMF pulses lasting five minutes (203 kHz,
350 A) at room temperature. After each pulse, the NPs were magnetically sedimented
and the cuvettes were placed in a 30 °C spectrophotometer (Beckman Coulter DU 800)
where absorbance at 480 nm was detected. Absorbance at 380 nm was used for baseline
correction. A total of 6 five-minute pulses were applied with intervening 5 minute periods
of “off” time for a total time of 1h per experiment. Trials were performed in triplicate.

5.3.13 Toxicity of Dox-NPs in MCF-7 cells
MCF-7 breast cancer cells were cultured in DMEM, 10% FBS, and 1% Pen strep and
were plated into one of two 96 well plates which had been cut down to fit within the coil
of the AMF generator. NP∙Dox-OH, NP∙Dox-2OH, or bare NPs (control) were dispersed in
PBS buffer (50 µL/well) and then diluted with supplemented medium (200 µL/well).
When cells had grown to 40% confluence, the medium was removed and replaced with
the NP formulations. One 96 well plate was placed within the coil of the AMF generator
and cells were exposed to 15 minutes pulsed AMF (350A, 203 kHz, 3 min on, 3 min off, 30
min total time). Between pulses cells were incubated at 37 °C. After 48 hours, toxicity
was assayed by trypan blue exclusion. The medium was removed, wells were washed 2X
with 200 µL PBS. 100 µL trypsin was added and the plates were incubated for 5 min. 100
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µL medium was added to neutralize the trypsin and the contents of the wells were
transferred to microcentrifuge tubes. The cells were pelleted by centrifuge (1100 rpm, 5
min), and the supernatant was aspirated. Cell pellets were dispersed in 30 µL PBS buffer
plus 10 µL trypan blue. Live cells, which had excluded the blue dye, were counted using
a hemocytometer.

5.3.14 Synthesis of QAO-2OH anthracene derivative

To aminooxy precursor QAO-2OH (0.405 g, 1.89 mmol) in 2:1 MeOH:CH2Cl2 (25
mL) was added 9-anthracenecarboxaldehyde (0.582 g, 2.82 mmol). The mixture was
stirred at rt for 48h. The solvent was removed by rotary evaporation. The residue was
passed through a thin silica gel plug eluting with CH2Cl2:MeOH (9:1). The solvent was
evaporated by rotary evaporation to yield the product as a viscous yellow liquid (0.263 g,
35%). 1H NMR E isomer (400 MHz, CD3OD) δ 9.08 (s, 1H), 8.31 (d, J = 9.6 Hz, 2H), 7.87 (d,
J = 8.4 Hz, 1H), 7.55 (t, J = 7.6 Hz, 2H), 7.53 (t, J = 7.4 Hz, 2H), 4.72 (br s, 2H), 4.04 (m, 4H),
3.96 (m, 2H), 3.70 (m, 4H), 3.31 (s, 3H).

13C

NMR E isomer (100 MHz, CD3OD) δ 150.8;

132.5; 131.2; 130.9; 130.0; 128.1; 126.4; 125.8; 123.7; 68.8; 66.2; 63.6; 56.8; 51.2.
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5.3.15 Dextran sulfate coating of NPs
49.5 mg NPs were dispersed in 100 mL DMSO. 100.3 mg dextran sulfate in DMSO
(100 mL) was added to the NPs with rapid stirring slowly by addition funnel. The mixture
was stirred 14h at rt. NPs were magnetically separated, the supernatant was removed by
aspiration, the precipitated particles were washed 2X with Millipore water and freeze
dried.

5.3.16 Coating of dextran sulfate NPs with QAO-2OH anthracene derivative
To 19.9 mg dextran sulfate-coated NPs in DMSO (30 mL) was added QAO-2OH
anthracene derivative (0.040 g, 0.10 mmol). The mixture was stirred at rt for 12h. Coated
NPs were magnetically separated, the supernatant was removed by aspiration, the
precipitated particles were washed 2X with Millipore water and freeze dried.

5.3.17 Release of QAO-2OH anthracene derivative from dextran sulfate NPs
A 2.5 mg/mL aqueous solution of the QAO-2OH anthracene derivative-loaded
dextran sulfate NPs was placed in a cuvette. The solution was vortex mixed and the
particles were magnetically sedimented. Absorbance of the solution phase was measured
at 382 nm UV-Vis. This procedure was repeated every 5 minutes for 30 min at rt. The
solution was then exposed to pulsed AMF for 30 minutes (5 min on, 2.5 min off). At 5 min
intervals after each pulse the particles were again magnetically separated and absorbance
at 382 nm was measured.
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5.3.18 CS2 and CS2/CH3I coating of NPs
In a typical procedure for coating NPs with CS2, 20-60 mg NPs would be heated in
a Kügelrohr distillation apparatus under vacuum at 125 °C for 4 hours to remove surfacebound water. A pre-heated stir bar and CS2 (2-3 mL) would then be added and the
solution would be stirred for 4h at rt. The particles would then be magnetically separated
and dried under vacuum. For methyl capping, iodomethane (1-2 mL) would be added to
the particles and the solution would be stirred for 12h at rt. Excess iodomethane would
be evaporated under N2 stream in a fume hood and, following that, the coated NPs would
be dried under vacuum for up to 48h.

5.3.19 Synthesis of deuterated ammonium salt 3

Following a modified procedure by Sommer et al.,171 to benzylamine (0.49 g, 4.57
mmol) in DMF (2.3 mL) was added N,N-diisopropylethylamine (1.6 mL, 9.15 mmol). The
mixture was stirred for 15 minutes and cooled to 0 °C with an ice bath. CD3I (2.99 g, 20.6
mmol) was added dropwise and the mixture was allowed to come to rt and stirred 12h.
After removal of excess CD3I in vaccuo, hot EtOAc was added and the reaction was filtered
of a white precipitate. The filtrate was concentrated by rotary evaporation and the DMF
removed by azeotrope with toluene. The product was isolated by reverse phase flash
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column chromatography (RediSep Rf Gold C18Aq) as a white solid (1.07 g, 82%). 1H NMR
(400 MHz, CD3OD) δ 7.79 (d, J = 8.4 Hz, 2H); 7.69-7.60 (m, 3H); 4.90 (s, 2H); 13C NMR (400
MHz, CD3OD) δ 133.8; 131.7; 130.0; 128.6; 69.2, 52.2 (m); m/z calcd [C33H44N3O12]+
674.291953, observed 674.29305.

5.3.20 Coating of CS2 NPs with 3
20.8 mg NPs were heated at 125 °C under vacuum in a Kügelrohr. 0.7 mL CS 2 was
added and the solution was stirred at rt for several hours. Excess CS 2 was evaporated
under N2 stream. 0.63 mL of a 0.1M solution in DMSO of the ammonium salt was added
and the solution was stirred 19h. The particles were then magnetically separated and the
supernatant removed. Particles were washed with 2X 1mL water and freeze dried. As a
control, NPs were treated as above without the addition of CS2. TGA analysis was
performed on ≈5 mg of sample for three conditions: NPs + CS2, NPs + CS2 + 3, or NPs+ 3.
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5.3.21 Synthesis of anthracen-9-ylmethanamine (4)

Reagents and conditions: (a) NaBH4 (4.8 eq), THF/MeOH, rt
2.5 h; (b) Phthalimide, PPh3, DIAD, THF, 0 °C-rt, 16h; (c)
H2NNH2 monohyd., CH2Cl2:MeOH, rt, 14h

To 9-anthracene carboxaldehyde (2.51 g, 12.2 mmol) in 5:1 THF:MeOH (60 ml) was
slowly added NaBH4. The mixture was stirred 2.5h after which the reaction was quenched
with aq. NH4Cl. The precipitate was removed by filtration and the filtrate extracted with
diethyl ether (3X, 50 mL). The combined organic phases were washed with brine and
dried over sodium sulfate.

The product was purified by column chromatography

(EtOAc/CH2Cl3) to yield a yellow solid. Rf 0.55 (1:20 EtOAc: CH2Cl2). 1H NMR (400 MHz,
CDCl3) δ = 8.47 (m, 3H); 8.03 (d, J = 8.4 Hz, 2H); 7.57 (m, 2H); 7.49 (m, 2H) 5.68 (d, J = 5.2
Hz, 2H), 1.73 (br, 1H).
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To a solution of triphenylphosphine (2.82 g, 10.77 mmol), phthalimide (1.58 g,
10.77 mmol), and anthracene methanol in anhydrous THF (40 mL) at 0 °C was added
dropwise DIAD (2.18 g, 10.77 mmol). The mixture was stirred at rt for 16h. THF was
removed by rotary evaporation. The yellow solid was triturated in 50 mL rt diethyl ether
and the precipitated solids were collected over a Buchner funnel giving a yellow solid that
was used directly in the next step. 1H NMR (400 MHz, CDCl3)  5.87 (s, 2H), 7.48 (t, J =
7.4 Hz, 2H), 7.57-7.66 (m, 4H), 7.75-7.77 (m, 2H); 8.01 (d, J = 8.8 Hz, 2H), 8.48 (s, 1H); 8.66
(d, J = 9.2 Hz, 2H).
The anthryl phthalimide (0.667 g, 1.98 mmol) was dissolved in 2:1 CH2Cl2:EtOH (50
mL). Hydrazine monohydrate (0.495 g, 9.89 mmol) was added and the mixture was stirred
for 14h at rt. The product was purified by silica gel chromatography (9:1:0.1 CH2Cl2:
MeOH: NH4OH) to yield an amber solid (16 %, 2 step). 1H NMR (400 MHz, CDCl3)  1.70
(bs, 2H); 4.82 (s, 2H); 7.46-7.57 (m, 4H); 8.02 (d, J = 8.4 Hz, 2H); 8.33-8.40 (m, 3H).
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5.3.22 Preparation of thiocarbamate NPs 10

To xanthate ester NPs 8 (35.6 mg) in THF (2 mL) was added 20 mg of 4 in 0.3 mL.
The mixture was magnetically stirred at rt for 6h. The coated particles 10 (which had
changed color from brown to beige) were magnetically sedimented. The supernatant was
removed and the particles were washed with THF. With successive washing the particles
lost their pale coloring.

5.3.23 Elemental analysis
Elemental analyses were performed on ≈50 mg of sample by Midwest Microlab,
LLC.

5.3.24 CS2-modified NPs with variably hydroxylated ammonium salts
A stock solution of CS2 modified NPs in DMSO was aliquoted into 15
microcentrifuge tubes such that each tube contained ≈10 mg particles. 0.15 mL of 0.66M
solutions of each ammonium salt (Figure 3.3) were added to the particle solutions and
the mixtures were vortex mixed, sonicated (5 min) and placed on inverter for mixing for
20h. The coated NPs were then magnetically separated, the supernatant was removed
and the particles were washed with water (3X 0.5 mL) with intervening pelleting by
centrifugation (13000 rpm, rt, 5 min) and supernatant removal. The washed particles
were freeze dried. An unidentified orange solid was seen to pellet with the NPs.
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5.3.25 Synthesis of greigite NPs
Following a procedure describe by Chang et al.,123 6.5 mL water was deoxygenated
with N2 bubbling for 45 min. Iron II sulfate (1.82 g, 6.54 mmol) and Na 2S∙ 9H2O (1.57 g,
6.54 mmol) were added and a black precipitate formed immediately. Glacial acetic acid
was then added dropwise as the solution pH was monitored, until the pH reached 3.3.
Greigite NPs were pelleted by centrifugation (5000 rpm, 5 min, rt). After supernatant
removal the particles were washed with deoxygenated water (40 mL) and again pelleted
by centrifuge. The supernatant was once again removed and the particles were freeze
dried. The particles were not immediately responsive to a magnet, however after sitting
overnight at rt in a vial, they became magnetic.

5.3.26 Greigite NP coating with QAO-2OH anthracene derivative

To 1 mL of QAO-2OH anthracene derivative (25 mg/mL) in andhyd. DMSO was
added 50.6 mg greigite NPs. The mixture was stirred at rt for 48h. Coated particles were
pelleted by centrifugation (13000 rpm, 15 min, rt). The supernatant was removed and
the particles were washed with water (3X 1 mL) with intervening centrifugation and
supernatant removal. The particles were then freeze dried.
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5.4 Experimental Procedures for Chapter 4
5.4.1 Syntheses of cationic oxime ether lipids and intermediates

tert-butyl N,N-bis[2-(aminooxy)ethyl]carbamate (4.1).
[Steps a, b] To a solution of tert-butyl bis(2-hydroxyethyl)carbamate (5.01 g, 24.4
mmol), triphenylphosphine (14.1 g, 53.7 mmol) and N-hydroxyphthalimide (8.75 g, 53.6
mmol) in THF (245 mL) at 0 °C was added dropwise diisopropyl azodicarboxylate (DIAD)
(10.6 g, 52.4 mmol). The resultant red mixture was allowed to warm to rt. After stirring
for 12 h, the solvent was removed by rotary evaporation. Et 2O (150 mL) was added and
the mixture was cooled to 0 °C for 3 h. The resultant suspension was decanted to remove
an off-white precipitate. The decanted solution was chilled to –20 °C for another 3 h and
again decanted to remove a second crop of precipitated solids. The solvent then was
removed by rotary evaporation and a mixture of hexanes:EtOAc, 1:1 (60 mL) was added
to the crude residue. The precipitated solids were collected using a Buchner funnel,
dissolved in a minimal volume of CH2Cl2, and passed through a plug of silica gel, eluting
with a gradient of CH2Cl2: EtOAc, 1:0 to 0:1. The isolated product containing minor
impurities was recrystallized by first dissolving in a minimal volume of hot EtOAc and then
adding hexanes (final ratio: 2:1 hexanes/EtOAc). The bis-phthalimide, tert-butyl N,Nbis({2-[1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)oxy]ethyl})carbamate, obtained as a white
solid (2.07 g, 17%) was used directly in the next step; m.p. 139-141 °C; TLC, Rf 0.47
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(hexanes/EtOAc, 1:1, UV/ninhydrin stain); FT-IR 2972, 2956, 1793, 1736, 1729, 1697, 1412
cm-1; 1H NMR (400 MHz, CDCl3) δ 1.41 (s, 9H); 3.73 (m, 4H); 4.36 (m, 4H); 7.71 (m, 8H);
13C

NMR (125 MHz, CDCl3) δ 28.5; 47.7; 78.0, 80.5; 123.6; 129.1; 134.6; 155.4; 163.5.
To a solution of the isolated bis phthalimide carbamate (3.10 g, 6.26 mmol) in

CH2Cl2 (33 mL) at rt was added dropwise hydrazine monohydrate (1.57 g, 31.3 mmol).
After stirring at rt for 2.5 h, the reaction mixture was filtered to remove the white
precipitate, and the retentate was washed with small portions of CH2Cl2. The combined
filtrate was evaporated by rotary evaporation to afford bis-aminooxy carbamate 4.1 as a
clear oil (1.42 g, 96%); TLC, Rf 0.74 (CH2Cl2:MeOH, 9:1); FT-IR 3312, 2976, 2925, 2871,
1677, 1590 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.45 (s, 9H); 3.41 (br s, 2H),3.49 (br s, 2H);
3.74 (t, J = 5.2 Hz, 4H); 5.46 (br s, 4H, -ONH2); 13C NMR (100 MHz, CDCl3) δ 28.4; 46.0; 46.2;
73.2; 74.0; 79.7; 155.8. HRMS m/z calcd [C9H22N3O4] + [M + H]+: 236.16048, observed
236.16065.
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(21E)-14,20-dioxa-13,17,21-triazatritriaconta-12,21-diene (4.2)
Bis-aminooxy carbamate 4.1 (0.10 g, 4.21 mmol) was dissolved in CH2Cl2 (20 mL).
To this solution was added dodecyl aldehdye (1.71 g, 9.26 mmol), prepared from dodecyl
alcohol by Swern oxidation.172 After stirring the reaction for 10 h at rt, the solvent was
removed by rotary evaporation and the crude product was purified by silica column
chromatography (CH2Cl2: EtOAc, 1:0 to 9:1) to afford 4.2 (2.23 g, 93%) as a colorless oil.
The mixture of (E,E):(E,Z) diastereomers was used directly in the next step without isomer
separation; TLC, Rf 0.53, 0.42 (CH2Cl2/EtOAc, 9:1, p-anisaldehyde stain); 1H NMR (400
MHz, CDCl3) (E,E)-isomer (major): δ 0.88 (t, J = 5.6 Hz, 6H); 1.25 (m, 34H), 1.45 (s, 9H); 1.62
(m, 2H); 2.17 (q, J = 6.2 Hz, 4H); 3.47 (m, 4H); 4.11 (m, 4H); 7.37 (t, J = 6.0 Hz, 2H); 13C NMR
(100 MHz, CDCl3) δ14.1, 22.6, 25.7, 26.2, 26.7, 28.4, 29.1, 29.3, 29.4, 29.5, 29.6, 29.8, 31.9,
47.3, 71.7, 72.2, 79.5, 151.3, 152.3, 155.4.
The bis-oxime ether 4.2 (1.57 g, 2.77 mmol) was dissolved in a chilled 1:1 mixture
of trifluoro-acetic acid: CH2Cl2 (7.0 mL) and the mixture was stirred at rt for 3 hours. The
solvent was evaporated by rotary evaporation and Et2O (50 mL) was added to dissolve
the residue. The Et2O solution was washed with sat. NaHCO3 (50 mL). The aqueous wash
layer was extracted with Et2O (2 x 30 mL) and the combined Et2O phase was dried (NaSO4)
and then evaporated by rotary evaporation to yield bis-oxime ether amine (1.25 g, 96%)
as an amber liquid; 1H NMR (400 MHz, CDCl3) (E,E)-isomer: δ 0.88 (t, J = 7.0 Hz, 6H); 1.25
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(m, 32H); 1.47 (m, 4H); 1.98 (br, 1H); 2.16 : (q, J = 7.2, 4H); 2.96 (m, 4H); 4.14 (q, J = 5.3
Hz, 4H); 7.39 (t, J = 6.5 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 14.1, 22.6, 25.7, 26.2, 26.7,
29.1, 29.3, 29.4, 29.5, 29.6, 31.9, 48.6, 48.7, 48.8, 72.3, 72.7, 151.5, 152.4.

(21E)-17-(2,3-dihydroxypropyl)-17-methyl-14,20-dioxa-13,17,21-triazatritriaconta-12,21dien-17-ium iodide (Lipid 1)
Following a modified version of the procedure for glycidol epoxide opening
described by Kuwabe et al.,173 to a solution of the amine generated in the previous step
(1.09 g, 2.33 mmol) in 1:1 water/ethanol (12 mL) was added racemic glycidol (0.568 g,
7.67 mmol) and acetic acid (0.073 g, 1.22 mmol). The reaction flask was covered with foil
and stirred in the dark at 55 °C for 48 h. Note: reactions of this type were later performed
without acid at 1M in ethanol (95%), with 1 eq. glycidol over 12h at rt. The ethanol was
removed by rotary evaporation and Et2O (50 mL) was added to dissolve the residue. The
Et2O solution was washed with sat. NaHCO3 (50 mL). The aqueous wash layer was
extracted with Et2O (2 x 50 mL) and the combined Et2O phase was dried (NaSO4) and then
evaporated by rotary evaporation.

The residue was purified by silica column

chromatography (CH2Cl2: CH3OH, 19:1 to 9:1) to afford 4.5 (1.01 g, 80%) as a yellow oil;
TLC, Rf = 0.47 (CH2Cl2/MeOH, 9:1, p-anisaldehyde stain); 1H NMR (400 MHz, CDCl3) (E,E)isomer: δ 0.88 (t, J = 6.6 Hz, 6H); 1.26 (m, 32H); 1.46 (m, 4H); 2.17 (q, J = 7.1 Hz, 4H); 2.71
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(m, 2H); 2.95 (br, 4H); 3.48 (m, 1H); 3.72 (dd, J = 4.0, 11.2 Hz, 2H); 3.88 (br, 1H); 4.15 (m,
4H); 7.38 (t, J = 6.4 Hz, 2H); HRMS m/z calcd [C31H64N3O4] + [M + H]+: 542.48913, observed
542.48952.
A pressure tube was charged with a solution of 4.5 (0.85 g, 1.57 mmol) in CH2Cl2
(3.5 mL). To the solution was added iodomethane (2.23 g, 15.7 mmol). The tube was
sealed and then heated at 60 °C for 6 h. On cooling, the tube was opened and the solvent
and excess iodomethane were evaporated using a nitrogen stream in a closed fume hood.
The residue was purified by silica column chromatography (CH2Cl2: CH3OH 1:0 to 9:1) to
yield lipid 1 (0.941 g, 88%) as an amber oil; TLC, Rf = 0.68 (CH2Cl2/MeOH, 9:1, panisaldehyde stain); 1H NMR (400 MHz, CDCl3) (E,E)-isomer: δ 0.85 (t, J = 7.2 Hz, 6H); 1.23
(m, 30H); 1.44 (m, 4H); 2.15 (q, J = 7.4 Hz, 4H); 3.37 (s, 3H); 3.68 (m, 3H); 3.85-4.01 (m,
5H); 4.45 (m, 5H); 7.39 (t, J = 6.2 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 13.9, 16.8, 22.6,
26.0, 26.1, 26.4, 29.1, 29.2, 29.3 (2 signals), 29.4, 29.5, 31.8, 51.6, 62.7, 62.9, 63.1, 64.1,
65.1, 66.3, 66.9, 67.3 (2 signals), 153.7, 154.3; HRMS m/z calcd [C32H66N3O4]+ : 556.50478,
observed 556.50476.
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16,22-dioxa-15,19,23-triazaheptatriaconta-14,23-diene
Bis-aminooxy carbamate 4.1 (0.105 g, 0.446 mmol) was dissolved in CH2Cl2 (4.0
mL). To this solution was added tetradecanal (0.208 g, 0.982 mmol), prepared from
tetradecanol by Swern oxidation.172 After stirring the reaction for 10 h at rt, the solvent
was removed by rotary evaporation and the crude product was purified by silica column
chromatography (CH2Cl2: EtOAc, 1:0 to 9:1) to afford tert-butyl N,N-bis({2[(tetradecylideneamino)oxy]ethyl})carbamate (4.3) (0.199 g, 71%) as a colorless oil. The
mixture of (E,E):(E,Z) diastereomers was used directly in the next step without isomer
separation; TLC, Rf 0.50, 0.46 (hexanes/EtOAc, 4:1, ninhydrin stain); FT-IR 2954, 2923,
2853, 1698, 1466, 1406, 1366 cm-1; 1H NMR (400 MHz, CDCl3) (E,E)-isomer (major): δ 0.88
(t, J = 6.6 Hz, 6H); 1.26 (m, 44H), 1.45 (s, 9H); 2.16 (q, J = 6.9 Hz, 4H); 3.46 (m, 4H); 4.11
(m, 4H); 7.37 (t, J = 6.0 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ14.1, 22.7, 25.7, 26.2, 26.7,
28.4, 29.1, 29.3, 29.4, 29.5 (2 signals), 29.6 (3 signals), 29.7, 31.9, 47.6, 47.3, 71.7, 72.2,
79.5, 151.25, 152.2, 155.4.
The bis-oxime ether 4.3 (0.467 g, 0.748 mmol) was dissolved in 1:1 mixture of
trifluoro-acetic acid: CH2Cl2 (3.2 mL) and the mixture was stirred at rt for 3 hours. The
solvent was evaporated by rotary evaporation and Et2O (30 mL) was added to dissolve
the residue. The Et2O solution was washed with sat. NaHCO3 (30 mL). The aqueous wash
layer was extracted with Et2O (2 x 20 mL) and the combined Et2O phase was dried (NaSO4)
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and then evaporated by rotary evaporation to yield the bis-oxime ether amine (0.36 g,
91%) as an off-white solid; TLC, Rf 0.66 (CH2Cl2/MeOH, 9:1, ninhydrin stain); FT-IR 2955,
2917, 2849, 1463 cm-1; 1H NMR (500 MHz, CDCl3) (E,E)-isomer: δ 0.88 (t, J = 6.7 Hz, 6H);
1.25 (m, 40H),1.47 (m, 4H); 1.98 (br, 1H); 2.16 : (q, J = 7.2, 4H); 2.96 (m, 4H); 4.14 (q, J =
5.3 Hz, 4H); 7.39 (t, J = 6.5 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 14.3, 22.9, 25.9, 26.4,
26.9, 29.4, 29.6 (2 signals), 29.7 (2 signals), 29.8, 29.9 (2 signals), 32.1, 48.8, 71.8, 152.0.
HRMS m/z calcd [C37H74N3O4] + [M + H]+: 624.56738, observed 624.56784.
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3-(16,22-dioxa-15,19,23-triazaheptatriaconta-14,23-dien-19yl)propane-1,2-diol (13)
Following a modified version of the procedure for glycidol epoxide opening
described by Kuwabe et al.,173 to a solution of the amine prepared in the previous step
(0.166 g, 0.317 mmol) in ethanol (0.28 mL) was added racemic glycidol (0.035 g, 0.476
mmol). The reaction flask was covered with foil and stirred in the dark at rt for 57 h. The
solvent then was removed by rotary evaporation and the residue was purified by silica
column chromatography (CH2Cl2: CH3OH, 1:0 to 9:1) to afford bis-oxime ether 4.6 (0.078
g, 41%) as a light yellow oil; TLC, Rf = 0.59 (CH2Cl2/MeOH, 9:1, p-anisaldehyde stain); FTIR 3380, 2921, 2854, 1465, 1380, 1041 cm-1; 1H NMR (400 MHz, CDCl3) (E,E)-isomer: δ 0.88
(t, J = 6.6 Hz, 6H); 1.25 (m, 40H),1.45 (sex, J = 6.8 Hz, 4H); 2.17 (q, J = 7.1 Hz, 4H); 2.87 (m,
2H); 3.11 (br, 4H); 3.52 (m, 1H); 3.72 (dd, J = 3.8, 11.4 Hz, 1H); 3.88 (br, 1H); 4.21 (m, 4H);
7.39 (t, J = 6.4 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 14.3, 22.9, 26.0, 26.4, 26.9, 29.4, 29.6
(3 signals), 29.7, 29.9 (2 signals), 32.1, 54.1, 54.2, 58.3, 64.6, 67.8, 70.2, 152.4. HRMS m/z
calcd [C35H72N3O4] + [M + H]+: 598.5517, observed 598.5517.
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19-(2,3-dihydroxypropyl)-19-methyl-16,22-dioxa-15,19,23-triazaheptatriaconta-14,23dien-19-ium iodide (Lipid 2)
[Step f] A pressure tube was charged with a solution of 4.6 (0.078 g, 0.131 mmol)
in CH2Cl2 (2.0 mL). To the solution was added iodomethane (0.372 g, 2.62 mmol). The
tube was sealed and then heated at 55 °C for 18 h. On cooling, the tube was opened and
the solvent and excess iodomethane were evaporated using a nitrogen stream in a closed
fume hood. The residue was purified by silica column chromatography (CH2Cl2: CH3OH
9:1) to yield lipid 4 (0.062 g, 64%) as a hygroscopic yellow solid; TLC, Rf = 0.71
(CH2Cl2/MeOH, 9:1, phosphomolybdic acid stain); FT-IR 3329, 2921, 2854, 1790, 1734,
1702, 1466, 1368, 1271, 1186, 1056 cm-1; 1H NMR (400 MHz, CDCl3) (E,E)-isomer: δ 0.87
(t, J = 6.8 Hz, 6H); 1.25 (m, 40H); 1.46 (m, 4H); 2.18 (q, J = 7.1 Hz, 4H); 3.40 (s, 3H); 3.74
(m, 3H); 3.94 (m, 6H); 4.50 (m, 5H); 4.65 (m, 1H); 7.42 (t, J = 6.2 Hz, 2H); 13C NMR (100
MHz, CDCl3) δ 14.3, 22.9, 26.3 (2 signals), 26.7, 29.4, 29.6 (3 signals), 29.7, 29.9, 32.1, 51.9,
62.9, 64.5, 66.3, 66.4, 67.0, 67.5, 154.0, 154.6; HRMS m/z calcd [C36H74N3O4] + 612.5674,
observed 612.5673.
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Tert-butyl N,N-bis[2-({[(9Z)-octadec-9-en-1-ylidene]amino}oxy)ethyl]carbamate (4.4)
Bis-aminooxy carbamate 4.1 (0.495 g, 2.10 mmol) was dissolved in CH2Cl2 (12 mL).
To this solution was added oleyl aldehyde (1.966 g, 8.42 mmol), prepared from oleyl
alcohol by Swern oxidation.172 After stirring the reaction for 12 h at rt, the solvent was
removed by rotary evaporation and the crude product was purified by silica column
chromatography (CH2Cl2: EtOAc, 1:0 to 19:1) to afford 4.4 (0.731 g, 47%) as a colorless oil.
The mixture of (E,E):(E,Z) diastereomers was used directly in the next step without isomer
separation; TLC, Rf 0.32, 0.25 (CH2Cl2, phosphomolybdic acid stain); FT-IR 3006, 2923,
2855, 1700, 1462, 1407, 1366, 1150 cm-1; 1H NMR (400 MHz, CDCl3) (E,E)-isomer (major):
δ 0.88 (t, J = 6.6 Hz, 6H); 1.30 (m, 48H), 1.45 (s, 9H); 1.99 (m, 8H); 2.16 (q, J = 7.2 Hz, 4H);
3.47 (m, 4H); 4.12 (m, 4H); 5.35 (m, 4H); 7.37 (t, J = 6.0 Hz, 2H); 13C NMR (125 MHz, CDCl3)
δ14.1, 22.7, 25.8, 26.3, 26.8, 27.2, 27.3, 28.5, 29.2, 29.2, 29.3, 29.4 (2 signals), 29.6, 29.7
(2 signals), 29.8, 31.9, 32.6, 47.4, 71.8, 72.2, 79.5, 110.1, 129.7, 130.0, 151.2, 152.2, 155.4.
HRMS m/z calcd [C45H86N3O4] + [M + H]+: 732.66128 , observed 732.66145.

162

(9Z,36Z)-20,26-dioxa-19,23,27-triazapentatetraconta-9,18,27,36-tetraene
The bis-oxime ether 4.4 (0.281 g, 0.383 mmol) was dissolved in a 1:1 mixture of
trifluoro-acetic acid: CH2Cl2 (4 mL) and the mixture was stirred at rt for 1 h. The solvent
was evaporated by rotary evaporation and Et2O (60 mL) was added to dissolve the
residue. The Et2O solution was washed with sat. NaHCO3 (60 mL). The aqueous wash
layer was extracted with Et2O (2 x 40 mL) and the combined Et2O phase was dried (NaSO4)
and then evaporated by rotary evaporation to yield the bis-oxime ether amine as an
amber oil which was used without further purification; TLC, Rf 0.29 (CH2Cl2/MeOH, 19:1,
phosphomolybdic acid stain); FT-IR 3006, 2923, 2855, 1462, 1068 cm-1; 1H NMR (400 MHz,
CDCl3) (E,E)-isomer: δ 0.87 (t, J = 6.8 Hz, 6H); 1.28 (m, 44H),1.45(m, 4H); 2.01 (m, 8H); 2.16
: (q, J = 7.2, 4H); 2.49 (br, 1H); 3.02 (m, 4H); 4.16 (t, J = 5.4 Hz, 4H); 5.36 (m, 4H); 7.39 (t,
J = 6.0 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 14.2, 22.8, 25.7, 26.3, 26.8, 27.2, 27.3, 29.2,
29.3, 29.4, 29.8 (2 signals), 32.0, 32.7, 48.5, 48.7, 71.8, 72.2, 129.8, 130.1, 151.7, 152.6.
HRMS m/z calcd [C40H78N3O2] + [M + H]+: 632.60886, observed 632.60907.
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3-[(9Z,36Z)-20,26-dioxa-19,23,27-triazapentatetraconta-9,18,23,36-tetraen23yl]propane-1,2-diol (4.7)
Following a modified version of the procedure for glycidol epoxide opening
described by Kuwabe et al.,173 to a solution of the amine produced in the previous step
(0.154 g, 0.243 mmol) in ethanol (0.25 mL) was added racemic glycidol (0.020 g, 0.268
mmol). The reaction flask was covered with foil and stirred in the dark at rt for 16 h. The
solvent then was removed by rotary evaporation and the residue was purified by silica
column chromatography (CH2Cl2: CH3OH, 1:0 to 9:1) to afford bis-oxime ether 4.7 (0.066
g, 38%) as a light yellow oil; TLC, Rf = 0.66 (CH2Cl2/MeOH, 19:1, phosphomolybdic acid
stain); FT-IR 3423, 2955, 2923, 2854, 1728, 1462, 1274, 1123, 1072, 738 cm-1; 1H NMR
(400 MHz, CDCl3) (E,E)-isomer: δ 0.87 (t, J = 6.6 Hz, 6H); 1.27 (m, 44H),1.45 (m, 4H); 2.00
(m, 8H); 2.16 (q, J = 7.1 Hz, 4H); 2.65 (m, 2H); 2.88 m, 4H); 3.03 (br, 2H); 3.47 (m, 1H); 3.71
(m, 2H); 4.12 (m, 4H); 5.33 (m, 4H); 7.37 (t, J = 6.2 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ
14.2, 22.8, 25.9, 26.4, 26.9, 27.3 (2 signals), 29.3, 29.4 (3 signals), 29.5, 29.6, 29.8 (2
signals), 29.9, 32.0, 32.7, 38.8, 54.0, 57.6, 64.5, 68.2, 68.3, 71.1, 71.6 (2 signals), 129.8,
130.1, 151.6, 152.4. HRMS m/z calcd [C43H84N3O4]
706.64573.
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+

[M + H]+: 706.64563, observed

(9Z,36Z)-23-(2,3-dihydroxypropyl)-23-methyl-20,26-dioxa-19,23,27triazapentatetraconta-9,18,27,36-tetraen-23-ium iodide (Lipid 3)
A pressure tube was charged with a solution of 4.7 (0.053 g, 0.075 mmol) in CH2Cl2
(1.0 mL). To the solution was added iodomethane (0.213 g, 1.50 mmol). The tube was
sealed and then heated at 50 °C for 6 h. On cooling, the tube was opened and the solvent
and excess iodomethane were evaporated using a nitrogen stream in a closed fume hood.
The residue was purified by silica column chromatography (CH2Cl2: CH3OH 19:1 to 9:1) to
yield lipid 3 (0.040 g, 63%) as a yellow semisolid; TLC, Rf 0.63 (CH2Cl2/MeOH, 9:1,
phosphomolybdic acid stain); FT-IR 3459, 3336, 3001, 2969, 2955, 2923, 2855, 1736,
1457, 1365, 1269, 1228, 1219, 1123, 1072, 958, 742 cm-1; 1H NMR (400 MHz, CDCl3) (E,E)isomer: δ 0.86 (t, J = 6.4 Hz, 6H); 1.26 (m, 44H); 1.45 (m, 4H); 1.99 (m, 8H); 2.16 (q, J = 6.9
Hz, 4H); 3.39 (s, 3H); 3.71 (m, 3H); 3.95 (m, 6H); 4.50 (m, 6H); 5.33 (m, 4H); 7.40 (t, J = 5.8
Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 14.2, 22.8, 26.2 (2 signals), 26.6, 27.3 (2 signals),
29.2, 29.3 (2 signals), 29.4 (2 signals), 29.6, 29.7, 29.8 (2 signals), 32.0, 32.7, 51.8, 62.7,
62.8, 62.9, 63.1, 64.3, 66.0, 66.3, 66.9, 67.4, 129.8, 130.1, 153.8 154.5; HRMS m/z calcd
[C44H86N3O4] + 720.66128, observed 720.66168.
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5.4.2 Synthesis of doxorubicin hexadecanyl acyl hydrazone (Dox-AH)

To doxorubicin hydrochloride (0.053 g, 0.092 mmol) in anhydr. CH3OH (10 mL) was
added hexadecane hydrazide prepared as in Effenberger et al. 152 (0.033g, 0.122 mmol),
aniline (0.007 g, 0.077 mmol), and trifluoroacetic acid (0.008 g, 0.070 mmol). The reaction
was stirred at rt for 10h. The CH3OH was removed by rotary evaporation and the product,
a red solid, was recrystallized from CH3OH (0.065 g, 85%); 1H NMR (400 MHz, CD3OD) δ
0.89 (t, J = 6.6 Hz); 1.10-1.38 (br m, 28H); 1.43 (t, J = 5.4 Hz, 2H); 1.67 (t, J = 6.8 Hz, 1H);
1.84-1.98 (m, 1H); 1.99-2.12 (m, 1H); 2.26-2.45 (m, 3H); 2.55 (dd, J = 14.0, 6.5 Hz, 1H);
2.90 (d, J = 17.6 Hz, 1H); 3.16 (br m, 1H); 3.35 (s, 3H); 3.45 (d, J = 17.2 Hz1H 3H); 3.58 (br
d, J = 12.8 Hz 1H); 3.62-3.71 (m, 1H); 4.04 (s, 3H); 4.21 (dd, J = 8.4 Hz, 6.1 Hz, 1H); 4.62 (q,
J = 14.8 Hz 2H); 5.07 (t, J = 6.2 Hz, 1H); 5.48 (br s, 1H); 7.59 (t, J = 9.6 Hz, 1H), 7.85 (t, J =
8.1 Hz, 1H); 7.98 (t, J = 10.0 Hz, 2H).

13C

NMR (175 MHz, DMSO-d6) δ 186.5 (2 signals),

186.5, 174.0, 160.7, 156.5, 154.2, 152.2, 136.9, 136.3, 135.7, 134.8, 120.0, 119.7, 119.0,
110.6, 110.5, 98.9, 72.4, 72.1, 66.31, 66.0, 56.6, 56.0, 46.6, 33.9, 31.3, 31.1, m 29.1-29.0,
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28.9, 28.8 (2 signals), 28.7, 28.1, 24.1, 22.1, 16.8, 14.0; HRMS m/z calcd [C43H62N3O11]+
796.4379, observed 796.43916.

5.4.3 Synthesis of core-shell Fe3O4-SiO2 NPs
SiO2@Fe3O4 nanoparticles were prepared using a modified procedure by Pinho et
al.127 Commercially available Fe3O4 ferrofluid (Ferrotec EMG 304, 0.25 mL, ca. 58 mg)
dispersed in water (25 mL) was added in 1 mL aliquots to a solution of EtOH (78 mL) and
NH4OH (1.55 mL, 28-30%) under rapid mechanical stirring. Tetraethyl orthosilicate (TEOS)
(0.532 mL) was added to the colloidal suspension and was stirred for 12 h at rt. The NPs
were magnetically sedimented for 1h on a neodymium permanent magnet. To collect
additional particles, the colloidal supernatant was removed and centrifuged at 6000 rcf
for 1h at rt. The ethanolic supernatant was removed by aspiration and the combined NP
pellets were washed with EtOH (2x 8mL) with intervening centrifugation (16100 rcf, 20
min, rt) and supernatant removal. After a final wash and centrifugation cycle in water (8
mL) with supernatant removal, the NPs were dispersed in water (4 mL) and freeze-dried
resulting in a brown powder (165.4 mg).
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5.4.4 CML formation and stability
Lipids 1, 2, and 3 (6.45 mM) in DMSO were each mixed with 1 mg SNP for up to
24h. Dynamic light scattering (DLS) measurements (0.5 mg SMP/mL) were made on the
mixture at intervals. 3D plots over 24 hour time intervals of the histograms of relative
number of particles versus diameter are given in the appendix. In the case of lipids 2 and
3, particles aggregated at mixing times approaching 24h to diameters outside a useful
range. The following table lists weighted average diameters from size histograms
calculated for the DMSO suspension of CML with lipid 1 at 24h mixing time and for a water
suspension of CML with lipid 1 (after magnetic separation, supernatant removal, and
resuspension, 0.25 mg SNP/mL).
Solvent

Diameter (nm)

Relative
abundance

DMSO

Weighted avg.
diameter (nm)

62.62
0.59
68.2
72.89
0.29
84.85
0.12
Water
44.56
0.29
51.5
50.60
0.42
57.46
0.21
65.24
0.08
DLS measurements of CML with lipid 1 in DMSO and water
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5.4.5 ζ-potential of CML
Lipid 1 (6.45 mM) in DMSO was mixed with 1 mg SNP for 5h. CML were
magnetically separated, the supernatant was removed, the particles were rinsed with
water, and resuspended in water (0.25 mg SNP/mL) for ζ-potential measurements (see
appendix). The mean ζ–potential was 31.72 +/- 2.9 mV.

5.4.6 Calculation of lipid molecules per NP
The mass of an SNP was calculated based on volume and density according to
McCarthy et al.124 as 2.073*10^-17g. Volume was estimated based on average SNP
diameter from transmission electron microscope images. A typical coating of SNP with
lipid used a weight ratio of 0.3-0.4 mg lipid/mg SNP to achieve the plateau of ζ-potential
shown in Figure 4.8 of the manuscript. The number of lipid molecules per SNP that this
ratio represents was calculated according to: (moles lipid/g SNP) (mass of 1 SNP)
(Avogadro’s #).

5.4.7 Titration of SNP with cationic lipid 1
Multiple concentrations of lipid 1 were prepared by serial dilution with water in
microcentrifuge tubes. 0.5 mL of a 0.6 mg/mL stock solution of SNP in water were added
to each tube. Solutions were agitated for several hours. Zeta potentials of the solutions
were measured directly after dilution to 0.2 mg SNP/ mL.
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5.4.8 Estimation of lipid: Dox-AH ratio
Thin films of lipid 1 and DOX-AH were made by dissolving varying ratios of the two
species in CHCl3/CH3OH and removing the solvent in vacuo. To the thin films was added
water for a concentration of 2 mM (lipid 1 and DOX-AH combined) and the mixtures were
vortex mixed and solicited 10 min, 50% duty, 1 min intervals. DLS measurements were
taken for each solution in water (2mL). Figure 4.5 shows the plot of the percent of DOXAH added versus the diameter of the liposomes: the diameter with the highest relative
number of particles from the size histogram.

5.4.9 Cell toxicity study
Lipid films were prepared by dissolving lipid, or lipid + DOX-analog mixtures (3:1
molar ratio) in CH3OH in microcentrifuge tubes and removing the solvent in vacuo. SNP
were dispersed in molecular grade water (0.185 mg/mL) by briefly sonicating. Aliquots of
SNP suspensions were added to the thin films (lipid: 0.108 mM, lipid:DOX-analog mixture
0.081:0.027 mM) and the mixtures were stirred at rt 12h. The solutions were diluted 10%
with 10x PBS prior to addition to cells.
MCF-7 breast cancer cells were grown in supplemented media (DMEM, 10% FBS,
1% Pen strep) in 35mm culture dishes. Prior to treatment, cells were plated in 12-well
dishes (50,000 cells/well) for biological triplicates and incubated for 24h. Treatment
formulations described above were added directly into cell growth media (2 mL): 0.05 mg
SNP, 29.2 total nanomoles lipid or lipid + DOX-analog mixture per well in 0.3 mL volume.
After 2h incubation at 37 °C the medium was removed and replaced with fresh medium.
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Cell viability was assayed after 48h incubation by removing media, rinsing 2X with PBS,
adding 0.25 % trypsin-EDTA 1X (0.2 mL), incubating for 5 minutes, neutralizing with 0.2
mL DMEM, diluting 1:1 with trypan blue and counting live cells (in replicate for each
condition) with a hemocytometer.

5.4.10 Preparation of oxime-ether liposomes and nucleic acid complexes
Lipids were solubilized in CHCl3 at a concentration of 10 mg/mL. Lipids (1 mg) were
placed in glass vials and then mixed with equimolar amount of the co-lipid DOPE. Lipid
films were prepared using rotary evaporatoration under reduced pressure, and kept
overnight in a desiccator at room temperature. Lipids films were hydrated with 3 mL of
enzyme free water under vortexing and were probe sonicated for 10 minutes on ice bath
with 1 min cycle of sonication and 1 min rest to obtain 0.33 mg/mL of lipid in the
liposomes.

The resulting OEL liposome preparations were either used for further

complexation with nucleic acids (described below), or alternatively, the OEL liposomes
were stored at 4°C and used within two weeks of their preparation.
To prepare oxime-ether lipid/nucleic acid complexes, the lipids at different
concentrations were introduced to fixed concentration of nucleic acids at 500 nM (DS
RNAs or RNA/DNA hybrids or DNA duplexes) and incubated for 30 min at room
temperature. After incubation, the mixture was diluted 10 fold by using either enzyme
free water/buffer or serum media at room temperature. The final concentration of
nucleic acids was 50 nM and the lipid concentrations were typically in the range of 1-20
µM. These preparations were then used immediately.
171

5.4.11 Cell culture for gene transfection studies
MDA-MB-231 (human breast cancer) cells either stably expressing enhanced
green fluorescent protein (GFP) or non-GFP cells were maintained in a Dulbecco’s
modified Eagle’s medium (DMEM) 10% (v/v) heat-inactivated FBS (fetal bovine serum),
100 i.u./mL penicillin and 100 μg/mL streptomycin under a humidified 5% CO2 incubator
at 37°C. On the basis of the requirement of the experiments either GFP expressing or nonGFP MDA-MB-231 cells were used.

5.4.12 Binding affinity of oxime ether lipids with hybrid DNA/RNA
Binding affinities of lipids 1-3 with nucleic acids were determined by conducting
fluorescent anisotropy/polarization measurements using Tecan Infinite M1000 (Tecan,
USA). Fluorescent Alexa-488 labeled RNA/DNA hybrid duplexes (200 nM) were incubated
with various concentrations of the lipids. Changes in fluorescent (anisotropy/polarization)
values of hybrid duplexes upon binding to the lipids with respect to the hybrids alone was
measured at λex 470 nm and λem 517 nm.
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5.4.13 Cell viability for gene transfection studies
Viability of the MDA-MB-231 human breast cancer cells was determined on
treatment with lipids alone and in complexation with DS RNAs. 20,000 cells/well were
seeded in 96 well plates in serum containing media 24 hours prior to experiments. Lipids
at different concentrations with and without DS RNAs (50 nM final) were added to the
cells in triplicate in serum containing media and incubated for 4 hours at 37° C. After
incubation, the media was replaced with fresh serum-containing media. The cells were
then incubated for another 24 h at 37° C. At the end of incubation, cell titer blue reagent
was added to each well according to the manufacturer’s protocol and the cells were
further incubated for 4 hours at 37° C. The fluorescence of the resofurin (converted from
resazurin by viable cells) was measured at λex 560 nm and λem 590 nm with an auto cutoff in a fluorescent ELISA plate reader (Spectra MAX, Molecular Devices, Sunnyvale, CA).

5.4.14 Transfection and GFP silencing assay
One day before the experiments 60,000 cells/well of MDA-MB-231 cells and
30,000 cells/well of MDA-MB-231/GFP were plated in two separate 24 well plates for
uptake and silencing experiments in serum containing media. On the day of transfection,
liposomes complexed with either Alexa-488 RNA/DNA hybrid duplexes or dicer substrates
of RNA duplexes (DS RNAs) were added to the cells in serum containing media. The cells
were then incubated for 4h at 37° C. After 4h, the media was replaced with the fresh
serum media. Uptake efficiency of RNA/DNA hybrid duplexes and silencing of GFP was
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quantified using Cell Quest software after 1 day and 3 days of transfections respectively
by fluorescence-activated cell sorting (FACS).
Approximately 72 hours after the transfection, MDA-MB-231/GFP were imaged
with a Nikon 200 TE inverted microscope (Melville, NJ) using Meta Morph software
(Universal Imaging Co., Downingtown, PA) to determine the silencing efficiency of GFP by
liposome/ DS RNAs complexes. PanFluor 20X, ELWD, NA=0.45 objective and a Nikon B2E/C, 465–495/505/515–555 cube (Chroma Technology Corp., Rockingham, VT) were
used for GFP imaging.
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A.1. NMR SPECTRA
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A.2. ZETA-POTENTIAL MEASUREMENTS
Zeta-potential for NPs based on work up

Rinsed NPs

Multiply rinsed NPs

Acid rinsed NPs
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Zeta potential of CS2-modified NPs

Zeta potential of CML with lipid 1
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A.3. EXCITATION-EMISSION SPECTRA

Excitation-emission spectra for FITC derivatives
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A.4. DYNAMIC LIGHT SCATTERING MEASUREMENTS

3D stack plots of DLS
measurements over 24 mixing time
with lipid 1 (A), 2 (B), and 3 (C).
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A.5. FLUORESCENCE AND BRIGHT-FIELD
MICROSCOPE IMAGES
Fluorescence (green filter) and bright-field microscope images were acquired after
2h treatment with CML/SNP formulations on an EVOS FL Cell Imaging System at
magnifications of 10x or 20x.
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Fluorescence images of MCF-7 cells after 2h treatment with SNP
formulations and controls.
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Bright-field images of MCF-7 cells after 2h treatment with SNP
formulations and controls.
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Chapter 2 reproduces work with kind permission from Springer Science and Business
Media: Springer, Metabolomics 2012, 8, 989-996. Mattingly, S. J.; Xu, T.; Nantz, M. H.;
Higashi, R. M.; Fan, T. W. –M.
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A.7. LIST OF ABBREVIATIONS
ATR attenuated total reflectance
CML cationic magnetoliposome
DLS dynamic light scattering
DMEM Dulbecco's modified eagle medium
DOPE 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine
Dox∙HCl Doxorubicin hydrochloride
Dox-AH Doxorubicin acyl hydrazone
DRIFT diffuse reflectance infrared Fourier transform
EA elemental analysis
EES excitation-emission spectrum
FITC fluorescein isothiocyanate
FT-ICR-MS Fourier-transform ion-cyclotron resonance mass spectrometry
MS mass spectrometry
NP iron oxide nanoparticle
PBS phosphate buffered saline
QAO quaternary aminooxy
QDA quaternary dodecyl aminooxy
*QDA 13CD3-labeled QDA
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QOA quaternary octyl aminooxy
SNP silica-coated iron oxide nanoparticle
TGA thermogravimetric analysis
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